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ABSTRACT 
Activation of mammalian stress responsive pathways by plant secondary metabolites may 
contribute to the protection against certain chronic diseases afforded by fruit and vegetable 
consumption. This work focuses on the identification of plant compounds that activate the stress-
responsive enzyme quinone reductase (QR) by stabilizing the transcription factor NF-E2 related 
factor-2 (Nrf2). Screening methanolic extracts of plants from Western Canada for QR induction 
in a mouse hepatoma cell line (Hepa-1c1c7) led to the identification of twenty-one extracts 
capable of doubling the activity of QR. Bioassay-guided fractionation of six extracts led to the 
identification of novel classes of compounds with QR-inducing activity including fatty-acid 
derived polyacetylenes, phthalides, and cannabinoids. Studies using low molecular weight thiols 
and the recombinantly expressed protein Keap1, the principal negative regulator of Nrf2, 
supported a mechanism of QR activation involving covalent modification of Keap1 cysteines for 
the polyacetylenes and phthalides. Analysis of transcriptional changes in response to treatment 
with a panel of QR-inducing compounds provided strong support for Nrf2 activation by the 
polyacetylene (3S,8S)-falcarindiol and the isothiocyanate (R)-sulforaphane and weaker support 
for the compounds (3R,8S)-falcarindiol, 6-isovaleryl-umbelliferone (6-IVU) and (Z)-ligustilide. 
Additionally, transcript level analyses supported a role for the aryl-hydrocarbon receptor in QR-
activation by (3R,8S)-falcarindiol, (Z)-ligustilide, (R)-sulforaphane, 6-IVU and cannabidiol and 
suggested that treatment with polyacetylenes with a (3R)-configuration, (Z)-ligustilide and 6-
IVU causes substantial changes in the expression of genes associated with lipid homeostasis and 
energy metabolism. As a whole, this work provides evidence that compounds that activate QR 
(and Nrf2) are widely distributed in the Canadian flora. However, of these QR activators, few are 
active at concentrations that are expected to be achieved through dietary consumption. 
Nevertheless, the most exceptional compounds isolated in this work, the compounds (3S,8S)-
falcarindiol and epoxyfalcarindiol are highly potent and appear to be or are expected to be 
specific for activating Nrf2 and thus warrant attention with respect to dietary implications and as 
drug candidate leads.   
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1. Diet and health 
The impact of diet on health has been recognized for centuries. Sailors stocking citrus 
fruits to prevent scurvy is a classic example. Basic nutritional requirements must be met to 
prevent diseases of deficiency. The development of our understanding of basic nutrition and the 
prevention of deficiency-associated diseases can be regarded as one of the great medical 
successes of the 20
th
 century. However, the mechanisms by which diet affects the development 
of chronic diseases are inadequately understood. A large body of epidemiological research links 
intake of fruits, vegetables and whole grains above the levels required for basic nutritional needs 
to decreased incidence of chronic diseases such as cardiovascular diseases and certain cancers 
including those of the of the respiratory and gastrointestinal tracts (WHO 2003; Dauchet et al. 
2006; He et al. 2006; Vainio et al. 2006; He et al. 2007; WCRF-AICR 2007). Typical reductions 
in risk are in the range of 10-20% for intake of 3-10 servings of fruits and vegetables per day 
(WHO 2003). 
In addition to plant intake, other dietary habits may also be protective against diseases of 
aging. Low to moderate alcohol consumption is associated with decreased mortality (Grønbæk 
2004) and reduced caloric intake promotes longevity in a range of organisms (Fontana et al. 
2010). What link if any exists amongst these seemingly disparate dietary interventions? A 
commonality exists in their ability to cause mild stress and by doing so, activate adaptive stress 
responses (Mattson 2008). 
1.2. Hormesis 
Stress in biological systems can be defined as a perturbation of homeostasis. Homeostasis 
refers to the process of maintaining a constant internal environment. Organisms are constantly 
dealing with both externally and internally-derived stresses. Examples of stresses at the 
biochemical level include alterations in pH, osmotic pressure, gas concentrations (oxygen, 
carbon dioxide) as well as exposure to foreign compounds (xenobiotics). 
2 
 
It has long been acknowledged that a mild dose of stress can be beneficial and show the 
opposite effect of a large dose. For example, low doses of physical or mental exercise lead to 
enhanced performance, whereas high doses are debilitating (Radak et al. 2008). The 
phenomenon that small quantities of an agent cause the opposite effect of large quantities is 
known as hormesis (Calabrese et al. 2007). Calabrese and colleagues have shown that hormesis 
is a widely observed biological phenomenon (Calabrese et al. 2003; Calabrese 2008). As shown 
in Figure 1-1, typical hormetic response curves display a J or inverted U shape depending on the 
endpoint measured (Hayes 2006). The traditional dose-response relationships, the threshold 
model and linear non-threshold model, are presented for comparison. These traditional models 
are often used in toxicological studies  for extrapolation from high doses to low doses. However, 
this practice does not accurately predict the effects of low doses in situations where hormesis 
occurs. Therefore, despite the additional efforts required, testing at low doses is essential to 
accurately determine a dose response. It should be noted that hormesis is not always beneficial. 
For example, low concentrations of some anti-cancer drugs and herbicides have been shown to 
increase tumour and weed growth, respectively (Wiedman et al. 1972; Calabrese et al. 2003).  
The hormetic dose-response can occur as the result of direct stimulation, 
overcompensation in response to a disruption of homeostasis or as an adaptive response to 
protect against further insult (Calabrese 2008). By activating stress responses at low doses that 
do not overwhelm the cell, hormetic agents can increase capacity for dealing with stress 
including that from other insults. An example of such cross protection occurs in mosquito larvae 
exposed to high, but sub-lethal temperatures. These mosquitoes not only show increased 
tolerance to subsequent exposures to higher temperatures, but also show increased resistance to 
the insecticide propoxur (Patil et al. 1996).  
From an evolutionary perspective, hormetic mechanisms confer a survival advantage by 
increasing the ability to cope and adapt to environmental and internal harms. Of particular 
importance to heterotrophs is the ability to cope with noxious compounds found in the food they 
consume. 
 
3 
 
 
Figure 1-1. Dose response curves. (a) Inverted U-shaped hormetic model portraying low-dose enhancement 
and high-dose impairment of normal function. (b) J-shaped hormetic model portraying low-dose reduction and 
high-dose augmentation of adverse dysfunction. (c) The threshold model. (d) The linear non-threshold model. 
Redrawn from (Hayes 2006). 
1.2.1. Dietary hormesis 
There is increasing support for the ability of dietary agents and caloric restriction to 
prevent chronic diseases by activating hormetic pathways (Mattson 2008; Son et al. 2008). In 
other words, our diet can modulate adaptive stress responses that, in addition to protection 
potentially harmful dietary compounds, may offer protection against chronic diseases. Examples 
of the signalling pathways involved include those mediated by the transcription factors nuclear 
factor-erythroid-derived 2-related factor-2 (Nrf2) and nuclear factor of kappa light chain gene 
enhancer in β cells (NF-κB), as well as cell-survival signalling kinases and histone deacetylases 
including sirtuins. These regulatory proteins in turn influence the expression of antioxidant 
proteins, xenobiotic-metabolizing enzymes, transporters, growth factors, proteasomal proteins, 
heat shock proteins, and DNA repair enzymes.  
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Several signalling pathways may work in concert during a hormetic response. For 
example, the benefits of caloric restriction in mice include extension of life span and increased 
resistance to chemically induced carcinogenesis (Fontana et al. 2010). While sirtuin-forkhead 
box protein O (FOXO) pathways are suspected to confer life span extension, the Kelch-like 
ECH-associated protein 1 (Keap1)-Nrf2-antioxidant responsive element (ARE) pathway 
(described below) has been shown to be responsible for chemopreventive benefits (Guarente et 
al. 2005; Pearson et al. 2008). Although the upstream events that lead to the activation of these 
pathways are not completely understood it is evident that these signalling pathways form an 
integral part of the overall hormetic effect.  
1.2.2. Phytochemicals as activators of hormetic stress responses 
Plants produce an estimated 200,000 metabolites, the majority of which are specialized 
compounds called phytochemicals (Goodacre et al. 2004). These compounds are not required for 
basic metabolism and serve supplementary ecological roles such as deterring herbivory, 
communication with other plants or mutualistic microorganisms, inhibiting the growth of 
neighboring plants, combating infections, and attracting seed dispersers and pollinators (Wink 
2010).  
The diversity of phytochemicals has been exploited by humans as a primary source of 
medicines and investigational drugs. Paclitaxel (anti-cancer), morphine (analgesic) and 
artemisinin (antimalarial) are examples of important phytochemical drugs used in Western 
medicine. Additionally, plant-based medicines are integral to many widely practiced traditional 
medicines such as Ayurveda and traditional Chinese medicine. Although not all traditional 
medicines have undergone scientific scrutiny, in many cases the active phytochemicals have 
been isolated and are used as drugs today (Fabricant et al. 2001).  
Human exposure to phytochemicals is not limited to plant-derived medicines. Food 
plants, spices, tea and coffee provide dietary exposure to a wide range of phytochemicals on a 
daily basis. Along with fibre, these compounds are thought to be responsible for benefits such as 
protection against certain cancers and diseases of aging that are afforded by plant consumption.  
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As plants have historically comprised an important part of the human diet it is not 
surprising that stress responses exist for coping with exposure to a range of potentially harmful 
phytochemicals. What was unexpected however, was the finding that these same stress responses 
may protect against diseases of aging. The reason for this cross-protection is that stresses 
associated with exposure to phytochemicals, such as electrophilic metabolites, reactive oxygen 
species and inflammation, are also associated with the pathogenesis of diseases of aging. 
Activation of these stress responses is hormetic: at low doses the increased protection afforded 
by activation of the stress response outweighs the harms of exposure whereas at high doses the 
protective response is overwhelmed. Therefore it is essential to identify compounds with the 
greatest selectivity for activating a stress response as these compounds will have a large 
therapeutic window and greater overall positive effects. 
  Examples of such hormetic stress-response-activating phytochemicals include 
sulforaphane, curcumin, xanthohumol and quercetin (Uda et al. 1997; Thimmulappa et al. 2002; 
Dietz et al. 2005; Scapagnini et al. 2006). Sulforaphane is an isothiocyanate which can be 
obtained in high amounts from broccoli sprouts. Sulforaphane and related isothiocyanates impart 
the spicy taste of broccoli sprouts and other cruciferous vegetables. Curcumin I is a bright yellow 
polyphenol abundant in the roots of turmeric (Curcuma longa). Xanthohumol is a prenylated 
chalcone from hop (Humulus lupulus). Quercetin is a flavonoid found in high amounts in onions, 
and fruits such as strawberries and apples (Hertog et al. 1992). Although these compounds have 
been shown to modulate numerous cellular pathways, they share the ability to modulate what is 
emerging as an exceptionally important pathway, the Keap1-Nrf2-ARE axis (Bacon et al. 2003; 
Surh 2003; Menon et al. 2007; Dinkova-Kostova et al. 2008). 
1.3. The Keap1-Nrf2-ARE axis 
The transcription factor Nrf2 is a master regulator of cellular antioxidant and protective 
capacity (Kobayashi et al. 2006). Nrf2 directs the expression of numerous cytoprotective genes 
(see Table 1-1 for a partial list) through transcriptional enhancers called antioxidant responsive 
elements (ARE, also known as electrophile responsive elements). Examples of compounds that 
activate Nrf2-mediated transcription (Nrf2 activators) are presented in Table 1-2.  
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Table 1-1. Cytoprotective genes regulated by Nrf2 (modified from (Holtzclaw et al. 2004)) 
Gene name Cytoprotective role Reference(s) 
QUINONE REDUCTASE (QR) 
Diverts quinones from redox cycling and 
sulfhydryl depletion, maintains vitamin E 
in reduced form, stabilizes p53 
(Ross et al. 2000) 
GLUTATHIONE S-TRANSFERASES 
Conjugates electrophiles, detoxifies 
oxidants, reduces peroxides, regenerates 
reduced ascorbate 
(Talalay et al. 1978; Kelly et 
al. 2000) 
HEME OXYGENASE-1 (HO-1) 
Rate limiting step in heme degradation 
leading to production of the protective 
molecules bilirubin and carbon monoxide 
(Gong et al. 2002) 
-GLUTAMYLCYSTEINE 
SYNTHETASE 
GSH synthesis (Mulcahy et al. 1995) 
GLUTATHIONE REDUCTASE Regenerates reduced glutathione (Ansher et al. 1986) 
GLUTATHIONE CONJUGATE 
EXPORTER 
Eliminates glutathione conjugates (Bock et al. 2000) 
THIOREDOXIN Reduces oxidants (Kim et al. 2001) 
THIOREDOXIN REDUCTASE Regenerates reduced thioredoxin (Cho et al. 2004) 
UDP-
GLUCURONOSYLTRANSFERASES 
Conjugates UDP to electrophiles 
(Talalay et al. 1978; Bock et 
al. 2000) 
AFLATOXIN ALDEHYDE 
REDUCTASE 
Detoxifies aflatoxin B1 (Kelly et al. 2000) 
DIHYDRODIOL 
DEHYDROGENASE 
Epoxide metabolism (Ciaccio et al. 1994) 
CATALASE Converts hydrogen peroxide to molecular 
oxygen and water 
(Otieno et al. 2000; Cho et al. 
2005) 
SUPEROXIDE DISMUTASE 
Converts superoxide to hydrogen 
peroxide 
(Otieno et al. 2000) 
FERRITIN Sequesters Fe 
(Pietsch et al. 2003; Cho et al. 
2005) 
MULTIDRUG RESISTANCE 
PROTEINS 1 AND 2 
Export of xenobiotics 
(Bock et al. 2000; Cho et al. 
2005) 
LEUKOTRIENE B4 
DEHYDROGENASE 
Suppresses inflammation (Primiano et al. 1998) 
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Table 1-2. Endogenous Nrf2 activators 
Compound Structure Class Reference 
15-Deoxy-Δ12,14-
prostaglandin J2 
 
Prostaglandin 
(Kim et al. 
2008) 
Nitric oxide  Gas 
(Buckley et al. 
2008) 
S-Nitrosocysteine 
 
Cysteine-gas adduct 
(Buckley et al. 
2008) 
Table 1-3. Plant-derived Nrf2 activators 
Plant compound Structure Class Sources Reference 
Quercetin   
 
Flavonoid 
Fruits, 
onion 
(Lee-Hilz et al. 
2006) 
Sulforaphane 
 
Isothiocyanate Broccoli 
(Thimmulappa 
et al. 2002) 
Xanthohumol 
 
Chalcone Hop 
(Dietz et al. 
2005) 
Resveratrol 
 
Stilbene Grape 
(Kode et al. 
2008) 
Ixocarpalactone A 
 
Withanolide Tomatillo (Su et al. 2004) 
Curcumin I 
 
Polyphenol Turmeric 
(Scapagnini et 
al. 2006) 
8 
 
 Figure 1-2. Regulation of Nrf2 by Keap1. (A) Under basal conditions Nrf2 associates with Keap1 and is 
ubiquitylated by the ubiquitin ligase, Cullin3, and consequently degraded. (B) Nrf2-activators, such as the 
withanolide depicted here, cause a conformational change in Keap1 such that Cullin3 can no longer 
ubiquitylate Nrf2. Inhibition of Nrf2 degradation leads to the accumulation of Nrf2 and the activation of Nrf2 
targeted genes.  
Nrf2 is constitutively expressed and under basal conditions is degraded by the ubiquitin 
proteasomal pathway with a half life of less than 20 min (Kobayashi et al. 2006). A cytosolic 
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protein, Keap1, mediates the degradation of Nrf2 by acting as an adapter for a Cullin3-based 
ubiquitin ligase (Figure 1-2) (Kobayashi et al. 2004; Zhang et al. 2004). Ubiquitin ligases are 
proteins that regulate, often with the co-operation of an adapter protein, the abundance of target 
proteins by mediating their ubiquitylation. Ubiquitylation then serves as a signal for the 
proteasomal degradation of the target protein, in this case Nrf2. 
Keap1 possesses several reactive cysteine residues. Modification of these cysteine 
residues by Nrf2 activators such as sulforaphane (Tables 1-2 and 1-3), interferes with the ability 
of Keap1 to function as a ubiquitin ligase adapter and thus stabilizes Nrf2. Nrf2 then translocates 
to the nucleus and directs transcription of genes that possess an ARE. Although it is clear that 
Nrf2 is a vital component of the adaptive stress machinery, some of the details regarding the 
regulation of this transcription factor and the related implications for human health await 
investigation. Here I briefly summarize the discovery and current state of knowledge regarding 
the Keap1-Nrf2-ARE axis. 
1.3.1. The discovery of Nrf2 and its targets 
The discovery of Nrf2 was a result of the investigation of xenobiotic detoxification. The 
detoxification of xenobiotics often involves metabolism to make the compound more polar and 
therefore, more easily excreted. Classically, xenobiotic metabolism is divided into two phases 
(Williams 1959). First, polar functionalities are introduced by phase I enzymes which include 
many cytochrome P450 superfamily enzymes. Phase II (conjugating) enzymes then add large 
polar moieties such as glucuronic acid, sulphate, acetate or glutathione to the products of phase I 
metabolism thereby deactivating and assisting elimination of the xenobiotic. 
Investigation of the promoter regions of several phase II genes led to the identification of 
a common regulatory sequence. This sequence was named the ARE as it was responsive to 
several phenolic antioxidants (Rushmore et al. 1990; Favreau et al. 1991). Similarity of the ARE 
motif to the binding motif of the transcription factor, nuclear factor-erythroid derived 2 (NF-E2), 
led to the investigation of transcription factors related to NF-E2 and the subsequent identification 
of Nrf2 as the primary mediator of gene expression through the ARE (Itoh et al. 1997). Nrf2 has 
been identified in several vertebrates including human, rat, mouse, chicken, zebrafish, and the 
African clawed frog (Malik et al. 2009).  
10 
 
1.3.2. Insights from Nrf2
-/- 
mice 
Nrf2
-/-
 mice are viable and can survive under normal laboratory conditions. However, 
these mice commonly develop lupus-like autoimmune disorders (Ma et al. 2006) and display 
increased sensitivity to acute toxicity, carcinogen exposure, as well as inflammation and 
oxidative stress. Unlike Nrf2
+/+
 mice, Nrf2
-/-
 mice are not protected from these insults by dietary 
Nrf2 activators (Kobayashi et al. 2006). Nrf2-deficient mice display increased acetaminophen-
induced hepatotoxicity (Enomoto et al. 2001), diesel exhaust-induced DNA adduct formation 
(Aoki et al. 2001), cisplatin-induced nephrotoxicity (Liu et al. 2009), damage from ischemia 
reperfusion in kidney and brain (Shih et al. 2005; Liu et al. 2009), elastase-induced pulmonary 
inflammation and emphysema (Ishii et al. 2005), chemically-induced skin papilloma (auf dem 
Keller et al. 2006) and streptozotocin-induced diabetic nephropathy (Jiang et al. 2010) and are 
unable to efficiently resolve inflammation (Itoh et al. 2004). 
Microarray analyses of Nrf2
-/-
 mice have led to the discovery that in addition to 
antioxidant proteins and xenobiotic metabolizing enzymes Nrf2 also regulates the transcription 
of heat shock proteins, proteasomal subunits, transporters, enzymes involved in regeneration  of 
reduced nicotinamide adenine dinucleotide phosphate (NADPH) and primary metabolism, as 
well as numerous kinases, phosphatases, transcription factors, immunity related proteins, cell 
adhesion proteins, cell cycle and growth regulating proteins (Li et al. 2002; Thimmulappa et al. 
2002; Kwak et al. 2003; Lee et al. 2003; Lee et al. 2003; Kraft et al. 2004; Li et al. 2004; Cho et 
al. 2005; Hu et al. 2006; Hu et al. 2006; Shen et al. 2006; Yates et al. 2009). Subsequently, direct 
evidence for Nrf2-regulation of some of these genes has been reported (Pietsch et al. 2003). 
Thus, Nrf2 has a multifaceted set of targets that increase the capacity of the cell for 
dealing with both endogenous and exogenous chemical insults: phase II xenobiotic-metabolizing 
enzymes deactivate harmful xenobiotics; antioxidant proteins and enzymes neutralize reactive 
oxygen and nitrogen species and bolster the levels of intracellular small molecule antioxidants 
such as glutathione; efflux transporters remove products of phase II metabolism; influx 
transporters provide the necessary compounds to enable the above responses (i.e. entry of the 
amino acids necessary for glutathione synthesis) and heat shock proteins and the proteasome aid 
in the refolding or elimination of denatured proteins caused by reactive oxygen species (ROS) or 
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reactive metabolites. In addition, regulation of the cell signalling machinery including kinases, 
phosphatases, transcription factors, and proteins regulating cell cycle and growth allow for 
coordination of cellular events.  
As the cellular harms of inflammation and xenobiotic exposure are often the same, (e.g. 
electrophiles, reactive oxygen species, dysfunctional proteins) it makes sense that there is a 
convergence of the response to these superficially different stresses through Nrf2 activation. 
Exploiting this convergence is the basis for using dietary Nrf2 activators for disease prevention 
as controlled activation of Nrf2 by dietary agents will confer cross-protection against 
inflammation and redox stress that are thought to underlie the development of chronic diseases. 
How are these different stimuli integrated into a single consolidated Nrf2-driven 
response? Keap1, the sensor protein regulating the cellular abundance of Nrf2, is responsive to 
both electrophilic endogenous signalling molecules and electrophilic xenobiotics. 
1.3.3. Regulation of Nrf2 by Keap1 
In 1999, it was noted that disruption of the N-terminal domain of Nrf2 enhanced the 
activity of Nrf2 and was hypothesized that this domain may interact with a negative regulator 
(Itoh et al. 1999). This repressor was identified by yeast-2-hybrid screening and named Keap1 
(Itoh et al. 1999). Constitutive activation of Nrf2 in Keap1
-/- 
mice verified the repression of Nrf2 
by Keap1 (Wakabayashi et al. 2003). 
Keap1 possesses numerous cysteine residues (25 in mouse, 27 in human), several of 
which are highly reactive toward electrophiles due to their proximity to basic residues (Snyder et 
al. 1981; Itoh et al. 2004). Keap1 represses Nrf2 by acting as an adapter for a Cullin3-based 
ubiquitin ligase thereby directing Nrf2 degradation (Figure 1-2) (Cullinan et al. 2004; Kobayashi 
et al. 2004). Small molecule Nrf2 activators are thought to cause a conformational change in the 
structure of Keap1, which impairs the ability of Keap1 to direct the ubiquitylation of Nrf2 and 
may result in ubiquitylation of Keap1 itself (Eggler et al. 2005). This model is supported by 
experiments using a protein synthesis inhibitor showing that only de novo synthesized Nrf2 
translocates to the nucleus and by experiments showing that proteasome inhibitors lead to the 
nuclear accumulation of Nrf2 (Stewart et al. 2003; Kobayashi et al. 2006). 
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1.3.3.1. Keap1 and Nrf2 structure 
High resolution structures of Keap1 and Nrf2 are not available, although a low-resolution 
cryo-EM-based structure was recently published for mouse Keap1 ((Ogura et al. 2010) Figure1-
3). Keap1 possesses several distinct domains; a Broad complex-Tramtrac-Bric-a-brac (BTB) 
domain near the N-terminus is necessary for dimerization and interaction with Cullin3, a double 
glycine repeat (DG) domain which is necessary for interaction with Nrf2 and an intervening 
region (IVR) (Figure 1-3). 
 
 
Figure 1-3. Keap1 and Nrf2 structures. A) Cartoon depicting important domains and regions of Keap1 
(green, shown as a dimer) and Nrf2 (blue). BTB = Broad complex-Tramtrac-Bric-a-brac, IVR = intervening 
region, DG = double glycine repeat, ETGE = glutamic acid-threonine-glycine-glutamic acid, DLG =  aspartatic 
acid-leucine-glycine.B) Keap1 dimer cryo-EM density map superimposed on the x-ray diffraction-based 
structure of the Keap1-DG domain (orange or red). Modified from (Ogura et al. 2010). 
Nrf2 possesses two motifs, DLG (aspartatic acid-leucine-glycine) and ETGE (glutamic 
acid-threonine-glycine-glutamic acid), that can bind a Kelch motif of the Keap1 DG domain, 
albeit with 100-fold difference in affinity (Tong et al. 2006; Tong et al. 2006; Tong et al. 2007). 
The “hinge and latch model” proposes that the high affinity ETGE-Kelch interaction functions as 
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a hinge whereas the lower affinity DLG-Kelch interaction (on the other Keap1 monomer) 
functions as a latch that can be opened by modification of Keap1 such that the lysines on Nrf2 
targeted for ubiquitylation are out of reach of the Cullin3 ubiquitin ligase. Consistent with this 
model, the lysine residues that are ubiquitylated in Nrf2 lie between the DLG and ETGE motifs 
(Zhang et al. 2004). 
1.3.3.2. Modification of Keap1 cysteines results in impaired ubiquitylation of Nrf2 
Modification of cysteine residues of Keap1, either by alkylation or oxidation, has long 
been thought to be the molecular sensor for electrophilic compounds. Due to the presence of 
electron withdrawing groups, electrophilic compounds have a region that is deficient in electrons 
and are susceptible to reactions with nucleophiles, which are electron-rich. Under basic 
conditions, the thiol group of cysteine is deprotonated to form the thiolate ion which is an 
effective nucleophile. As several of the cysteines of Keap1 are flanked by basic residues, these 
cysteines are particularly reactive with electrophiles. 
Multiple classes of compounds have been shown to activate Nrf2 and all share the feature 
of being thiol reactive or having metabolites that are thiol reactive (Linnewiel et al. 2009). 
Furthermore, the potencies of inducers parallels their reactivity with thiol groups (Dinkova-
Kostova et al. 2001). Mass spectrometric identification of Keap1 adducts with various 
electrophiles have identified a handful of cysteines that are often alkylated (Luo et al. 2007; 
Kansanen et al. 2009). Three of these Keap1 cysteines (Cys151, Cys273 and Cys288) are 
required for suppression of Nrf2 in vivo (Yamamoto et al. 2008). In addition, using mutant 
Keap1 protein with various amino acid substitutions for Cys151, Eggler et al. (2009) reported 
that the molar volume of the residue at this position is positively correlated with the magnitude 
of response of an ARE-luciferase reporter, suggesting that a greater bulk of modification leads to 
increased interference with Nrf2 ubiquitylation.  
Some insight into the roles played by individual cysteines was achieved by investigating 
the two homologues of Keap1 found in zebrafish (Kobayashi et al. 2009). Both homologues, 
Keap1a and Keap1b, regulate Nrf2 degradation but differ in their specificities for Nrf2 activators 
(Kobayashi et al. 2009). Keap1a possesses a cysteine equivalent to Cys273 in human Keap1 and 
is only responsive to the endogenous Nrf2 activators, prostaglandins 15d-PGJ2 and PGA2 
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(Kobayashi et al. 2009). Conversely, Keap1b, possesses a cysteine equivalent to Cys151 in 
human, and is responsive to numerous xenobiotics including sulforaphane, 1,2-napthoquinone 
andebselen (Kobayashi et al. 2009). Thus, it appears that Keap1 has multiple “sensing” cysteines 
capable of responding to different compounds and perhaps even discriminating between 
endogenous signalling compounds and xenobiotics. Indeed, an analysis of the cysteines modified 
in vitro by various agents supports this hypothesis since 15d-PGJ2 and PGA2 alkylate Cys273, 
whereas many dietary compounds alkylate Cys151 (Kansanen et al. 2009). 
The current structural evidence for Keap1 suggests that Cys272 and Cys288 are in close 
proximity to the Kelch motif. As the Kelch motif appears to be involved in binding Nrf2, these 
cysteines residues may be positioned for triggering a shift in the structure of Keap causing‘the 
latch to open’. Cys151, on the other hand, is far from this substrate binding region on the stem of 
the ‘cherry’ (BTB domain). Modification of Cys151 is therefore unlikely to interfere with 
binding of Keap1 to Nrf2 and may alternatively interfere with interactions between Keap1 and 
the Cullin3 ubiquitin ligase . 
1.3.4. Regulation of Nrf2 and Keap1 via phosphorylation 
Phosphorylation is thought to provide a limited contribution to Nrf2 stability and 
transcriptional activity (Sun et al. 2009). A number of kinases have been shown to phosphorylate 
Nrf2 including PKR-like endoplasmic reticulum kinase (PERK), protein kinase C, casein kinase-
2, phosphatidylinositol 3-kinase, mitogen-activated protein kinase (MAPK) and p38 (Lee et al. 
2001; Huang et al. 2002; Cullinan et al. 2003; Cullinan et al. 2004; Andreadi et al. 2006; Apopa 
et al. 2008). Phosphorylated residues include Ser40, Ser215, Ser408, Ser558, Thr559 and Ser577 
(Huang et al. 2002; Sun et al. 2009). 
Keap1 is also phosphorylated in vivo at the conserved Tyr141 which may be required for 
recruitment of Cullin3 (Jain et al. 2008). In addition, treatment with hydrogen peroxide resulted 
in the removal of this phosphate, suggesting that stress-induced dephosphorylation of Keap1 may 
be another sensory mechanism. In addition, modulation of nuclear export and import signals in 
Nrf2 and Keap1 by either phosphorylation or alkylation may also be important for controlling 
Nrf2 activity (Jain et al. 2005; Velichkova et al. 2005). 
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1.3.5. Nrf2 activators and anti-inflammation 
A striking positive correlation exists between the anti-inflammatory activity and potency 
of Nrf2 activators in mouse macrophages and embryonic fibroblasts (Dinkova-Kostova et al. 
2005; Liu et al. 2008). This correlation suggests the presence of a common target and/or 
mechanism of action.  
There are at least three mechanisms by which Nrf2 activators can effect anti-
inflammation. Firstly, through upregulation of anti-inflammatory targets of Nrf2 such as heme 
oxygenase-1 (HO-1) (Gong et al. 2002). Secondly, increased levels of Nrf2 may reduce the 
activity of the inflammatory transcription factor NF-κB by competing for the co-activator cAMP 
response element-binding protein (CBP) (Liu et al. 2008). And finally, by inhibiting NF-κB by 
covalently modifying cysteines present in its DNA-binding domain and/or the activation loop of 
the NF-κB activating protein, inhibitor of NF-κB kinase (IκK)-α, as has been documented for 
sulforaphane, xanthohumol and bardoxolone methyl (Heiss et al. 2001; Ahmad et al. 2006; 
Harikumar et al. 2009). 
1.3.6. Phase I metabolism and AhR activation 
Although phase I (oxidation) and phase II (conjugation) enzymes often work in concert to 
eliminate xenobiotics, they are regulated by different transcription factors. While phase II 
enzymes are regulated as part of the Nrf2 regulon, phase I enzymes are regulated by multiple 
transcription factors including the aryl-hydrocarbon receptor (AhR). The AhR is ligand 
activated, with a preference for planar aromatic compounds such as dioxin or benzo(a)pyrene, 
and directs transcription through its cognate binding element, the xenobiotic-responsive element 
(XRE) (Denison et al. 2003). Well described targets of the AhR include cytochrome P450 
(CYP)-1A1, CYP1A2, and CYP1B1. The AhR also provides feed-forward activation of Nrf2 via 
XREs in the Nrf2 promoter (Miao et al. 2005). 
The AhR is also involved in endocrine regulation. The enzymes CYP1A1 and CYP1B1 
are involved in estrogen metabolism (Dannan et al. 1986; Spink et al. 1992). Furthermore, 
activation of the AhR can interfere with estrogen receptor activity through competition for 
cofactors. An additional negative aspect to AhR activation is the potential of AhR targets to 
cause bioactivation of xenobiotics to harmful compounds (Shimada et al. 1996). 
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As the structural features required for inducing the AhR (planar aromatic) and Nrf2 
(electrophilic) are not mutually exclusive it is possible for a single compound (i.e. planar 
aromatic and electrophilic) to activate both transcription factors. Due to the negative health 
consequences associated with exposure to AhR activators, compounds that activate Nrf2 without 
activating the AhR are predicted to confer greater health promoting benefits.  
Importantly, the enzyme that I use for identifying Nrf2 activators in this work, quinone 
reductase (QR), is a target of both the AhR and Nrf2 (Favreau et al. 1991). In order to identify 
selective Nrf2 activators it is important to exclude AhR regulation as a possible means of QR 
induction. 
1.3.7. The role of Nrf2 activators in chronic disease prevention 
Though much remains to be resolved regarding the molecular dynamics of Nrf2 
activation, it is clear that this transcription factor plays an essential role in protection against 
electrophile and oxidative stresses and therefore is expected to play a role in the development of 
chronic diseases in which such stresses are implicated. Indeed, Nrf2 activators or direct Nrf2 
activation are protective in animal models of brain injury (Zhao et al. 2007), hypertension (Wu et 
al. 2004), colon cancer (Yuan et al. 2007), and cardiac hypertrophy (Li et al. 2009). Cell culture 
models have also demonstrated protection by Nrf2 activators against ultraviolet (UV)-A 
radiation (Kimura et al. 2009), cigarette smoke (Kode et al. 2008), glutamate excitotoxicity (Li et 
al. 2007), spinal cord injury (Liu et al. 2008), aflatoxin B1 cytotoxicity (Pokharel et al. 2006) and 
cisplatin cytotoxicity (So et al. 2006).  
In the case of protection in an rat model of cardiovascular disease, supplementation with 
broccoli sprouts, a rich source of the Nrf2 activator sulforaphane, also conferred protection to the 
offspring of female test animals regardless of the offspring diet suggesting that the modifications 
of gene expression effected by Nrf2 activators may have long-lasting, epigenetic effects (Noyan-
Ashraf et al. 2006). 
Several clinical trials are in progress examining the effect of the Nrf2 activators 
sulforaphane and bardoxolone methyl in clinical conditions where ROS stress or inflammation 
are involved such as chronic kidney failure in patients with diabetes or chronic obstructive 
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pulmonary disorder (Reata Pharmaceuticals 2012). Previous clinical trials with the compound 
oltipraz were not successful, however this compound was much less potent than sulforaphane or 
bardoxolone methyl (effective in vitro concentrations of 15 µM (oltipraz) vs. 0.2 µM 
(sulforaphane) or 0.002 µM (bardoxolone methyl)). Phase 2 trials of bardoxolone methyl showed 
that this compound effectively restores kidney function in diabetics with chronic kidney disease 
and is currently in phase 3 clinical trials (Pergola et al. 2011; Reata Pharmaceuticals 2012).  
Although the results with bardoxolone methyl are promising, the results of sulforaphane-
based interventions will also be of great interest. In contrast to bardoxolone methyl, which is a 
synthetic patented drug, sulforaphane is readily available through broccoli and other cruciferous 
vegetables. As sulforaphane is a benchmark for diet-based Nrf2 activation, the results of these 
trials will provide valuable evidence to support or refute the use of a dietary approach to 
reducing inflammation and oxidative stress for chronic disease prevention. 
Serum concentrations of sulforaphane that are required for activity in vitro can be 
achieved relatively easy as its precursor, glucoraphanin, is abundant in broccoli sprouts (~300 
µmol/g dry weight), has a high bioavailability (approximately 80%) and the concentrations 
required for activity are quite low (Fahey et al. 1997). The concentration of sulforaphane 
required to double activity of QR (CD) in vitro is approximately 0.2 µM. More modest increases 
in activity, such as a 25% or 50%, can be achieved at 0.05 or 0.1 µM. A dose of 40 g of broccoli 
sprouts (150 µmol of the sulforaphane precursor glucoraphanin) in humans leads to peak serum 
concentrations (including metabolites) greater than 2 µM (Clarke et al. 2011). In contrast, 
quercetin has a CD value of 13 µM, a concentration that is likely never achieved under an 
average diet. Consumption of a large portion of fried onions (340 g fresh weight) with 224 µmol 
(68 mg) equivalents of quercetin only led to an average peak plasma concentration of 0.74 µM 
(Hollman et al. 1997).  
Another consideration is that the local exposure concentration to a xenobiotic may greatly 
exceed systemic concentration. It may be possible for lower exposures of an Nrf2 activator to 
cause an effect in these tissues and furthermore, as these same tissues are more prone to exposure 
to potentially harmful xenobiotics, may afford a higher relative level of protection against 
carcinogenesis in these tissues. Consistent with this hypothesis, cancers of the digestive tract 
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such as the stomach and colon appear to be the most effected by fruit and vegetable consumption 
(WCRF-AICR 2007). 
 
1.4. Objectives 
Despite the importance of the Nrf2-ARE axis in the dietary hormetic response, much 
remains to be learned regarding the diversity of Nrf2 activators, their mechanism of action, and 
their overall effects on the cell and organism. This study aimed to expand our understanding of 
the distribution and mechanism of action of Nrf2-activating phytochemicals by: 
1) Identifying plant extracts that have potent QR-inducing activity, a proxy for Nrf2 induction. 
2) Isolating the active components from active extracts using QR-bioassay-guided fractionation 
and identifying the purified compounds using UV spectrometry, NMR and mass spectrometry 
3) Investigating the mechanism of action of the purified compounds by studying their effects on 
Keap1 (or models of Keap1 cysteines) and on transcript levels using qRT-PCR and RNA-seq.  
 
  Hypotheses to be tested:  
1) Induction of the antioxidant enzyme QR by plant extracts will not be correlated with their 
direct antioxidant potential. 
2) QR inducing activity will be due to induction of the Keap1-Nrf2-ARE axis caused by covalent 
modification of cysteine thiols of Keap1. 
3) Treatment with QR inducing compounds will lead to changes in transcript levels of genes that 
are known to be controlled by Nrf2. 
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CHAPTER 2 
SCREENING WESTERN CANADIAN PLANTS FOR QR INDUCING ACTIVITY 
2.1. Introduction 
As discussed in Chapter 1, activating Nrf2 through pharmacological or dietary means is a 
promising approach to prevent or delay diseases that involve inflammation or oxidative stress. In 
order to expand the number of lead compounds for drug development and provide informed 
dietary guidance with respect to activating Nrf2, a greater understanding of the distribution and 
potency of Nrf2 activators in plants is necessary. 
2.1.1. The Canadian flora 
Canada is home to over 3000 native plant species, 147 of which are endemic (WCMC 
1994). To my knowledge, no screen examining the Canadian flora has been undertaken for Nrf2 
activators. I focused on the Western Canadian flora because of the ready access to plant material 
and regional relevance. 
2.1.2. QR induction as a guide for identifying Nrf2-activating extracts 
Screening for Nrf2 activation directly using Western blots or electromobility shift assays 
is not practical for a large screen. Measuring changes in the level of a downstream target of Nrf2 
such as the level of a transcript or protein can simplify the screening process. I chose to use the 
enzymatic activity of the Nrf2 target QR as a marker for Nrf2 activation. 
QR is an enzyme that plays multiple protective roles in animal cells (reviewed in 
(Dinkova-Kostova et al. 2010)). QR prevents the redox-cycling of quinones and associated 
generation of reactive oxygen species by catalyzing the two-electron reduction of quinones using 
either NADH or NADPH. The corresponding hydroquinones can then be acted on by 
conjugating enzymes which halts the redox-cycling process. QR also possesses superoxide 
scavenging activity (Siegel et al. 2004) and prevents the degradation of the tumor suppressor p53 
by acting as a gatekeeper for the 20S proteasome (Asher et al. 2005). 
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Many of the Nrf2 activators identified to date were isolated using QR induction as a 
guide (Fahey et al. 2004). Examples include isothiocyanates from broccoli, wasabi and 
watercress, curcumin from turmeric, resveratrol from grapes, and withanolides from tomatillo 
(Fahey et al. 2004). The ‘Prochaska’ assay is a commonly used method for quantifying QR 
activity. This protocol involves treating mouse Hepa-1c1c7 cells (grown in 96-well plates) with 
the compound or extract of interest and harvesting the cells after 24 or 48 h. Cells are lysed and 
QR activity and protein concentration are determined via chromogenic reactions. The QR 
activity of treated cells is compared to solvent-treated controls to determine the level of QR 
induction. Hepa-1c1c7 cells are used because of their high inducibility and similarity to 
hepatocytes (Hankinson 1979; De Long et al. 1986).  
 
Figure 2-1. QR bioassay reaction scheme. Cell lysates are incubated with menadione, MTT and an NADPH 
regenerating system consisting of glucose-6-phosphate, NADP and glucose-6-phosphate dehydrogenase. Using 
NADPH, QR reduces menadione to menadiol. Menadiol then spontaneously reduces MTT. The concentration 
of reduced MTT is measured spectrophotometrically at 595 nm. 
  The chromogenic reaction that forms the basis of the ‘Prochaska’ assay is shown in Figure 
2-1. QR catalyzes the reduction of menadione to menadiol which in turn reduces the dye 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The level of reduced MTT is 
measured by absorbance at 595 nm. The other substrate for the QR catalyzed reaction, NADPH, 
is produced enzymatically using glucose-6-phosphate dehydrogenase and glucose-6-phosphate. 
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The protein concentration is determined for each lysate to correct for differential growth and 
variation in the number of cells plated per well.  
2.1.3. Direct antioxidant activity vs. indirect antioxidant activity  
Nrf2 activators are of interest because they increase the cellular capacity for dealing with 
oxidative stresses and resolving inflammation. As such Nrf2 activators have also been referred to 
as “indirect antioxidants” (Dinkova-Kostova et al. 2008). Conversely, direct antioxidants such as 
β-carotene, flavonoids, vitamins C and E that react directly with free radicals have also received 
attention as a means to combat oxidative stress. A primary difference is that direct antioxidants 
prevent redox signalling in general whereas Nrf2 activators activate an adaptive stress response 
that increases the ability to cope with the various stressors associated with redox signalling (Lee 
et al. 2003; Wu et al. 2011).  
Although several studies have shown that high concentrations of antioxidants are 
protective in vitro, supplementation with antioxidants in vivo has largely failed as a means to 
prevent chronic disease (Bjelakovic et al. 2007). Several large intervention trials with direct 
antioxidants (vitamins C, E and beta-carotene) have shown that supplementation with relatively 
large doses have no effect on mortality from cancer or cardiovascular disease (Sesso et al. 2008; 
Lin et al. 2009) and that beta-carotene may increase lung cancer risk in smokers (Jeon et al. 
2011). A recent study showed that daily supplementation with 400 IU of vitamin E and 1000 mg 
of vitamin C greatly reduced the benefit of exercise as judged by sensitivity to insulin (Ristow et 
al. 2009). Despite the lack of clinical evidence to support their use, direct antioxidants continue 
to be widely marketed. 
Phytochemicals with direct antioxidant activity can possess additional biological 
activities. For instance, compounds such as quercetin and epigallocatechin-gallate are direct 
antioxidants as well as being Nrf2 activators. In fact, the ARE to which Nrf2 binds is so called 
because the first compounds known to activate it were phenolic antioxidants such as t-
butylhydroquinone (Rushmore et al. 1990). However, as not all Nrf2 activators are antioxidants, 
the name ARE is misleading. The lesser-used name ‘electrophile responsive element’ is more 
accurate. Despite this, I have chosen to use ARE in this work due to its greater prevalence in the 
literature. 
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Despite their different modes of action, direct antioxidants and Nrf2 activators share a 
limited degree of structural similarity. Direct antioxidants require functional groups to stabilize 
the molecule following acceptance or donation of an electron. On the other hand, Nrf2 activators 
require functional groups that provide an electrophilic center that can modify cysteine residues of 
Keap1. Functional groups such as carbonyls or conjugated π-bonds can contribute in both 
situations. Therefore, although limited, there exists some rational for the hypothesis that extracts 
with potent direct antioxidant activity are more likely to activate Nrf2. To test this hypothesis I 
have chosen to assay the panel of extracts for direct antioxidant capacity and compare with QR 
induction, my proxy for Nrf2 activation.  
Several methods to assay direct antioxidant activity involve a compound for which the 
visible light absorbance differs greatly between its radical and non-radical forms. Examples 
include the diphenylpicrylhydrazyl (DPPH) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-
sulphonic acid (ABTS) reagents. I have chosen to use the DPPH assay as it is compatible with 
the extraction solvent used for screening (methanol) and it is widely used (Cheng et al. 2006). 
2.1.4. Selection of plant material for screening 
Since closely related plants display similar phytochemical compositions, a variety of 
plant species is desirable to increase the effective number of compounds being screened. 
Availability and ecological status (i.e. endangered or abundant) are also important to consider. 
Plants with distributions limited to Western Canada were favored over widespread species. 
Phytochemical variation occurs between different plant parts and between individuals of 
the same species. Therefore collecting the whole plant or multiple plant parts and using several 
individuals from different growing conditions ensures that the variety of compounds produced by 
a given species is represented in an extract. 
2.1.5. Drying, grinding and extraction of plant material 
Drying plants prior to extraction is essential for standardizing yields and facilitating 
extraction. To avoid decomposition of thermolabile compounds I have selected 37°C as a 
maximal temperature for drying. Compounds that rapidly decompose at or below 37°C are less 
desirable as they would also decompose in the human body. 
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The diversity of plant natural products provides a challenge when selecting a single 
solvent for extraction. Previous screens for bioactive plants have used extraction solvents with 
intermediate polarity such as methanol, ethanol or ethyl acetate which result in extracts enriched 
in compounds of intermediate polarity. This is beneficial as compounds with intermediate 
polarity possess functional groups required for bioactivity while being of low enough polarity to 
penetrate biological membranes. I chose methanol as an extraction solvent. 
Filtered methanolic extracts are appropriate for chemical assays such as the DPPH assay 
(Cheng et al. 2006). However, biological assays cannot tolerate high concentrations of organic 
solvents. I have chosen to completely remove methanol and resuspend in dimethylsulfoxide 
(DMSO) for biological assays. Advantages to using DMSO include its relatively low toxicity 
(safe to use in most cell lines up to 1% v/v), its ability to dissolve a large range of compounds 
and the fact that it has very low volatility. Low volatility is desirable when resuspension volumes 
are small and the solution may be stored between use. To facilitate throughput, a specific volume 
of extract, rather than specific mass of dried extract was used during DMSO stock preparation. 
2.2. Materials and methods 
2.2.1. Preparation of extracts and samples for screening 
Plant material was collected in the wild or purchased through plant suppliers or grocers. 
The location of harvest or source for each plant was recorded. Plants were identified by Nick Page, 
Jonathan Page or David Konkin. Plant tissue was cut into small pieces and dried at 37°C. Dried 
material was ground with a coffee grinder, screened at 0.5 mm and extracted with 8.3 mL methanol 
per g of plant material. Extraction was conducted in the dark with stirring for 24 h prior to vacuum 
filtration using Whatman #1 filter paper and Millipore Spin-X centrifugal filtration. One-mL of 
filtered extract was dried under vacuum at room temperature and resuspended in 50 µL or 30 µL of 
DMSO. A sample of filtered methanolic extract was used for the DPPH radical scavenging assay. 
Unless otherwise specified, chemicals were obtained from Sigma-Aldrich. 
2.2.2. Cell culture 
Hepa-1c1c7 cells (American type culture collection) were maintained in 75 cm
2
 flasks 
using α-minimal essential medium without nucleosides containing Glutamax (Invitrogen) 
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supplemented with 10% charcoal-treated fetal bovine serum (FBS) (Spencer et al. 1990), 100 
U/mL penicillin G and 100 µg/mL streptomycin in a humidified incubator at 37°C and 5% CO2. 
Cells were subcultured at 70-80% confluency using trypsin-ethylenediaminetetraacetic acid 
(EDTA) solution. Early divisions of the culture (< 20 passages) were used for bioassays. Cultures 
were stored in liquid nitrogen with 5% DMSO.  
2.2.3. QR bioassay 
Hepa-1c1c7 cells were grown in 96-well plates at approximately 5000 cells per well in 200 
µL medium. After 24 h the medium was replaced and dilutions of pure compounds or extracts 
dissolved in DMSO were added to the medium. The final concentration of DMSO was 0.1% (v/v). 
Dilutions were tested in duplicate. After 48 h the cells were rinsed with 200 µL of Dulbecco’s 
phosphate buffered saline (D-PBS) and 50 µL of a solution containing 0.08% digitonin and 2 mM 
EDTA (pH 7.8) was added to each well. The solution was incubated for 10 min at 37°C followed 
by 10 min at room temperature with orbital shaking. Thirty-µL of lysate was used for the QR assay 
as previously described (Prochaska et al. 1988) and 20 µL was used for protein determination 
using bicinchoninic acid (Smith et al. 1985). Experimental QR activities were compared to the 
activities of DMSO treated controls. Concentrations required to double activity were determined 
by plotting the dose-response curve and identifying the concentration at which the curve 
intersected a two-fold increase in activity. QR measurements were discarded at concentrations 
that reduced protein content to less than 50% of the control value. 
2.2.4. DPPH radical scavenging assay 
The DPPH bioassay was adapted from the procedure used by Ursini et al. (1994). Using 
methanol, 8 or more two-fold serial dilutions were prepared from each methanolic extract. One-
hundred-µL of 100 µM DPPH (Sigma-Aldrich) radical in methanol was added to 10 μL of each 
dilution in 96-well plates. After a 10 min incubation at room temperature the absorbance at 530 nm 
was measured. A separate dilution series of each extract prepared in methanol was prepared to 
correct for the absorbance of the extract at 530 nm. Ten-µL of methanol or 50 mM ascorbic acid in 
methanol was used to determine the assay start and endpoints, respectively. The inhibitory 
concentration required to reduce the radical concentration by 50% (IC50) values were calculated by 
logarithmic regression. 
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2.3. Results and discussion 
2.3.1. Optimization of the QR bioassay 
The QR bioassay was validated using sulforaphane as a positive control. Several 
experimental parameters were examined in order to ensure robustness and reproducibility. A 48 
h incubation with inducers led to greater intensity of response than a 24 h incubation. A longer 
incubation time may allow a greater accumulation of QR. Using fetal bovine serum treated with 
activated charcoal slightly reduced the basal level of induction (Figure 2-2). This may be due to 
the removal of Nrf2 activators such as cyclopentenone prostaglandins, J2-isoprostanes or nitric 
oxide (Kim et al. 2006; Gao et al. 2007; Liu et al. 2007). As plating 5000 cells per well did not 
substantially alter the intensity of response compared to 10000 cells per well (Figure 2-3), I used 
5000 cells per well to allow more plates to be seeded from the same size starter culture. Although 
these preliminary experiments were not replicated and therefore statistical comparisons between 
conditions were not conducted, the findings are supported by previous work (Fahey et al. 2004). 
 
Figure 2-2. Effect of cell concentration and charcoal-treated FBS on basal QR activity. Relative basal QR 
activity of untreated Hepa-1c1c7 plated at 10000 or 5000 cells per well with (+ CT) or without charcoal-
treated FBS in the culture medium. Results from a single experiment with 2 technical replicates. 
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Figure 2-3. Effect of cell concentration and charcoal-treated FBS on QR induction. Fold-changes in QR 
activity of Hepa-1c1c7 cells in response to sulforaphane concentrations ranging from 0.0075 µM to 0.60 µM 
when plating different numbers of cells (10000 or 5000) and using charcoal-treated (+ CT) FBS in the culture 
medium. Results from a single experiment with 2 technical replicates. 
The responsiveness of Hepa-1c1c7 cells declines with the number of passages (the 
number of times the culture is divided) (Fahey et al. 2004). Only cells that were passaged less 
than 20 times were used. I experimented with directly plating cells from frozen stocks but found 
that this resulted in a higher number of apoptotic cells and reduced responsiveness in the 
bioassay (data not shown). Allowing the cells to divide after thawing enriched the culture with 
healthy rapidly-dividing cells. In general, cells that were under stress displayed decreased 
inducibility in the QR bioassay due to an elevated QR baseline. 
2.3.2. Procurement of plant material and extract preparation 
Plant selection criteria included availability, abundance, dietary consumption, use as 
traditional medicine and the phylogenic relationship of the plant to the other plants in the screen. 
Many plants were collected in British Columbia by Nick Page, others I collected in Saskatchewan 
(Table A1).  Extracts were prepared in a manner that facilitated a reasonable throughput using 6 g 
of dried material and an extract volume of 50 mL. To reduce degradation, extracts were stored in 
the dark at 4ºC. 
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2.3.3. QR bioassay screening results  
Methanolic extracts from 162 plants were screened for QR induction. Six two-fold 
dilutions were tested for each extract at concentrations of 4, 2, 1, 0.5, 0.25, 0.125 or 2.4, 1.2, 0.6, 
0.3, 0.15 mg/mL (mg of dried material used for extraction per mL of medium). Due to the 
viscosity of certain extract resuspensions used to prepare these dilutions, I increased the volume 
of DMSO used for dissolving the samples from 30 µL to 50 µL which resulted in the lower range 
of test concentrations for those samples (2.4 mg/mL and lower). 
The greatest level of induction was often achieved at concentrations with measurable 
toxicity as judged by a decrease in the protein content of the well. Since I normalized for cell 
growth by comparing specific QR activity (activity per mass of protein present), I often found 
high induction levels at extract concentrations that reduced the protein concentration. These 
measurements were considered unreliable and results were discarded in cases where protein 
content dropped to less than 50% of the DMSO-treated controls. 
Induction levels ranged from 0.34-fold (Elaegnus commutata, wolfwillow, leaves) to 
2.97-fold (Cicorium intibus, chicory, roots). The maximal level of induction achieved at any 
concentration was used to index the extracts. The complete list of extracts sorted by maximal QR 
induction can be found in Table 2-1. The distribution of the maximal induction values are given 
in Figure 2-4.  
 
Figure 2-4. Distribution of maximal levels of QR induction of the 162 extracts tested. 
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Extracts are sorted by family in appendix table A1Several families of plants consistently 
showed elevated results.. These included the Umbelliferae, Compositae, Araliaceae and 
Grossulariaceae which possessed average maximal induction values of 1.87, 1.67, 1.65, and 1.52-
fold, respectively. Conversely, the extracts prepared from members of the Ericaceae were nearly 
devoid of QR-inducing activity (average maximal induction of 0.98-fold), although fruit extracts of 
Arctostaphylos uva-ursi (kinnickinnick) and Vaccinium myrtillus (bilberry) were exceptions with 
maximal induction values of 1.65 and 1.51-fold.  
Rosaceae was the best represented family with 22 extracts tested. In general Rosaceae 
extracts were weak inducers (average maximal induction of 1.25-fold). However, two Rosaceae 
extracts, Sorbus americana (American mountain-ash, fruit) and Sorbus aucuparia (European 
mountain-ash, fruit) stood out with maximal induction values of 2.32 and 2.15-fold, respectively. A 
chalcone glycoside has been reported from the fruits of the related species Sorbus commixta (Bhatt 
et al. 2009). Due to the similarity of this chalcone to the known QR inducer xanthohumol (Miranda 
et al. 2000), I suspect that related chalcones may be contributing to the QR induction by the S. 
americana and S. aucuparia extracts. 
 Families for which a limited number of extracts were prepared but showed promise 
included the Gentianaceae (Centantaurium erytheae, European centaury, maximal QR induction 
= 2.40-fold, and Gentiana sceptrum, king gentian, maximal QR induction = 2.18-fold) and 
Labiatae (Scutellana lateriflora, blue skull cap, max. QR = 2.24-fold, Ocimum basilicum, basil, 
maximal QR induction = 1.67-fold ). A methanol extract of the Labiatae plant Scutellaria 
baicalensis has been previously shown to induce QR in Hepa-1c1c7 cells (Park et al. 1998). These 
authors did not subject the extract to bioassay-guided fractionation, rather they provided evidence 
that a major flavonoid from this plant, baicalin, possessed weak QR-inducing activity (CD value ~ 
150 µM).  
The two extracts of A. latifolia (yellow-sand verbena, roots or aerial tissues) produced 
considerable QR induction (maximal QR induction for roots = 2.52-fold, maximal QR induction 
of aerial parts = 1.76-fold), indicating that active compounds may be distributed throughout the 
plant. 
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Table 2-1. Summary of extract sources, results in QR a30nd DPPH assays and traditional use history.  
Common name Species and author Family Plant part 
Max 
QR
a 
Conc. 
at max 
QR
b 
DPPH 
IC50
c
 
(mg/mL)
 
Tradit
-ional 
use
d 
Blood 
medicine
e 
wild chicory Cichorium intybus L. Compositae roots 2.97 2.0 15.3 yes no 
celeriac Apium graveolens var. rapaceum Umbelliferae roots 2.67 1.0 107 yes no 
yellow sand-verbena Abronia latifolia Eschsch. Nyctaginaceae roots 2.52 0.3 75.2 no  
common tansy Tanacetum vulgare L. Compositae flowers 2.51 0.3 2.28 yes no 
devil's club Oplopanax horridus (Sm.) Miq. Araliaceae leaves and stems 2.45 2.0 4.08 yes yes 
European centaury Centaurium erythaea Raf. Gentianaceae whole plant 2.40 1.2 10.8 no  
American mountain-ash Sorbus americana Marsh. Rosaceae fruit 2.32 0.60 13.1 yes yes 
bitter root Lewisia rediviva Pursh Portulacaceae roots 2.32 0.30 9.75 yes yes 
osha Ligusticum porteri J.M. Coult. & Rose Umbelliferae roots 2.27 0.15 2.06 yes no 
blue skull cap Scutellana lateriflora L. Labiatae leaves 2.24 2.0 1.15 yes no 
king gentian Gentiana sceptrum Griseb. Gentianaceae leaves and stems 2.18 2.4 5.38 no  
European mountain-ash Sorbus aucuparia L. Rosaceae fruit 2.15 0.30 3.73 yes no 
feverfew Tanacetum parthenium (L.) Schultz-
Bip. 
Compositae leaves and 
flowers 
2.14 0.25 16.8 yes no 
cretan viper's-bugloss Echium creticum L. Boraginaceae aerial parts 2.11 2.4 28.6 no no 
red-osier dogwood Cornus alba L. Cornaceae fruit 2.09 2.4 5.3 yes no 
sheep sorrel Rumex acetosella L. Polygonaceae leaves 2.08 4.0 42.7 yes no 
big sagebrush Artemisia tridentata Nutt. Compositae aerial tissues 2.07 0.30 2.12 yes no 
pestle parsnip Lomatium nudicaule (Pursh) Coult. & 
Rose 
Umbelliferae leaves 2.06 4.0 2.87 yes no 
osha Ligusticum porteri J.M. Coult. & Rose Umbelliferae roots 2.04 0.30 3.86 yes no 
devil's club Oplopanax horridus (Sm.) Miq. Araliaceae fruit 2.02 2.4 2.09 yes yes 
boneset Eupatorium perfoliatum L. Compositae leaves and 
flowers 
2.01 2.0 4.78 yes no 
bitter blend tea Various Various various 1.99 0.30 6.83   
parsnip Pastinaca sativa L. Umbelliferae roots 1.99 4.0 142 yes no 
gotu kola Centella asiatic (L.) Urban Umbelliferae stems and leaves 1.92 0.60 2.91 no  
springbank clover Trifolium wormskioldii Lehm. Leguminosae whole plant 1.91 1.2 9.22 yes no 
elecampane Inula helenium L. Compositae n/a 1.85 0.15 21.8 yes no 
radish Raphanus sativus L. Cruciferae root 1.85 4.0 27.2 no  
old man's beard Usnea sp. Parmeliaceae lichen 1.84 0.60 115   
Siberian ginseng Eleutherococcus senticosus (Rupr. & 
Maxim.) Maxim. 
Araliaceae roots 1.84 2.0 126 no  
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soapberry Shepherdia canadensis (L.) Nutt Elaegnaceae fruit 1.84 2.4 10.9 yes no 
echinacea Echinacea sp. Compositae roots 1.81 2.4 5.92   
angled luffa Luffa acutangula (L.) Roxb Cucurbitaceae skin of fruit 1.80 2.4 40.5 no  
echinacea Echinacea angustifolia DC Compositae roots 1.80 2.4 2.43 yes yes 
stink currant Ribes bracteosum Dougl. ex Hook Grossulariaceae fruit 1.78 2.4 10.3 yes no 
tai zi shen Pseudostellaria sp. Caryophyllaceae n/a 1.78 2.4 326   
bitter gourd Momordica charantia L. Cucurbitaceae fruit 1.77 1.2 117 no  
yellow sand-verbena Abronia latifolia Eschsch. Nyctaginaceae aerial parts 1.76 1.2 2.41 no  
burdock Arctium minus (Hill) Bernh. Compositae roots/rhizomes 1.75 0.5 4.79 yes yes 
american arnica Arnica chamissonis Less. Compositae roots/rhizomes 1.74 2.0 13.9 no  
balsam root Balsamorhiza sp. Compositae leaves and roots 1.72 0.6 5.24   
dijon mustard Brassica juncea (L.) Czerniak Cruciferae seeds 1.72 0.5 15.9 yes no 
licorice Glycyrrhiza glabra L. Leguminosae roots 1.72 4.0 29.1 yes no 
maria's swedish bitters Various Various various 1.72 2.4 24.6   
chai hu Buplerum sp. Umbelliferae n/a 1.71 1.2 34.8   
basil Ocimum basilicum L. Labiatae leaves 1.67 4.0 23.1 no  
domestic plum Prunus sp. Rosaceae fruit, no pit 1.67 2.4 26.2   
French artichoke Cynara scolymus L. Compositae flesh 1.66 1.0 10.8 no  
cocoa Theobroma cacao L. Sterculiaceae powder 1.65 2.4 4.72 no  
kinnikinick Arctostaphylos uva-ursi (L.) Sprengel Ericaceae fruit 1.65 2.4 0.901 yes yes 
milk thistle Silybum marianum (L.) Gaertn. Compositae seeds 1.65 4.0 37.8 no  
turmeric Curcuma longa L. Zingiberaceae roots 1.64 1.0 2.16 no  
pestle parsnip Lomatium nudicaule (Pursh) Coult. & 
Rose 
Umbelliferae whole plant 1.63 0.30 149 yes no 
wax currant Ribes cereum Dougl. Grossulariaceae fruit 1.61 2.4 2.39 yes no 
licorice Glycyrrhiza glabra L. Leguminosae roots 1.60 1.0 3.62 yes no 
cotoneaster Cotoneaster sp. Rosaceae fruit 1.57 2.4 3.56   
ribgrass Plantago lanceolata L. Plantaginaceae leaves 1.56 4.0 8.04 no  
bindweed Convolvulus sp. Convolvulaceae seed 1.54 1.2 12.7   
chili pepper Capsicum annuum L. Solanaceae fruit 1.54 2.4 13.2 yes no 
dandelion Taraxacum officinale Weber ex Wigg. Compositae leaves 1.54 4.0 17.6 yes yes 
cough root Lomatium dissectum (Nutt.) Mathias 
& Constance 
Umbelliferae roots 1.53 0.60 4.34 yes yes 
gymnema Gymnema sylvestre (Retz.) Sm. Asclepiadaceae leaves 1.53 0.15 6.93 no  
ginseng Panax ginseng Araliaceae n/a 1.53 0.60 199 no  
bilberry Vaccinium myrtillus L. Ericaceae fruit 1.51 2.4 5.39 yes no 
elderberry Sambucus calliicarpa Caprifoliaceae fruit 1.51 2.4 15.4 yes no 
red currant Ribes rubrum L. Grossulariaceae fruit 1.51 2.4 38.8 yes no 
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qu mai Dianthus sp. Caryophyllaceae n/a 1.50 0.60 67.4   
crowberry Empetrum nigrum L. Empetraceae fruit 1.49 0.60 1.31 yes no 
parsley Lomatium grayi (Coult. & Rose) 
Coult. & Rose 
Umbelliferae leaves 1.49 4.0 26.1 no  
cascara Rhamnus purshiana DC Rhamnaceae n/a 1.47 1.2 4.73 no  
chokecherry Prunus virginiana L. Rosaceae fruit 1.45 2.4 22.1 yes yes 
red flowering currant Ribes sanguineum Pursh Grossulariaceae fruit 1.44 2.4 0.73 no  
western snowberry Symphoricarpos occidentalis Hook. Caprifoliaceae fruit 1.44 2.4 0.71 yes no 
wasabi Wasabia wasabi (Siebold) Makino Cruciferae rhizomes 1.43 4.0 143 no  
wild sarsparilla Aralia nudicaulis L. Araliaceae roots/rhizomes 1.43 0.50 118 yes yes 
nasturtium Tropaeolum sp. Tropaeolaceae flowers 1.41 4.0 1.33   
creeping juniper Juniperus horizontalis Moench Cupressaceae fruit 1.40 0.075 1.51 yes no 
entire-leaved gumweed Grindelia integrifolia DC. Compositae flowers 1.39 1.2 11.9 no  
high-bush cranberry Viburnum sp. Caprifoliaceae fruit 1.38 1.2 0.81   
horny goat weed Epimedium sagittatum (Sieb. & Zucc.) 
Maxim. 
Berberidaceae leaves 1.38 0.30 0.811 no  
black hawthorn Crataegus douglasii Lindley Rosaceae fruit 1.37 2.4 1.76 yes no 
jie geng Platycodon sp. Campanulaceae n/a 1.37 0.075 71.6   
cherry Prunus sp. Rosaceae fruit 1.36 2.4 65.1   
chokecherry Prunus virginiana L. Rosaceae fruit 1.36 2.4 17.5 yes yes 
san qi Panax pseudoginseng Araliaceae n/a 1.35 0.30 313 no  
wolf willow Elaegnus commutata Bernh. ex Rydb. Elaegnaceae fruit 1.34 1.2 3.22 yes no 
ribwort Plantago lanceolata L. Plantaginaceae leaves 1.33 2.4 2.61 no  
broccoli Brassica oleracea L. Cruciferae sprouts 1.32 4.0 6.48 yes no 
grape Vitis vinifera L. Vitaceae skin of fruit 1.31 2.4 3.11 no  
bacopa Bacopa sp. Scrophulariaceae whole plant 1.30 0.15 0.11   
European bittersweet Solanum dulcamara L. Solanaceae fruit 1.30 2.4 9.38 yes no 
bloodroot Sanguinaria canadensis L. Papaveraceae roots 1.29 0.0094 8.93 yes yes 
lettuce Lactuca sativa L. Compositae leaves 1.28 4.0 56.8 yes no 
hawthorn Crataegus sp. Rosaceae fruit 1.27 2.4 4.74   
twisted stalk Streptopus sp. Liliaceae fruit 1.27 2.4 117   
concord grape Vitis labrusca L. Vitaceae fruit 1.25 2.4 76.3 yes yes 
red elderberry Sambucus racemosa L. Caprifoliaceae fruit 1.25 2.4 13.9 yes no 
black gooseberry Ribes lacustre (Pers.) Poir. Grossulariaceae fruit 1.24 2.4 3.65 yes no 
bunchberry Cornus canadensis L. Cornaceae fruit 1.24 1.2 4.44 yes no 
nasturtium Tropaeolum sp. Tropaeolaceae flowers 1.23 2.4 3.06   
carrot Daucus carota L. Umbelliferae roots 1.22 4.0 19.6 yes yes 
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false lily-of-the-valley Maianthemum dilatatum (A. Wood) 
Nels. & J.F. Macbr. 
Liliaceae fruit 1.22 0.30 23.9 yes yes 
pokeweed Phytolacca americana L. Phytolaccaceae fruit 1.22 0.60 1.43 yes yes 
mangosteen Garcinia mangostana L. Guttiferae husks 1.20 0.075 0.861 no  
valerian Valeriana officinalis L. Valerianaceae roots 1.18 0.25 18.6 no  
common snowberry Symphoricarpos albus (L.) S.F. Blake Caprifoliaceae fruit 1.17 2.4 1.28 yes no 
himalaya blackberry Rubus discolor Weihe & Nees Rosaceae fruit 1.17 0.15 1.56 no  
pispsissewa Chimaphila umbellata (L.) W. Barton 
(Euras.) 
Ericaceae leaves 1.16 1.0 0.291 yes yes 
red huckleberry Vaccinium parvifolium Sm. Ericaceae fruit 1.15 2.4 27.9 yes no 
bitter gourd Momordica charantia L. Cucurbitaceae fruit 1.14 1.2 48.1 no  
wang bu liu xing Vaccaria hispanica (Miller) Rauschert Caryophyllaceae seed 1.14 0.075 221 no  
goji Lycium sp. Solanaceae fruit 1.12 2.4 14.8   
yellow gentian Gentiana lutea L. Gentianaceae roots 1.12 0.50 37.2 no  
broccoli Brassica oleracea L. Cruciferae crowns 1.10 10 15.9 yes no 
comfrey Symphytum offincinale L. Boraginaceae roots 1.09 2.4 20.5 yes no 
Oregon grape Mahonia aquifolium (Pursh) Nutt. Berberidaceae fruit 1.08 0.30 9.15 yes yes 
bitter cherry Prunus sp. Rosaceae fruit 1.07 0.15 1.51   
passion flower Passiflora sp. Passifloraceae flowers and 
leaves 
1.06 2.4 5.34   
astragalus Astragalus sp. Leguminosae roots 1.04 0.60 107   
nootka rose Rosa nutkana Presl Rosaceae hip, no seeds 1.02 1.2 1.33 yes no 
black salsify Scorzonera hispanica Compositae roots 1.01 0.019 8.79 no  
codonopsis Codonopsis sp. Campanulaceae roots 1.00 0.60 105   
carolina rose Rosa carolina L. Rosaceae hip 0.99 0.60 0.52 yes no 
cranberry Vaccinium oxycoccus L. Ericaceae fruit 0.99 2.4 120 yes no 
irish moss Chondrus crispus Stackhouse Gigartinaceae leaves 0.99 4.0 >120 no  
Oregon grape Mahonia aquifolium (Pursh) Nutt. Berberidaceae bark 0.98 0.075 11.7 yes yes 
hop Humulus lupulus L. Cannabaceae hop cones 0.97 0.15 1.06 yes no 
rhubarb Rheum rhabarbarum L. Polygonaceae stems 0.97 0.50 5.87 no  
lady's leek Allium cernuum Roth Liliaceae bulbs 0.95 0.50 85.1 yes no 
potato Solanum tuberosum L. Solanaceae root, no skin 0.94 2.4 236 yes no 
wild sarsparilla Aralia nudicaulis L. Araliaceae leaves 0.93 0.25 6.58 yes yes 
cranberry Vaccinium oxycoccus L. Ericaceae fruit 0.92 0.075 8.15 yes no 
genistein soy complex Glycine max (L.) Merr Leguminosae n/a 0.92 1.2 119 no  
iceberg lettuce Lactuca sativa L. Compositae leaves 0.91 0.60 39.6 yes no 
red delicious apple Malus sp. Rosaceae skin of fruit 0.90 1.2 5.74   
poracher root Pteridium aquilinium (L.) Kuhn Dennstaedtiaceae roots 0.88 0.075 2.64 yes yes 
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trailing blackberry Rubus ursinus Cham. & Schlecht. Rosaceae fruit 0.88 0.15 0.88 yes no 
yellow dock Rumex crispusL. Polygonaceae roots 0.88 0.60 1.24 yes yes 
vaccaria Vaccaria saponaria Caryophyllaceae seed 0.86 0.15 204 no  
common wild rose Rosa woodsii Lindl. Rosaceae hip 0.85 0.075 0.381 yes yes 
lingonberry Vaccinium vitis-idaea L. Ericaceae fruit 0.84 0.075 5.66 no  
green tea Camellia sinesis (L.) Kuntze Theaceae leaves 0.83 0.30 0.191 no  
high-bush cranberry Viburnum sp. Caprifoliaceae fruit 0.83 0.075 1.92   
domestic blueberry Vaccinium corymbosum L. Ericaceae fruit 0.82 2.4 5.58 yes no 
labrador tea Ledum groenlandicum Oeder Ericaceae leaves 0.81 0.25 1.51 yes yes 
pin cherry Prunus pensylvanica L. f. Rosaceae fruit 0.81 2.4 10.9 yes yes 
potato Solanum tuberosum L. Solanaceae skin of root 0.79 0.30 34.9 yes no 
salal Gaultheria shallon Pursh Ericaceae fruit 0.79 0.60 0.651 yes no 
calendula Calendula sp. Compositae flowers 0.78 0.30 47.4   
salmon berry Rubus spectabilis Pursh Rosaceae fruit 0.78 0.60 1.55 yes no 
blueberry Vaccinium sp. Ericaceae fruit 0.77 0.15 2.65   
grape Vitis vinifera L. Vitaceae fruit 0.77 0.60 4.83 no  
goldenrod Solidago virgaurea Compositae n/a 0.74 0.075 5.65 yes no 
blueberry Vaccinium sp. Ericaceae fruit 0.73 0.075 2.07   
yuan zhi Polygala sp. Polygalaceae n/a 0.69 0.075 11.6   
arjuna Terminalia arjuna (DC) Wight & Arn. Combretaceae bark 0.68 0.15 0.21 no  
saskatoon berry Amelanchier alnifolia Nutt. Rosaceae fruit 0.67 2.4 4.12 yes yes 
blueberry Vaccinium sp. Ericaceae fruit 0.65 0.60 2.21   
valley seed Bassia scoparia (L.) Voss Chenopodiaceae seed 0.51 0.075 4.95 no  
wolf willow Elaegnus commutata Bernh. ex Rydb. Elaegnaceae leaves 0.34 0.15 0.121 yes no 
antelope-brush Purshia tridentata (Pursh) DC. Rosaceae aerial tissues toxic n/d 0.361 yes no 
ashwagandha Withania somnifera (L.) Dunal Solanaceae roots toxic n/d 15.9 no  
elecampane Inula helenium L. Compositae roots toxic n/d 31.1 yes no 
raspberry Rubus idaeus L. Rosaceae fruit n/t n/t 4.04 yes yes 
thimbleberry Rubus parviflorus Nutt. Rosaceae fruit n/t n/t 1.49 yes  
a
indicates the highest QR induction value for the extract. 
b
indicates the concentration (mg of dried material used for extraction per mL of medium) at which Max QR was achieved. 
c
 indicates the concentration requires to neutralize 50% of a 100 µM DPPH solution 
d
indicates whether traditional uses are reported for the species in Moerman (1998). 
e
 indicates whether traditional use included the indication of a blood medicine. 
n/a indicates that the plant part for source material was not provided.  
n/d indicates that the value could not be determined. 
n/t indicates that the plant was not included in the assay. 
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For extracts prepared from distinct parts of the plant, extracts prepared from roots or 
rhizomes (# = 36, average maximal QR induction of 1.61) tended to be more potent than from 
aerial parts (leaves, stems, or flowers, # = 35, average maximal QR induction of 1.48) or 
fruit/seeds (# = 71, average maximal QR induction of 1.27). As fruit often serve as a means of 
attracting seed dispersers fewer noxious compounds are expected in fruit compared to vegetative 
tissues. 
Certain extracts, such as Elaegnus commutata (wolf-willow, leaves, maximal QR 
induction = 0.34-fold) appeared to decrease the activity of QR. Although it is out of the scope of 
this project, these extracts could potentially provide leads for Keap1-activating/Nrf2-suppressing 
compounds. Also, if shown to be selective for cancerous cells, the highly-toxic nature of extracts 
such as Inula helenium (elecampane), Purshia tridentata (antelope-brush), Withania somnifera 
(ashwaganda) or Sanguinaria canadensis (blood root) could provide anti-cancer leads. 
From a review of the literature associated with many of the extracts with high QR 
activation it was noted that traditional use of ‘blood medicine’, medicines believed to purify or 
influence the blood, appeared frequently. Could this historical use be associated with the presence 
of Nrf2 activators and provide a basis for understanding their traditional use? To answer this 
question I investigated the traditional use of all screened extracts. 
Of the 162 plant extracts screened for QR activation, 133 were prepared from plants 
identified to the species level and were considered in the analysis of traditional uses. Of these, 133 
plants, 88 had documented traditional North American medicinal uses (Moerman 1998). Twenty-
eight of these had an indication of ‘blood medicine’. I considered substantial QR-inducing activity 
as greater than 1.5-fold induction. Thirty-six of the 88 plants (40.9 %) with use as traditional 
medicines had substantial QR-inducing activity. Nine of the 28 plants (32.1%) with use as ‘blood 
medicine’ had substantial QR-inducing activity. As this proportion is lower that that occurring for 
any traditional use, ‘blood medicine’ does not appear to be a reliable indicator of QR induction. 
2.3.4. Potential improvements to the QR screen 
Although this screen was highly successful at identifying plant extracts with QR-inducing 
activity several improvements are possible.  
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Basing the test concentrations on weight of the extract rather than the weight of dried plant 
material would provide a better comparator for intrastudy results and facilitate comparison with 
studies from other laboratories. I would also reduce the uppermost concentration tested to ensure 
complete dissolution and limit the viscosity of the solution.  
The 316-fold range covered using six 3.16-fold dilutions was not wide enough to 
consistently capture non-toxic concentrations and necessitated additional testing. Using a slightly 
higher dilution ratio such as 5-fold would increase the range covered to 3125-fold to avoid repeat 
testing. 
To avoid edge effects the outer perimeter of wells on each 96-well plate were plated but not 
used for the QR bioassay (Lundholt et al. 2003). I would consider testing for edge effects in this 
system if undertaking another large screen as the savings gained by using these wells would be 
substantial.  
False-positives could result via gas-transfer of volatile compounds between wells. Volatile 
inducers such as allyl-isothiocyanate can cause induction in adjacent wells and even non-volatile 
inducers such as dimethyl-fumarate have been reported to cause induction in adjacent wells (Fahey 
et al. 2004). As I tested duplicates of each concentration beside each other, I would expect a 
difference between the two duplicates in cases where volatile transfer was a concern. I did not 
observe such a pattern. 
False-negatives may have resulted due to instability or insolubility of active compounds in 
the extraction application solvent (DMSO). Adding surfactants or additional amphipathic 
molecules such as polyethylene glycol 400 may prevent such false-negatives but may also cause 
complications such as increased toxicity. 
The extraction procedure may have caused false-negatives by preventing interactions 
between compartmentalized precursor compounds and enzyme(s) required for their activation. This 
may explain the lack of QR induction by broccoli, a well-known source of the Nrf2 activator 
sulforaphane. In nature, insect damage causes the mixing of cells containing glucoraphanin and 
myrosinase which results in the production of sulforaphane. Although, homogenizing material 
prior to drying may help with this type of scenario, it may cause unwanted degradation of other 
compounds.  
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Since each extract contained a cocktail of phytochemicals, it is possible that high toxicity 
caused by one group of compounds may have masked the presence of QR inducers. Dividing the 
extract prior to screening could reduce masking if toxic compounds are separated from the Nrf2 
activators. 
2.3.5. Screening extracts for direct antioxidant activity using the DPPH antioxidant assay  
The DPPH IC50 value is reported for each extract in Table 2-1. The most potent antioxidant 
extracts are summarized in Table 2-2. Green tea and rose hips are known to have high antioxidant 
activity and were among the top eight extracts tested (Valcic et al. 1999; Gao et al. 2000).  
Although antioxidants can vary in their reactivity with different radical species, the 
commonly used antioxidant assays for examining plant tissues, DPPH, ABTS, and ferric reducing 
antioxidant capacity (FRAP) consistently give similar relative results or ranking of plant extracts 
(Ozgen et al. 2006). Therefore I would expect a very similar potency ranking of extracts if a 
different antioxidant assay was conducted. 
The DPPH assay IC50 values of each extract are plotted against their corresponding 
maximal QR induction values in Figure 2-5. I hypothesized that there would not be a correlation 
between direct antioxidant activity and the QR bioassay. There was no significant correlation (y = 
0.0002x, R
2 
= 0.0006, p = 0.75) therefore the null hypothesis was not rejected. Direct antioxidant 
activity should not be used as a predictor of QR-bioassay activity or indirect antioxidant activity.  
2.4. Conclusions 
A wide range of activity was noted in both the QR and DPPH assays, with the top QR-
activating extracts providing leads for bioassay-guided fractionation. Neither traditional use as 
‘blood medicines’ nor direct antioxidant activity were found to be useful predictors of QR-
inducing activity. 
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Table 2-2. Extracts with the greatest antioxidant capacity.   
Common name Species and author DPPH IC50
a
 (mg/mL) Max QR
b
 
bacopa Bacopa sp. 0.110 1.30 
wolf willow 
Elaegnus 
commutata Bernh. 
ex Rydb. 
0.121 0.34 
green tea 
Camellia sinesis 
(L.) Kuntze 
0.191 0.83 
arjuna 
Terminalia arjuna 
(DC) Wight & Arn. 
0.210 0.68 
pipsissewa 
Chimaphila 
umbellata (L.) W. 
Barton (Euras.) 
0.291 1.16 
antelope-brush 
Purshia tridentata 
(Pursh) DC. 
0.361 toxic 
common wild rose Rosa woodsii Lindl. 0.381 0.85 
carolina rose Rosa carolina L. 0.520 0.99 
a
 indicates the concentration required to neutralize 50% of a 100 µM DPPH solution 
b
indicates the highest QR induction value for the extract. 
 
Figure 2-5. Comparison of maximal QR induction with DPPH assay IC50 values. 
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CHAPTER 3 
ISOLATION AND IDENTIFICATION OF PUTATIVE NRF2 ACTIVATORS IN PLANT 
EXTRACTS 
3.1. Introduction 
 Of the extracts identified as QR-inducing, the 21 extracts capable of doubling the activity 
of QR were considered the strongest leads for isolating Nrf2 activators. Five extracts (Ligusticum 
porteri, Oplopanax horridus, Aralia nudicaulis, Abronia latifolia, Lewisia rediviva) were selected 
for fractionation based on the amplitude of induction, concentration required for activity, use 
history, novelty of the plant and the fact that QR induction had not been shown for these plants at 
the time of initial investigation. Cannabinoids were also isolated from Cannabis sativa in order to 
investigate the roles of QR and Nrf2 in the reported protective effects of these compounds. Due to 
a lack of positive results, the fractionation of L. rediviva is not reported here. 
3.1.1. Ligusticum porteri 
     Native to high altitude environments in western North America, L. porteri Coult. & Rose 
(Apiaceae) is a perennial forb with pinnately compound leaves and small white flowers (Terrell et 
al. 2009). Common names for L. porteri include ‘osha’ and ‘bear-root’. L. porteri roots have a long 
history of use by Native Americans, particularly the Tarahumara, for treating a wide variety of 
ailments including respiratory infections and inflammation (Appelt 1985; Linares et al. 1987). For 
the Tarahumara, the plant is closely associated with bears which reportedly dig up the root and rub 
it on their fur (Terrell et al. 2009).  
     Two methanolic extracts of L. porteri roots, prepared from different sources, were tested 
in preliminary screening. Although the supplier of the dried L. porteri attests to the authenticity of 
the material, I was not able to obtain a voucher specimen for this plant. Both extracts displayed 
high values for maximal induction of QR (2.27- and 2.04-fold). Members of the Apiaceae plant 
family produce several classes of bioactive phytochemicals including polyacetylenes, coumarins 
and phthalides and include several food plants such as carrots, celery and parsnip (Murphy et al. 
2004; Zidorn et al. 2005; Beck et al. 2007). There were no reports of QR-inducing activity of the 
above classes of compounds at the time of initial investigation. 
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3.1.2. Oplopanax horridus and Aralia nudicaulis (Araliaceae) 
     O. horridus (Sm.) Torr. & Gray ex Miq. (devil’s club, Araliaceae) is a thorny shrub 
abundant in riparian habitats ranging from Alaska through British Columbia to the north-western 
United States (NatureServeExplorer 2010). Throughout its range indigenous people consider it one 
of the most important medicinal plants (Smith 1983). Infusions of O. horridus bark have a history 
of use as a tonic, blood medicine, emetic, and purgative as well as a treatment of diabetes and 
tuberculosis (Smith 1983).  
     A. nudicaulis L. (wild sarsparilla, Araliaceae) is an understory shrub abundant 
throughout the North American boreal forest (Johnson et al. 1995). A. nudicaulis forms large 
networks of underground rhizomes that project single compound leaves at regular intervals. 
Traditional uses for the rhizome of this plant include tonic, blood medicine, dermatological aid, 
and cough medicine (Moerman 1998).  
     Like other members of the Araliaceae, O. horridus and A. nudicaulis are known to 
produce fatty acid-derived polyacetylenes (Hansen et al. 1986) and triterpene saponins (Ma et al. 
1999). During the course of this work, Lee et al. (2009) reported that the QR inducing activity of 
a Panax ginseng extract was due to the polyacetylene, panaxytriol, and not saponins 
(ginsenosides) (Lee et al. 2009). 
     O. horridus was selected for fractionation based on positive results in the QR bioassay 
(2.45 and 2.02-fold maximal induction for extracts of stems/leaves and fruit, respectively). I 
chose to focus on the inner bark as this tissue was used widely for traditional medicine (Smith 
1983) and was reported to be phytochemically rich (Kobaisy et al. 1997). In response to the 
success achieved with O. horridus, the rhizomes of A. nudicaulis (maximal QR induction of 
1.43-fold in screening) were investigated to expand the panel of polyacetylenes and identify 
structure-activity relationships.  
3.1.3. Abronia latifolia 
A. latifolia Eschsch. (Nyctaginaceae), commonly called ‘yellow sand-verbena’, is a small 
prostrate perennial herb native to sandy locations along the Pacific coast from Vancouver Island, 
British Columbia south to San Miguel Island, California (Tillett 1967). The yellow color of A. 
latifolia flowers is unique amongst the 20 related Abronia species (Galloway 1975) and are visited 
by the endangered Myrtle’s silverspot butterfly (Speyeria zerene myrtleae) (Launer et al. 1992). A. 
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latifolia produces long edible taproots (Hedrick 1972). Although to my knowledge no medicinal 
uses have been reported for this plant, the roots provided a substantial food source for several 
indigenous groups including the Chinook (Hedrick 1972), Klallam (Gunther 1973) and Makah 
(Gunther 1973). The taste of A. latifolia roots is said to be similar to sugar beets (Gunther 1973).  
The only published study of the phytochemistry of A. latifolia focused on the flavonoid 
constituents of the aerial tissues and identified several known flavones and flavonols: hispidulin, 
luteolin, nepetin, quercetin, and axillarin, chrysosplenol D, and one novel C-methyl isoflavone, 
abronisoflavone (Wollenweber et al. 1993).  
Methanolic extracts of roots or aerial tissues of A. latifolia showed a maximal QR induction 
of 2.52-fold and 1.76-fold in the preliminary screen, respectively. Due to the British Columbia 
government considering this plant as at-risk, I choose to cultivate the plant from wild seed rather 
than collect a large amount of wild plant material for extraction and fractionation. 
3.1.4. Cannabis sativa 
C. sativa L. (Cannabaceae) is a dioecious herb that has long been used for its fibre, seed, oil 
and psychotropic effects (Li 1973). Although indigenous to central and southern Asia, C. sativa is 
now cultivated around the world. Cannabinoids, such as cannabidiolic acid (CBDA) and Δ9-
tetrahydrocannabinolic acid (THCA) are produced in glandular trichomes which cover the female 
flowers. 
Upon heating, CBDA and THCA decarboxylate to cannabidiol (CBD) and Δ9-
tetrahydrocannabinol (THC), respectively. THC, an agonist at mammalian cannabinoid receptors, 
is the primary component responsible for the psychotropic effects of cannabis (Pertwee 2008). 
CBD does not activate cannabinoid receptors although it may modulate the effects of THC by 
acting as an antagonist at these receptors (Mechoulam et al. 2007). CBD has garnered attention for 
its neuroprotective effects in animal models of ischemia and Alzheimer’s disease (Hampson et al. 
2000; Braida et al. 2003; Iuvone et al. 2004). However the mechanism(s) conferring this protection 
are not understood. 
A methanolic extract of C. sativa was a weak inducer of QR (concentration required to 
increase activity of QR by 50% (C50 value) ~ 15 µg/mL). Despite the weak activity, I decided to 
investigate whether cannabinoids where responsible for QR activation, as QR (and Nrf2) 
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activation by cannabinoids could provide a basis for understanding the neuroprotective effects of 
cannabinoids in animal models. 
3.1.5. Bioassay-guided fractionation techniques 
Identifying active components by fractionation involves dividing the mixture of interest, 
assaying its parts for activity and repeating this process on the most active fraction(s) until pure 
constituents are isolated. A variety of chemical separation methods (solvent-solvent partitioning, 
chromatography, crystallization, precipitation) can be employed.  
In practice, solvent-solvent partitioning is often selected for the initial separation as it 
quickly separates large quantities of material, is easily scaled up and is compatible with most 
compounds. Solvent-solvent partitioning separates compounds on the basis of differential 
solubility in two or more immiscible solvents. A solvent-solvent partitioning scheme that separates 
compounds into low polarity (high solubility in hexane), intermediate polarity (high solubility in 
chloroform) and high polarity (high solubility in water) is given in section 3.3.1.2. For the same 
reasons discussed in Chapter 2 regarding extraction solvent selection, the chloroform (intermediate 
polarity) fraction is typically enriched in bioactive compounds. 
Chromatography involves separating compounds in a solvent passing over a stationary 
phase. Differential interactions with the stationary phase allow temporal separation of different 
compounds. Chromatography can easily separate a complex mixture into a large number of 
discrete fractions. For initial separations with crude fractions, liquid chromatography using low-
pressure systems with self-packed columns or SPE (solid phase extraction) columns are time and 
solvent-efficient methods. The resolution of high performance liquid chromatography (HPLC) is 
advantageous during the final purification of individual compounds.  
3.1.6. Bioassays used to guide isolation of Nrf2 activators 
Two bioassays were used to guide the fractionation process: 1) the QR bioassay and 2) 
thiol-reactivity using mass spectrometric detection of glutathione-reactive compounds. QR 
bioassay-guided fractionation relies on the QR bioassay as described in Chapter 2. Although QR 
bioassay-guided fractionation is a reliable and proven method for identifying Nrf2 activators, the 
process is laborious. Since the thiol-reactive cysteines of Keap1 are thought to be the sensors 
regulating the abundance and transcriptional activity of Nrf2, screening for thiol-reactive 
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electrophiles is an alternative approach to identifying Nrf2 activators (Liu et al. 2005). 
Glutathione is a useful model of Keap1 thiols and is readily available, inexpensive and small 
(Liu et al. 2005). Compounds that react with glutathione in vitro can be identified by tandem 
mass spectrometry (MS) by looking for precursors of characteristic glutathione fragmentation 
products, such as precursors of mass-to-charge ratios (m/z) 130 or 272 under positive or negative 
ionization conditions, respectively (Dieckhaus et al. 2005). Not only is this approach much 
quicker than the QR bioassay (4 h vs. 4 days), but it also provides information regarding the 
structure of the reactive compound (m/z and UV characteristics) that can be used to guide 
isolation.  
3.1.7. Identification of isolated QR inducers 
An array of experiments including MS, ultraviolet-visible (UV-VIS) spectroscopy, infrared 
spectroscopy, nuclear magnetic resonance spectroscopy (NMR) as well as chromatographic 
retention time provide complimentary structural information of an unknown compound. In order to 
unequivocally determine the structure of an isolated compound it is necessary to either solve the 
structure using NMR spectroscopy or X-ray crystallography or show that it is identical to a 
standard (typically using HPLC retention time and UV-VIS absorbance or mass spectrum). As I 
am interested in novel compounds for which standards do not exist I have routinely completed 
NMR analyses of isolated compounds.  
3.2. Materials and methods 
3.2.1. General experimental procedures 
Flash chromatography was conducted on a Sepacore system (Buchi) equipped with a C-
630 UV monitor and a C-660 fraction collector. Unless otherwise specified, preparative HPLC was 
conducted on a preparative 1100 system (Agilent) equipped with a fraction collector and a 
Gemini-NX C18 column (Phenomenex, 250 × 21.2 mm, 5 µm). Reverse phase analytical HPLC 
was conducted on an Alliance system (Waters). Normal phase analytical HPLC was conducted 
on an 1100 system (Agilent). Volatile solvents were removed under vacuum using a rotavap with 
heating to 28°C. Unless otherwise indicated, NMR experiments were performed in deuterated 
chloroform (CDCl3) using an AV500 spectrometer (Bruker). Optical rotations were determined on 
a 341 polarimeter (Perkin-Elmer). High-resolution mass spectra were acquired on either an API 
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Qstar XL (Applied Biosystems), Q-Tof Ultima Global (Waters) or 4800 matrix-assisted laser 
desorption ionization (MALDI) tandem time of flight (TOF/TOF) mass spectrometer (Applied 
Biosystems). Cell culture reagents were obtained from Invitrogen. Unless otherwise specified, 
chemicals were obtained from Sigma-Aldrich.  
3.2.2. QR and cell viability assays 
Cell culture and QR bioassays were conducted as described in Chapter 2 with the 
exception of the incorporation of the Calcein AM (Invitrogen) cell viability assay into the QR 
bioassay workflow in the place of the rinse step. Each well was incubated in the dark with 200 
µL of 1.0 µM Calcein AM in D-PBS at 37°C for 20 min and cellular viability was determined by 
measuring fluorescence (485 nm excitation and 535 nm emission). DMSO treated controls were 
considered to be at 100% viability. A reference for 0% viability was determined by incubating 
two DMSO treated control wells with 70% ethanol for 20 min. The Calcein AM cell viability 
assay did not interfere with the subsequent QR assay (data not shown).  
3.2.3. Detection of glutathione adducts by tandem MS 
Detection of glutathione adducts by tandem MS was based on previously published 
procedures (Johnson et al. 2001; Liu et al. 2005). A methanolic extract or solution was added to an 
aqueous solution containing 1 mM reduced glutathione and 25 mM Tris-Cl, pH 8.0 to give a final 
concentration of 200 µM or 0.5 mg/mL of the small molecule or extract and 10% or less methanol 
(v/v). The solution was incubated at 37ºC for 90 min and analyzed on a 1100 HPLC (Agilent) 
interfaced to a Quattro LC (Micromass) quadrupole tandem mass spectrometer using an Xterra 
RP18 column (Waters, 2.1 × 100 mm, 3.5 µM), a flow rate of 0.2 mL/min and a gradient of 5% to 
100% organic solvent/water with 0.1% formic acid over 25 min. Acetonitrile and methanol were 
used as the organic solvent during analyses in positive and negative mode, respectively. Mass 
spectrometer source settings follow: cone voltage 20 V, radiofrequency (RF) lens 0.5, extractor 2, 
capillary 3.00, source block 120ºC, desolvation temp 350ºC. 
3.2.4. L. porteri 
3.2.4.1. Thiol-reactivity based separation 
Thirty-grams of dried L. porteri roots (Richter’s Herbs) were extracted with 250 mL of 
methanol. The extract was concentrated under reduced pressure and water was added to 10% (v/v). 
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After defatting with hexane, the methanol-water extract was partitioned with chloroform and the 
chloroform fraction washed with aqueous 1% NaCl to remove tannins (Figure 3-1, found in section 
3.3.1.2, pg. 55). The chloroform partition (2.4 g) was separated into 20 fractions by open column 
chromatography (silica gel, 30 g, 200-425 mesh) using a gradient of 5-100% acetone in hexane. 
Glutathione-based thiol trapping indicated that a major thiol-reactive compound was present in 
fractions 13 and 14. Coniferyl ferulate (1) was purified from these fractions by preparative reverse 
phase thin layer chromatography (TLC) (C18, 20 × 20 cm, 500 µm) using a 1 : 1 mixture of 
chloroform : acetone, and further purified by semi-preparative HPLC using a gradient of 60-100 % 
methanol/water and a Sunfire Prep C18 column (Waters, 10 × 250 mm, 5 µm) on a modular HPLC 
(Waters) with manual collection. 
coniferyl ferulate (1), UV (acetonitrile/H2O) λmax. (nm) 219, 270, 300sh, 320; 
1
H, 
13
C and 
HMBC NMR data in agreement with previous analysis (Lu et al. 2004). HRESIMS m/z 379.1196 
[M + Na]
+
 (calculated for C20H20O6Na, 379.1210). 
3.2.4.2. QR bioassay-guided separation 
Dried L. porteri roots (104 g) were extracted twice with 500 mL of methanol and 
partitioned according to the scheme given in Figure 3-1 (section 3.3.1.2, pg. 55). The chloroform 
fraction (2.7 g) was separated into six fractions by flash chromatography over a silica gel (200-425 
mesh) column (26 × 460 mm) using a gradient of 5-100% acetone in hexane. Fraction 2 was most 
active in the QR bioassay and was separated by flash chromatography using a reversed-phase 
cartridge (Buchi, RP18, 40-63 µm, 12 × 75 mm) and a gradient of 5-100% acetonitrile in water. 
Active subfraction F2-3 (110 mg) was purified by semi-preparative HPLC (Waters Sunfire 10 × 
250 mm C18 column, isocratic, 70% methanol/water) and yielded (Z)-ligustilide as the major 
component. (Z)-Ligustilide (2) was identified based on UV and 
1
H and 
13
C NMR experiments as 
well as comparison with an authentic standard (Chromadex). trans-6,7-Dihydroxyligustilide (3) 
was purified from an aqueous solution of (Z)-ligustilide, that had been incubated at 60°C for 18 h, 
by semi-preparative HPLC (isocratic 70% methanol/water) and identified by comparison of UV, 
1
H NMR and mass spectrometric data with published values (Pushan et al. 1984; Li et al. 2003). 
The presence of the two enantiomers 3a and 3b in the trans-dihydroxyligustilide (3) isolate was 
confirmed by chiral analytical HPLC (Regis Technologies 4.6 × 250 mm (R,R)-Whelk-O1 column, 
isocratic 95% hexane/5% isopropanol/0.1% acetic acid). 
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(Z)-ligustilide (2), UV (acetonitrile/H2O) λmax. (nm) 280, 327 in agreement with previous 
report (Li et al. 2003); 
1
H, and 
13
C NMR data in agreement with previous analysis (Gijbels et al. 
1982; Pushan et al. 1984). ESIMS+ m/z 191 [M + H]
+
 (calculated for C12H15O2, 191). 
trans-dihydroxyligustilide (3), UV (Acetonitrile/H2O) λmax. (nm) 280 in agreement with 
previous report (Li et al. 2003); 
1
H, and 
13
C and HBMC NMR data in agreement with previous 
analysis (Pushan et al. 1984). ESIMS+ m/z 225 [M + H]
+
 (calculated for C12H17O4, 225). 
3.2.5. O. horridus 
Flash chromatography was performed with a column (460 × 26 mm) packed with silica gel 
(EMD, 230-400 mesh). Semi-preparative HPLC separations were performed on a 1100 system 
using an Xterra C18 column (Waters, 100 × 7.8 mm, 5 µm) for isolation of falcarindiol from P. 
sativa or a Sunfire C18 column (Waters, 250 × 10 mm, 5 µm) for all other separations. Preparative 
chiral HPLC was conducted using a Chiracel OD column (Daicel, 500 × 50 mm, 20 µm). 
Analytical TLC was performed using silica gel and developed by hexane: ethyl acetate, 14:1. (R)-
sulforaphane was purchased from LKT laboratories. Analytical chiral HPLC separations were 
performed on an 1100 system using a Lux Cellulose-1column (Phenomenex, 250 × 4.6 mm, 5 
µm). Fetal bovine serum was obtained from Invitrogen or PAA Laboratories.  
O. horridus stems were collected in October 2008 near Pemberton Valley, BC, Canada. 
Taxonomic identification was done by Nick Page (Rainforest Applied Ecology, Vancouver, 
Canada). This plant is abundant in the area of harvest and not considered at risk 
(NatureServeExplorer 2010). A voucher specimen is deposited in the Herbarium of the University 
of Saskatchewan (accession #180047). Parsnip roots (P. sativa) were purchased from a 
supermarket in Saskatoon, SK, Canada. 
Dried O. horridus inner bark (296 g) was exhaustively extracted with methanol, and 
subjected to solvent-solvent partitioning as detailed in Figure 3-1 (section 3.3.2, pg. 57). The 
resulting residue (9 g) was separated by reverse phase flash chromatography (C18, 230-400 mesh, 
EMD) using a gradient of 40-100% acetonitrile in water. Preliminary fractions were combined on 
the basis of analytical TLC to give eleven fractions (I-XI). Pure compounds were isolated from 
these fractions by semi-preparative HPLC using water/acetonitrile in the following compositions 
(% acetonitrile): compounds 4, 5, 6, 7, gradient (42.5-70%); compounds 8 and 9, isocratic (62.5%); 
compound 10, gradient (62.5-79%); compounds 11 and 12, isocratic (82.5%). Additional 
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purification of compounds 8 and 9 was conducted by isocratic preparative HPLC (78% 
methanol/water (0.05%TFA)). Chiral preparative separation of 8 was performed using 10% 
isopropanol / 90% hexane as the eluent.  
Isolation of falcarindiol from P. sativa and Mosher’s ester preparation was conducted by 
Yuping Lu (Page lab). Mosher’s esters were prepared directly with MTPA-Cl as previously 
described
 
(Hoye et al. 2007).  
falcarintriol (4): colorless oil; [α]25D +169 (c 0.29, CHCl3); UV (MeCN/H2O) λmax 235, 248, 261 
nm; 
1
H, 
13
C and HMBC NMR data in Table 3-1, 
1
H and 
13
C NMR data in agreement with 
previous report (Papajewski et al. 1998); HRESIMS m/z 313.1775 [M + Na]
+
 (calculated for 
C18H26NaO3, 313.1774).
 
oplopantriol (5): colorless oil; [α]25D +186 (c 0.15, CHCl3); UV (MeCN/H2O) λmax 234, 247, 
260 nm; 
1
H, 
13
C and HMBC NMR data in agreement with previous report (Kobaisy et al. 1997); 
HRESIMS m/z 315.1953 [M + Na]
+
 (calculated for C20H26NaO3, 315.1930). 
falcarindiol-acetate (6): colorless oil; [α]25D +205 (c 0.44, CHCl3); UV (MeCN/H2O) λmax 235, 
248, 261 nm; 
1
H and 
13
C NMR data in agreement with previous report (Kobaisy et al. 1997); 
HRESIMS m/z 355.1884 [M + Na]
+
 (calculated for C20H28NaO4, 355.1879). 
oplopandiol-acetate (7): colorless oil; [α]25D +129 (c 0.10, CHCl3); UV (MeCN/H2O) λmax 234, 
247, 260 nm; 
1
H and 
13
C NMR data in agreement with previous report (Kobaisy et al. 1997); 
HRESIMS m/z 357.2027 [M + Na]
+
 (calculated for C20H30NaO4, 357.2036). 
(3S,8S)-falcarindiol (8a): colorless oil; [α]25D +322 (c 0.21, CHCl3); UV (MeCN/H2O) λmax 235, 
247, 261 nm; 
1
H and 
13
C NMR data in agreement with previous report (Kobaisy et al. 1997).
 
(3R,8S)-falcarindiol (8b): colorless oil; [α]25D +218 (c 0.21, CHCl3); UV (MeCN/H2O) λmax 
235, 247, 261 nm; 
1
H and 
13
C NMR data in agreement with previous report (Kobaisy et al. 
1997).
 
oplopandiol (9): colorless oil; [α]25D +271 (c 2.4, CHCl3); UV (MeCN/H2O) λmax 234. 247, 260 
nm; 
1
H and 
13
C NMR data in agreement with previous report (Kobaisy et al. 1997); HRESIMS 
m/z 285.1827 [M + Na]
+
 (calculated for C17H26NaO2, 285.1825 ).
 
47 
 
(16R)-falcariniol-acetate (10): colorless oil; [α]25D -27.3 (c 0.11, CHCl3); UV (MeCN/H2O) λmax 
233, 243, 257 nm; 
1
H and 
13
C NMR data in Table 3-1, 
1
H spectrum in agreement with previous 
report (Kobayashi et al. 1977); HRESIMS m/z 339.1922 [M + Na]
+
 (calculated for C20H28NaO3, 
339.1930). 
Table 3-1. NMR spectroscopic data for falcarintriol (4) and (16R)-falcarinol-acetate (10) 
 
falcarintriol (4)  (16R)-falcarinol-acetate (10)  
position δC, mult. δH, (J in Hz) HMBC
a  δC, mult. δH, (J in Hz) 
1 63.1,CH2
b 3.63, t (6.7) 2, 3  64.7, CH2 4.04, t (6.8) 
2 32.7, CH2 1.55, m 1, 3  25.9, CH2 1.60, m 
3 25.6, CH2 1.30, m   29.3, CH2
e 1.30, m 
4 28.8, CH2
c 1.30, m   29.2, CH2
e 1.30, m 
5 29.2, CH2
c 1.30, m   29.2, CH2
e 1.30, m 
6 29.3, CH2
c 1.30, m   29.0, CH2
e 1.30, m 
7 29.0, CH2
c 1.30, m   28.6, CH2
e 1.30, m 
8 27.6, CH2 2.10, m 7, 9, 10, 11, 12  27.1, CH2 2.01, m 
9 134.4, CH 5.58, m 7, 8, 10, 11, 12  133.0, CH 5.49, m 
10 127.9, CH 5.50, m 7, 8, 9, 11, 12  122.1, CH 5.36, m 
11 58.7, CH2 5.19, d (8.2) 9, 10, 12, 13, 14, 15  17.7, CH2 3.01, d (7.0) 
12 79.8, qC    74.4, qCf 
 
13 70.2, qCd    71.3, qCf 
 
14 68.8, qCd    64.1, qCf 
 
15 78.5, qC    80.2, qCf 
 
16 63.4, CHb 4.91, br d (5.2) 12, 13, 14, 15, 17, 18  63.5, CH 4.89, t (5.3) 
17 135.9, CH 5.92, ddd (17.1, 10.2, 5.2) 15, 16  136.3, CH 5.92, ddd (17.1, 10.2, 5.3) 
18a 117.1, CH2 5.45, ddd (17.1, 1.5, 1.0) 15, 16, 17  116.9, CH2 5.44, d (17.1) 
18b  5.24, ddd (10.2, 1.2, 1.0) 15, 16  
 
5.22, d (10.2) 
CO     171.3, qC 
 
COCH3     21.0, CH3 2.02, s 
aHMBC correlations are from protons stated to the indicated carbon. 
a-fassignments may be interchanged 
 
  
 
(E)-nerolidol (11): colorless oil; 
1
H and 
13
C data in agreement with previous reports (Mattes et 
al. 1987; Blanc et al. 2005). HRESIMS m/z 245.1869 [M + Na]
+
 (calculated for C20H26NaO3, 
245.1875). 
(3R)-falcarinol (12): colorless oil; [α]25D -32 (c 0.15, CHCl3); UV (MeCN/H2O) λmax 232.7, 
244.4, 257.4 nm; 
1
H and 
13
C NMR spectra in agreement with previous report (Nitz et al. 1990); 
HRESIMS m/z 267.1716 [M + Na]
+
 (calculated for C17H24NaO, 267.1719).
 
3.2.6. A. nudicaulis  
A. nudicaulis rhizomes were collected near Saskatoon, SK, Canada, August 2009. GPS 
coordinates: N52.09536, W106.69521. A voucher specimen was deposited in the SASK 
herbarium, Department of Plant Sciences, University of Saskatchewan. 
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Fresh rhizomes (593 g) were dried at room temperature, ground and sifted through a 2.4 
mm screen. The resulting 269 g of dried tissue was extracted with 9 L of methanol. The extract 
was concentrated to 150 mL under vacuum (25-28°C), water was added to 10% and the extract 
was extracted four times with an equal volume of hexane. The methanolic extract was diluted with 
water to give 75% water/25% methanol and was extracted four times with an equal volume of 
chloroform. An aqueous 1% NaCl solution was used to extract tannins from the chloroform 
partition. Solvents were then removed from each fraction under vacuum. The chloroform partition 
was subjected to flash chromatography (15 × 230 mm column packed with 200-425 mesh silica gel 
(Fisher), gradient of 10-100% ethyl acetate/hexane). Sixty-three fractions were collected and 
combined by the basis of TLC (Si gel with ratios of hexane : ethyl acetate from 1:1 to 1:4) and 
HPLC analysis to eight fractions (A through G). Following clean up on a Sep-pak Vac 20cc C18 
cartridge (Waters), the major compound panaxydol (14) was isolated by preparative C18 HPLC 
(79% methanol/water, isocratic). Falcarinol (13) was isolated by preparative HPLC (86% 
methanol/H2O, isocratic). Ginsenoyne D (15) was isolated by preparative HPLC (79% 
methanol/H2O, isocratic) and repurified by semi-preparative HPLC (85% methanol/H2O, 
isocratic). 1,2-dihydro-epoxyoplopandiol-acetate (16) was isolated by preparative HPLC (83% 
methanol, isocratic) and repurified by semi-preparative HPLC (79% acetonitrile/H2O, isocratic). 
Falcarinol-acetate (17) was isolated by preparative HPLC (83% methanol/H2O, isocratic) and 
repurified by semi-preparative HPLC (88% methanol/H2O, isocratic). Polyacetylenes 18-22 were 
isolated using a gradient of 60-93% methanol/water. Falcarinolol (23) was isolated by preparative 
HPLC (73% methanol/H2O, isocratic). For all purifications other than that of panaxydol (14), 
methanol was removed under vacuum and water was removed by lyophilisation. The HPLC eluate 
of panaxydol (14) was extracted with dichloromethane, dried with MgSO4, and concentrated under 
vacuum. 
falcarinol (13): colorless oil; [α]25D -27 (c 0.96, CHCl3); UV (MeCN/H2O) λmax 233, 244, 257 
nm; 
1
H and 
13
C NMR spectra in agreement with previous report (Nitz et al. 1990); HRESIMS 
m/z 267.1716 [M + Na]
+
 (calculated for C17H24NaO, 267.1719) ESIMS m/z 244.1 [M + H]
+
 .
 
panaxydol (14): colorless oil; [α]25D -113 (c 0.13, CHCl3); UV (MeCN/H2O) λmax 221, 232, 243, 
257 nm; 
1
H and 
13
C NMR data in agreement with previous report (Lu et al. 1998); HRESIMS 
m/z 283.16507 [M + Na]
+
 (calculated for C17H24NaO2, 283.16685). 
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ginsenoyne D (15): colorless oil; [α]25D -24.6 (c 0.07, CHCl3); UV (MeCN/H2O) λmax 221sh, 
230, 242, 256 nm; 
1
H and 
13
C NMR data in agreement with previous report (Hirakura et al. 
1991); ESIMS m/z 263.1 [M + H]
+
 (calculated for C17H27O2,263.2). 
1,2-dihydroepoxyoplopandiol-acetate (16): colorless oil; [α]25D -1.5 (c 0.07, CHCl3); UV 
(MeCN/H2O) λmax 234, 269, 285, 300, 318 nm; 
1
H data presented in Table 3-2; HRESIMS m/z 
343.18695 [M + Na]+ (calculated for C19H28NaO4, 343.18798). 
1
H, 
13
C, and HMBC NMR 
spectra are provided in Appendix A. 
falcarinol-acetate (17): colorless oil; [α]25D -2.9 (c 0.03, CHCl3); UV (MeCN/H2O) λmax 233, 
244, 259 nm; 
1
H spectrum in agreement with previous report (Kobayashi et al. 1977) and spectra 
for compound isolated from O. horridus (10); HRESIMS m/z 339.18976 [M + Na]+ (calculated 
for C20H28NaO3, 339.19307). 
panaxyne (18): colorless oil; [α]25D +17 (c 0.24, acetone); UV (MeCN/H2O) λmax 221sh, 227, 
244, 257 nm; 
1
H and 
13
C NMR data in agreement with previous report (Yang et al. 2008); 
HRESIMS m/z 243.13460 [M + Na]
+
 (calculated for C14H20NaO2, 243.13555).  
epoxyfalcarindiol (19): colorless oil; [α]25D +26 (c 0.37, CHCl3); UV (MeCN/H2O) λmax 221sh, 
232, 244, 258 nm; 
1
H and 
13
C NMR data in agreement with previous report (Fujimoto et al. 
1991); HRESIMS m/z 299.16168 [M + Na]
+
 (calculated for C17H24NaO3, 299.16177). 
 epoxyoplopandiol (20): colorless oil; [α]25D +48 (c 0.51, CHCl3); UV (MeCN/H2O) λmax 
221sh, 231, 257, 285, 311sh nm; 
1
H and 
13
C NMR data in agreement with previous report (Yang 
et al. 2010); HRESIMS m/z 301.17740 [M + Na]
+
 (calculated for C17H26NaO3, 301.17742).  
10-methoxyheptadeca-1-en-4,6-diyne-3,9-diol (21): colorless oil; [α]25D -22 (c 0.29, CHCl3); 
UV (MeCN/H2O) λmax 231, 243, 257, 267, 282 nm; 
1
H and 
13
C NMR data in agreement with 
previous report (Yang et al. 2008); HRESIMS m/z 315.1742 [M + Na]
+
 (calculated for 
C18H28NaO3, 315.1936).  
panaxydiol (22): colorless oil; [α]25D +4 (c 0.21, CHCl3); UV (MeCN/H2O) λmax 215, 241, 254, 
264, 285 nm; 
1
H and 
13
C NMR data in agreement with previous report (Schmiech et al. 2009); 
HRESIMS m/z 283.16640 [M + Na]
+
 (calculated for C17H24NaO2, 283.16685).  
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falcarinolol (23): colorless oil; [α]25D -30 (c 0.08, CHCl3); UV (MeCN/H2O) λmax 233, 244, 259 
nm; 
1
H NMR data in agreement with previous report (Kobayashi et al. 1977), 
1
H,  
13
C and 
HMBC NMR data presented in Table 3-2; HRESIMS m/z 297.18120 [M + Na]
+
 (calculated for 
C18H26NaO2, 297.18250). 
Table 3-2. NMR spectroscopic data for 1,2-dihydroepoxyoplopandiol-acetate (16) and 
falcarinolol (23) 
3.2.7. A. latifolia 
A. latifolia seeds were provided by Nick Page of Rainforest Applied Ecology. Thirty-
eight plants were grown in the NRC Saskatoon phytotron and greenhouse. A voucher specimen 
(accession #180331) was deposited in the SASK herbarium, Department of Plant Sciences, 
University of Saskatchewan.  
Root material (171 g) was cut into small pieces and dried at room temperature with air. 
Dried A. latifolia roots (43.3 g) were ground, screened at 0.85 mm and extracted with methanol. 
Three different extractions of the roots were undertaken to examine the difference between 
frozen roots, fresh tap roots and fresh small roots. After the first extraction and examination of 
the extracts by analytical HPLC the roots were combined on the basis of their similarity and 
 
1,2-dihydroepoxyoplopandiol-acetate (16) 
 
falcarinolol (23) 
positioni 
 
δH, (J in Hz)  
δC, mult. δH, (J in Hz) HMBC
a 
1 
 
3H, 1.03, t (7.5) 
 
63.2, CH2 3.65, t (6.7) 2, 3 
2 
 
2H,1.81, m 
 
32.8, CH2 1.58, m 1, 3, 4 
3 
 
1H, 5.34, t (6.5) 
 
25.7, CH2 1.35, m  
4 
 
 
 
29.4, CH2
e 1.35, m 
 
5 
 
 
 
29.3, CH2
e 1.35, m 
 
6 
 
 
 
29.0, CH2
e 1.35, m 
 
7 
 
 
 
28.9, CH2
e 1.35, m 
 
8 
 
1H, 4.36, dd (7.5,5.0) 
 
27.0, CH2 2.03, m 7, 9, 10, 12 
9 
 
1H, 3.13, dd (7.5, 4.0) 
 
133.1, CH 5.49, m 7, 8, 11 
10 
 
1H, 3.05, m 
 
122.0, CH 5.36, m 8, 11, 12 
11 
 
1.64, m 
 
17.7, CH2 3.03, d (6.7) 7, 8, 9, 10, 12, 13, 14, 15 
12 
 
1.50, m 
 
80.2, qC 
  
13 
 
1.30, m 
 
64.0, qCf 
  
14 
 
1.30, m 
 
71.2, qCf 
  
15 
 
1.30, m 
 
74.4, qC 
  
16 
 
1.30, m 
 
63.5, CH 4.91, br d (5.3) 13, 14, 15, 17, 18 
17 
 
3H, 0.88, t (6.5) 
 
136.2, CH 5.95, ddd (17.0, 10.2, 5.3) 15, 16 
18a 
 
 
 
117.0, CH2 0.99, t (17.0) 16, 17 
18b 
 
 
  
5.24, d (10.2) 16 
COCH3  
 
    
8’-OH 
 
3H, 2.1, d (5.0) 
    aHMBC correlations are from protons stated to the indicated carbon. 
b-fassignments may be interchanged 
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extracted together for a total of five extractions using 3.2 L methanol. The methanolic extract 
was concentrated and subjected to solvent-solvent partitioning as shown in Figure 3-10. 
The dicholormethane/chloroform partition was separated into 90 fractions by flash 
chromatography (26 × 460 mm column packed with 110 g of 230-400 mesh silica gel (Fisher), 
linear gradient of pure dichloromethane to pure methanol). Preliminary fractions were combined 
on the basis of UV absorption at 280 nm. Solvent was removed from a sample of each fraction 
and resuspended in DMSO at 10 mg/mL and tested in the QR bioassay. Fractions 1-3 (A-C) were 
separated on a Sep-pak Vac 12 cc 2g C18 SPE cartridge (Waters) using methanol/water as the 
eluent. The percentage of methanol used was 30 % to 100% in 10% steps for the combined 
fractions 1 and 2 and 40% to 100% in 20% steps for fraction 3. Fractions were combined on the 
basis of analytical HPLC and tested in the QR bioassay. From the three active fractions 16 
compounds were isolated by preparative HPLC. The solvent was removed under reduced 
pressure and lyophilisation and compounds were resuspended in deuterated methanol (MeOD) 
for 
1
H, j-mod 
13
C, HMQC and HMBC NMR. Compounds were tested in the QR bioassay 
following the acquisition of NMR spectra. 
2-(2,6-dihydroxyphenyl)-5-hydroxy-7-methoxy-6,8-dimethylchroman-4-one (24): UV 
(acetonitrile/H2O) λmax. (nm) 286; 
1
H NMR (MeOD) δ 6.98 (1H, t, J = 8.2 Hz, H-4’), 6.35 (2H, d, 
J = 8.2 Hz, H-3’, H-5’), 5.92 (1H, dd, J1 = 14.2 Hz, J2 = 2.9 Hz, H-2), 3.95 (1H, dd, J1 = 17.4 Hz, 
J2 = 14.2 Hz, H-3a), 3.72 (3H, s, OMe-7), 2.51 (1H, dd, J1 = 17.4Hz, J2 = 2.9 Hz, H-3b), 2.06 
(3H, s, Me-8), 2.01 (3H, s, Me-6). 
13
C NMR (CDCl3) δ 201.4 (C, C-4), 166.2 (C, C-7), 160.8 (C, 
C-5), 160.4 (C, C-4), 158.5 (C, C-2’, C-4’), 131.1 (CH, C-4’), 112.0 (C, C-1’), 111.3 (C, C-8), 
110.6 (C, C-6), 108.2 (CH, C-3’, C-5’), 105.8 (C, C-10), 73.80 (CH, C-2), 60.56 (CH3, OMe-7), 
41.21 (CH2, C-3), 8.63(CH3, Me-6), 8.00 (CH3, Me-8). HRESIMS observed m/z 331.11703 [M + 
H]
+
 (calculated for C18H19O6, 331.11762). Spectra included in Appendix A. 
compound (25): UV (acetonitrile/H2O) λmax. (nm) 291; 
1
H NMR (MeOD) δ 6.98 (1H, t, J = 8.2 
Hz, H-4’), 6.34 (2H, d, J = 8.2 Hz, H-3’, H-5’), 6.12 (1H, s, H-6 or -8), 5.95 (1H, dd, J1 = 14.1 
Hz, J2 = 3.0 Hz, H-2), 3.96 (1H, dd, J1 = 17.4 Hz, J2 = 14.2 Hz, H-3a), 3.84 (3H, s, OMe-7), 2.45 
(1H, dd, J1 = 17.4 Hz, J2 = 3.0 Hz, H-3b), 1.95 (3H, s, Me-8 or 6), 2.01 (3H, s, Me-6). 
13
C NMR 
(CDCl3) δ 200.0 (C, C-4), 163.5* (C, C-7), 161.4*(C, C-5), 160.4* (C, C-4), 158.5 (C, C-2’, C-
4’), 131.2* (CH, C-4’), 112.0* (C, C-1’), 111.3* (C, C-6 or C-8), 108.2* (CH, C-3’, C-5’), 103.6 
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(C, C-10), 91.80 (CH, C-6 or C-8), 73.92 (CH, C-2), 56.38 (CH3, OMe-7), 40.84 (CH2, C-3), 
6.98 (CH3, Me-6 or Me-8), * denotes signal inferred from HMBC spectrum. HRESIMS m/z 
317.10104 [M + H]
+
 (calculated for C17H17O6, 317.10197). Spectra included in Appendix A. 
boeravinone E (26), UV (acetonitrile/H2O) λmax. (nm) 278, 302sh, 340sh; 
1
H, 
13
C and HBMC 
data in agreement with previous analysis (Lami et al. 1991). HRESIMS m/z 329.06689, [M + H]
+
 
(calculated for C17H13O7, 329.06557).
 
3.2.8. C. sativa  
C. sativa ‘Finola’ hemp plants were grown in the NRC Saskatoon phytotron. Female 
flowers were dried at room temperature. Dried flowers (200 g) were extracted overnight with 1.5 L 
hexane, filtered and concentrated under vacuum at 40°C to give 14 g of residue. The residue (125 
mg) was resuspended in 0.75 mL of methanol, filtered with a Spin-X centrifugal filter (Corning) 
loaded onto a Sep-Pak vac 2 g C18 SPE cartridge (Waters) and eluted with 4 column volumes of 
methanol. The SPE eluate was filtered by Spin-X filter and CBDA was isolated using preparative 
HPLC (83% Methanol/H2O with 0.05% trifluoroacetic acid). The residue (378 mg)  was heated at 
120°C for 30 min resuspended in methanol and filtered on a Spin-X filter. CBD was isolated by 
preparative HPLC (80% Methanol/H2O with 0.05% trifluoroacetic acid). 
THCA was isolated from a colleagues’ crude THCA-rich fraction by preparative HPLC 
(85% Methanol/H2O with 0.05% trifluoroacetic acid). THC was isolated by preparative HPLC 
(88% Methanol/H2O with 0.05% trifluoroacetic acid) from a portion of the THCA-rich fraction 
that was heated to 130ºC for 40 min. 
Solvent was removed from HPLC eluates by rotary evaporation at 30°C and lyophilization. 
Cannabinoids were identified by LC-UV-MS, 
1
H and 
13
C NMR (Choi et al. 2004). Deuterated 
methanol was used as the solvent for NMR experiments. 
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3.3. Results and discussion 
3.3.1. Isolation of the active components from the methanolic extract of L. porteri roots 
 Due to the potential advantages of using thiol-reactivity as a guide to isolating Nrf2 
activators I decided to attempt this approach first. However, following the failure of this method 
I later turned to using QR bioassay-guided fractionation.  
3.3.1.1. Fractionation of the L. porteri extract guided by tandem MS-based detection of 
thiol-reactive extract components 
In order to efficiently use thiol-reactivity as a guide for isolation I conducted some 
preliminary experiments to select a positive control and optimize the detection method. A panel 
of known QR inducers including curcumin, resveratrol, sulforaphane and xanthohumol were 
used for optimization. A number of scanning methods were successful in detecting GSH-adducts. 
These included scanning for parents of m/z 272 or 306 in negative mode and parents of m/z 130 in 
positive mode. I chose to scan for parents of m/z 130 in positive mode due to a greater signal to 
noise ratio. Xanthohumol was selected for use as a positive control. Tuning of the mass 
spectrometer was optimized using the xanthohumol-GSH adduct and oxidized glutathione. 
A preliminary screen of solvent-solvent partitions (data not shown) showed that the L. 
porteri  chloroform partition was the most QR-active. Therefore, following extraction and solvent-
solvent partitioning, I proceeded to fractionate the chloroform partition using silica gel column 
chromatography. Two fractions showed a prominent glutathione-adduct that corresponded well 
with the primary compound in those fractions. The compound involved was isolated and identified 
as coniferyl ferulate (1). However, this compound proved to have negligible activity in the QR 
bioassay (<1.2-fold at 100 µM). Although the reason for the lack of QR-inducing activity was 
unclear, this finding emphasized the fact that not all thiol-reactive compounds will be Nrf2 
activators. The thiol reactivity-based screening approach was therefore abandoned and I returned to 
using QR bioassay-guided fractionation on a fresh extract.  
3.3.1.2. Alkylphthalides are the primary QR inducers in L. porteri roots 
Silica gel-based separation of a newly prepared chloroform partition of L. porteri led to the 
identification of QR-inducing activity in fractions that were less polar than the fractions that 
contained coniferyl ferulate (1) (Figure 3-1). This further confirmed that coniferyl ferulate was not 
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responsible for the extract’s QR-inducing activity. When the most active fraction (B) was separated 
on a reverse phase SPE cartridge, I found that the most active subfraction (B-3) included 
compounds with UV spectra similar to phthalides, a group of compounds previously reported from 
Apiaceae plants (Beck et al. 2007). Purification of the eight major compounds from this fraction 
revealed that while seven of these eight compounds displayed QR-inducing activity, a single 
compound had much higher activity than the rest (CD value of ~ 0.3 μg/mL compared to CD 
values of ~ 3 μg/mL). Analysis by 1H, 13C, and HMBC NMR showed that the most active 
compound was an isomer of ligustilide (Figure 3-2). A nuclear overhauser effect (NOE) 
experiment revealed the (Z)-geometry of the alkyl chain, giving (Z)-ligustilide (2) (Beck et al. 
2007). 
As previously described (Cui et al. 2006), pure (Z)-ligustilide (2) was unstable and rapidly 
degraded if stored in an aqueous solution. Following HPLC isolation, I  identified the major 
degradation product by NMR (
1
H, 
13
C, HMBC and NOE experiments) as trans-6,7-
dihydroxyligustilide (3). trans-6,7-Dihydroxyligustilide (3) was found to be optically inactive 
indicating that this isolate was a racemic mixture containing equal amounts of the enantiomers 
senkyunolide I (6S,7R-geometry) and ligustilidiol (6R,7S-geometry).  
trans-6,7-Dihydroxyligustilide (3) was also identified in a newly prepared methanolic 
extract of L. porteri roots. Given the spontaneous conversion of (Z)-ligustilide (2) to trans-6,7-
dihydroxyligustilide (3) under storage conditions the origin of this compound in the plant may also 
be non-enzymatic. 
The induction of QR by (Z)-ligustilide (2), trans-6,7-dihydroxyligustilide (3) and (R)-
sulforaphane is shown in Figure 3-3. Both (Z)-ligustilide and the racemic mixture of trans-6,7-
dihydroxyligustilide were relatively potent inducers of QR, with CD values of 2.0 µM and 2.2 µM, 
respectively. 
Hepa-1c1c7 cells tolerated high concentrations of (Z)-ligustilide and trans-6,7-
dihydroxyligustilide (Table 3-3). The concentrations required to reduce cell viability by 50% (IC50) 
values for these two compounds were 64 µM, and over 100 µM, respectively. The ratio of the IC50 
and CD values, referred to as the chemopreventive index (CI), indicates the margin between the 
desired effect and adverse toxicity. The CI values for (Z)-ligustilide and trans-6,7-
dihydroxyligustilide were 32 and > 45, respectively, indicating a large therapeutic window. 
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Figure 3-1. Separation scheme for methanol extracts of L. porteri roots. Concentrations required to double 
QR-activity (CD), µg/mL or relative activity (++ high activity, + moderate activity, low or no activity) are 
indicated in brackets.  
Recent analysis of the pharmacokinetics of (Z)-ligustilide revealed that the (6S,7R) 
enantiomer of trans-6,7-dihydroxyligustilide (3), senkyunolide I is a metabolite of (Z)-ligustilide 
(Yan et al. 2008). Thus, the QR-inducing activity of senkyunolide I and related metabolites may 
contribute to the activity of (Z)-ligustilide in vivo. 
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 Figure 3-2. Compounds isolated from L. porteri.  
 
Figure 3-3. QR induction following exposure to L. porteri alkylphthalides. Hepa-1c1c7 cells were exposed to 
alkylphthalides for 48 h and QR activity was compared to solvent treated controls. (R)-sulforaphane was 
included as a positive control. Results are the mean of at least three experiments ± the standard deviation. 
Table 3-3. Summary of bioassay results for L. porteri phthalides. 
Compound 
QR inducing activity 
CD
a
 (µM) 
Cell viability 
IC50
b
 (µM) 
CI 
(IC50/CD) 
(R)-sulforaphane 0.36 ± 0.08 8.1 ± 2.5 23 
(Z)-ligustilide (2) 2.0 ± 0.66  64 ± 8.9 32 
trans-6,7-
dihydroxyligustilide (3) 
2.2 ± 0.90 > 100 > 45 
a refers to the concentration required to double activity of the enzyme QR relative to DMSO treated controls. 
b refers to the concentration required to reduce cell viability to 50% in Hepa-1c1c7 cells.  
During this work, Dietz et al. (2008) reported that an extract of Angelica sinensis, a 
member of the Apiaceae used in traditional Chinese medicine (dang gui), was a strong inducer of 
QR. Bioassay-guided fractionation of this extract also led these investigators to (Z)-ligustilide and 
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senkyunolide I (6S,7R-dihydroxyligustilide) as the primary components responsible for QR-
inducing activity.  
3.3.2. C17-type polyacetylenes from O. horridus are potent inducers of QR 
Methanolic extracts of O. horridus stems or a sample that combined berries and leaves 
were active in the QR-bioassay screen (maximal QR induction of 2.02-fold at 2 mg/mL, and 2.45 
fold at 2 mg/mL, respectively). I choose to use the extract of the inner stem bark for bioassay-
guided fractionation because it was unclear whether the berries or leaves were responsible for 
activity in the combined extract and for the reason that the inner stem bark is the most commonly 
used part for traditional medicine (Moerman 1998).
 
     Solvent-solvent partitioning led to an increase in activity in the chloroform partition 
(Figure 3-4). Flash chromatography of the chloroform-soluble fraction yielded several 
polyacetylene rich fractions (fractions C through J) with high QR-inducing activity. Pure 
polyacetylenes were isolated from these fractions by preparative HPLC (Figure 3-5).
Figure 3-4. Separation scheme for methanol extract of O. horridus inner stem bark. Concentrations required to 
double QR-activity (CD values, µg/mL) are indicated in brackets. 
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Figure 3-5. Compounds isolated from O. horridus. 
1
H NMR, 
13
C NMR, and MS spectra for compounds 4-9, and 12 matched those of 
previously reported polyacetylenes from O. horridus (Kobaisy et al. 1997; Huang et al. 2010). 
However, the levorotary optical rotations of falcarinol (12) and falcarinol-acetate (10) were in 
contrast with the previously reported dextrorotary observations and indicated (R) rather than (S) 
configurations for these compounds (Larsen et al. 1970; Terada et al. 1989). As all previous 
polyacetylenes from O. horridus were assigned to have (3S) configurations, the observation of a 
(3R) configuration for falcarinol was puzzling. I used chiral HPLC to analyze the enantiopurity of 
falcarindiol-acetate (6), falcarindiol (8), oplopandiol (9) and falcarinol (12) to help resolve this 
discrepancy. Although only a single peak was detected for falcarindiol-acetate (6), oplopandiol (9) 
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and falcarinol (12), two stereoisomers of falcarindiol (8) were detected at a ~ 3:1 ratio. The less 
abundant falcarindiol stereoisomer (8b) displayed an equal retention time to (3R,8S)-falcarindiol 
isolated from Pastinaca sativa (parsnip). A colleague (Yuping Lu) had previously determined the 
P. sativa falcarindiol to have a (3R,8S) configuration by Mosher’s ester analysis.  
Purification of the falcarindiol stereoisomers by chiral HPLC led to the observation that 
both stereoisomers were strongly dextrorotary. Only two dextrorotary configurations of 
falcarindiol exist: (3R,8S) and (3S,8S)
 
(Ratnayake et al. 2002). As the less abundant stereoisomer, 
8b, was already identified as (3R,8S), the configuration of the more abundant stereoisomer, 8a, was 
assigned as (3S,8S). 
Detailed NMR analysis provided further support for these configurational assignments. 
Each falcarindiol stereoisomer was analyzed by 
1
H and 
13
C NMR under identical conditions 
(concentration, solvent composition and NMR set-up). Although proton and carbon NMR spectra 
of the two stereoisomers of falcarindiol were nearly identical, an obvious difference was noted for 
the signals corresponding to the proton at position 3. This difference would only be expected for a 
pair of diastereomers and is therefore consistent with the assignments of (3S,8S) and (3R,8S). 
My assignment of the more abundant O. horridus falcarindiol (8a) as (3S,8S) is compatible 
with the previous assignment by Kobaisy et al. (1997) of falcarindiol from O. horridus as (3S,8S). 
In addition, Yang et al.
 
(2010) recently reported that Oplopanax elatus produces the same two 
diastereomers of falcarindiol and that the (3S,8S)-falcarindiol (8a) was the more abundant 
diastereomer. 
Although the detection of falcarindiol (8) with a (3R,8S) configuration supports the idea 
that O. horridus produces hydroxylated polyacetylenes of both (3R) and (3S) configurations it does 
not fully explain the discrepancy between the present finding of (3R)-falcarinol (12) with the 
previous report of (3S)-falcarinol (Kobaisy et al. 1997). The possibility of distinct chemotypes of 
O. horridus warrants further inspection as these chemotypes could be useful for determining the 
enzymes(s) responsible for the (3R) configuration. 
Most polyacetylenes isolated and tested from O. horridus were potent QR inducers (Figure 
3-6)  having CD values in the low µM to sub-µM range (Table 3.4). The central hydroxyl group 
(8-OH in falcarindiol (8)) appeared to be integral to the activity of these polyacetylenes because 
(16R)-falcarinol-acetate (10) and (3R)-falcarinol (12), which lacked this group, did not consistently 
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double QR activity, and only reached this induction level with a substantial reduction in cell 
viability. The terminal double bond appeared to be required for maximal QR inducing activity 
although compounds possessing the reduced terminus (1,2-dihydrofalcarintriol (5) and 1,2-
dihydrofalcarindiol-acetate (7))also displayed less toxicity than the comparable compounds a 1,2 
double bond (falcarintriol (4) and falcarindiol-acetate (6)). Given the relatively low CI values for 
these compounds these decreases may be a reasonable tradoff. Oplopandiol (9) had both potent QR 
inducing activity (CD = 1.2 µM) and relatively low impact on cell viability (IC50 = 14.2 µM) 
giving a CI of 12.  The presence of an acetyl or hydroxyl group at the aliphatic terminus 
consistently reduced activity as well as toxicity. 
 
Figure 3-6. QR induction following exposure to O. horridus compounds. Hepa-1c1c7 cells were exposed to O. 
horridus compounds for 48 h and QR activity was compared to solvent treated controls. (R)-sulforaphane was 
included as a positive control. Results are the mean of at least three experiments ± the standard deviation. 
The most potent inducer of QR from O. horridus was (3S,8S)-falcarindiol (8a). Strikingly, 
this diastereoisomer was approximately six times more potent than the (3R,8S) -falcarindiol (8b) 
diastereomer. The Nrf2-inducing activity of falcarindiol and a related polyacetylene panaxytriol 
was reported during the preparation of a manuscript of this work
 
(Lee et al. 2009; Ohnuma et al. 
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2009). However, the former study did not report falcarindiol-configuration(s), nor the important 
difference in potency of the diastereomers.  
The sesquiterpene (E)-nerolidol (11) was isolated and identified due to its abundance in a 
potent fraction (fraction J). Although previously shown to possess anti-inflammatory activity 
(Tung et al. 2008), (E)-nerolidol had no activity in the QR bioassay, nor did this compound 
display synergy when tested at a concentration of 10 µM with falcarindiol (8) or oplopandiol (9) 
(data not shown).  
Table 3-4. Summary of bioassay results for O. horridus compounds. 
Compound 
QR inducing activity  
CD
a
 (µM) 
Cell viability  
IC50
b
 (µM) 
CI  
IC50/CD 
(R)-sulforaphane 0.24 ± 0.05 21.2 ± 3.0 88 
falcarintriol (4) 1.6 ± 0.8 15.4 ± 4.0 9.6 
1,2-dihydrofalcarintriol (5) 6.7 ± 1.7 > 32 > 4.8 
falcarindiol-acetate (6) 2.3 ± 1.0 18.4 ± 2.0 8.0 
 1,2-dihydrofalcarindiol-
acetate (7) 
12.4 ± 2.0 > 32 > 2.6 
(3S,8S)-falcarindiol (8a) 0.85 ± 0.22 4.5 ±3.5 5.3 
(3R,8S)-falcarindiol (8b) 4.8 ± 0.5 > 10 > 2.1 
oplopandiol (9) 1.2 ± 0.4 14.2 ± 7.9 12 
(16R)-falcarinol-acetate (10) N/A
c 
14.2 ± 7.5 - 
trans-nerolidol (11) N/A
c
 >32 - 
(3R)-falcarinol (12) N/A
c 
5.2 ± 0.7 - 
a refers to the concentration required to double activity of the enzyme QR relative to DMSO treated controls. 
b refers to the concentration required to reduce cell viability to 50% in Hepa-1c1c7 cells.  
c N/A indicates maximal magnitude of activation less than two-fold. 
 
3.3.3. Additional polyacetylenes from A. nudicaulis further define polyacetylene structure-
activity relationships 
The goal of fractionation of the A. nudicaulis methanolic root extract was to identify 
additional QR-inducing C17-type polyacetylenes and investigate structure-activity relationships. 
Therefore, in addition to pursuing the most active fractions, all abundant compounds with UV 
and mass spectra characteristic of C17-type polyacetylenes were isolated. Fractionation of the A. 
nudicaulis extract is summarized in Figure 3-7. 
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Figure 3-7. Separation scheme for methanol extract of A. nudicaulis roots. Concentrations required to double 
QR activity (CD) or concentration required to increase QR activity by 50% (C50), are indicated in µg/mL in 
brackets.  
As was the case for O. horridus, a multitude of bioactive C17-type polyacetylenes were 
present in the chloroform partition of A. nudicaulis. Eleven of these were isolated and identified 
following silica gel flash chromatography, preparative reverse phase HPLC and semi-preparative 
reverse phase HPLC (Figure 3-8). 
Although the structures of the polyacetylenes isolated from A. nudicaulis (Figure 3-8) 
closely resembled those from O. horridus, only two (falcarinol (13) and falcarinol-acetate (17))  
of the 11 compounds identified were also isolated from O. horridus. Of the compounds isolated, 
one (epoxyoplopandiol (20)) was novel, none were previously described from this plant, and 
none were previously identified as QR inducers. One distinct feature of several of the A. 
nudicaulis polyacetylenes was an epoxide group (position 9,10 in panaxydol (14)). 
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Figure 3-8. Compounds isolated from A. nudicaulis. 
The most abundant polyacetylene was panaxydol (14). Lu et al. (1998) have reported the 
configuration of this compound isolated from Panax ginseng, to be (3R, 9R, 10S). The specific 
rotation of panaxydol (14) (-113) in deuterated chloroform was similar to that reported for the 
(3R, 9R, 10S) stereoisomer (-96.1) by Lu et al. (1998). As eight stereoisomers are possible for 
this compound and Araliaceae plants have been shown to produce polyacetylenes with both 3R 
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and 3S configurations, I am cautious about assigning a configuration to panaxydol on the basis of 
optical rotation alone. On the other hand, falcarinol isolated from A. nudicaulis (13) has only a 
single stereocenter and therefore levorotary (negative) optical rotation for this compound is 
enough to assign a (3R) configuration on the basis that it matches the report by Zheng et al. 
(1999) for (3R)-falcarinol. Similarly the levorotary optical rotations for falcarinol-acetate (17) 
and falcarinolol (23) imply an (R) configuration for these compounds. The configuration of the 
remaining polyacetylenes could not be deduced based on optical rotation due the presence of 
multiple stereocenters. 
The QR bioassay results for purified A. nudicaulis polyacetylenes are presented in Figure 
3-9 and a summary of bioassay results is presented in Table 3-5. The potency of 
epoxyfalcarindiol (19) (CD value of 0.41 µM) exceeded that of the most potent polyacetylene 
isolated from O. horridus, (3S,8S)-falcarindiol (8a) (CD value of 0.85 µM). The structure of 
epoxyfalcarindiol (19) differed from falcarindiol (8) by an epoxide in the place of a double bond 
in falcarindiol (8).
Figure 3-9. QR induction following exposure to A. nudicaulis polyacetylenes. Hepa-1c1c7 cells were 
exposed to A. nudicaulis polyacetylenes for 48 h and QR activity was compared to solvent treated 
controls. (R)-sulforaphane was included as a positive control. Results are the mean of at least three 
experiments ± the standard deviation. 
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Table 3-5. Summary of bioassay results for A. nudicaulis compounds. 
Compound 
QR inducing activity  
CD
a
 (µM) 
Cell viability  
IC50
b
 (µM) 
CI  
IC50/CD 
(R)-sulforaphane 0.17 ± 0.08 5.8 ± 1.5 33.5 
falcarinol (13) N/A
c
 6.3 ± 0.6 - 
panaxydol (14) N/A
c
 2.6 ± 1.6 - 
ginsenoyne D (15) N/A
c
 3.1 ± 1.2 - 
1,2-dihydroepoxyoplopandiol- acetate (16) N/A
c
 16.1 ± 0.5 - 
falcarinol-acetate (17) N/A
c
 >32 - 
panaxyne (18) 16.1 ± 7.3 74.2 ± 7.1 4.6 
epoxyfalcarindiol (19) 0.24 ± 0.10 6.5 ± 1.3 27.2 
epoxyoplopandiol (20) 0.41 ± 0.17 10.9 ± 1.7 26.5 
21 13.2 ± 12.5 14.6 ± 5.3 1.1 
panaxydiol (22) 5.3 ± 3.3 18.6 ± 13.1 3.5 
falcarinolol (23) 7.8 ± 4.8 14.8 ± 1.1 1.9 
 
a refers to the concentration required to double activity of the enzyme QR relative to DMSO treated controls. 
b refers to the concentration required to reduce cell viability to 50% in Hepa-1c1c7 cells.  
c N/A indicates maximal magnitude of activation less than two-fold. 
Although the exact configuration was not determined for all of the compounds isolated, 
the same general correlations between structure and activity that were observed with O. horridus 
polyacetylenes were observed for the A. nudicaulis polyacetylenes. Table 3-6 summarizes the 
structure activity relationships of the A. nudicaulis and O. horridus polyacetylenes.  
Maximal QR-inducing activity required the presence of a second hydroxyl group 
(position 8 in falcarindiol) flanking the conjugated triple bonds, a terminal alkene (1,2 position in 
falcarindiol), an epoxide group in place of the double bond (9,10 in falcarindiol) and lack of 
modification to the aliphatic terminus.  
Information regarding the metabolism of falcarindiol-type polyacetylenes in humans is 
lacking but it is possible that the epoxylated compounds could be metabolites of their 
corresponding alkenes. As (3S,8S)-falcarindiol showed substantially increased QR-activity (six-
fold greater) compared to (3R,8S)-falcarindiol, it would be interesting to compare stereoisomers of 
epoxyfalcarindiol (19) for activity. If the configuration of the 3-hydroxyl group of 
epoxyfalcarindiol (19) isolated in this study was (R), there exists the possibility that the (3S) 
stereoisomer may possess even higher activity. A six-fold increase in activity of epoxyfalcarindiol 
(19) would lead to a CD value of only 40 nM and would place it in a very select group of 
compounds with CD values in the tens of nM range. 
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Table 3-6. Summary of structure activity relationships amongst polyacetylenes isolated from O. horridus and 
A. nudicaulis. 
 CD value
a 
 IC50 value
b 
 with without ratio  with without ratio 
Hydroxyl group (position 8) 
8b v 12 4.8 N/A -  >10 5.2 >1.9 
6 v 10 2.3 N/A -  18.4 14.2 1.2 
19 v 14 0.24 N/A -  6.5 2.6 2.5 
20 v 15 0.41 N/A -  10.9 3.1 3.5 
Mean 4.5 N/A -  >11.5 6.3 2.4 
Terminal double bond (position 1) 
4 v 5 1.6 6.7 0.2  15.4 >32 <0.5 
6 v 7 2.3 12.4 0.2  18.4 >32 <0.6 
8a v 9 0.85 1.2 0.7  4.5 14.2 0.3 
14 v 15 N/A N/A -  2.6 3.1 0.8 
19 v 20 0.24 0.41 0.6  6.5 10.9 0.6 
Mean 1.2 5.2 0.4  9.5 >18.4 <0.6 
Epoxide instead of double bond (position 9,10) 
19 v 8a 0.24 0.85 0.3  6.5 4.5 1.4 
20 v 9 0.41 1.2 0.3  10.9 14.2 0.8 
14 v 13 N/A N/A -  2.6 6.3 0.4 
Mean 0.3 1.0 0.3  6.7 8.3 0.9 
Hydroxyl group (position 17/18) 
4 v 8a 1.6 0.85 1.9  15.4 4.5 3.4 
5 v 9 6.7 1.2 5.6  >32 14.2 >2.3 
23 v 13 7.8 N/A -  14.8 6.3 2.3 
Mean 4.2 1.0 4.0  20.7 8.3 2.7 
Acetate group (position 17) 
6 v 8a 2.3 0.85 2.7  18.4 4.5 4.1 
7 v 9 12.4 1.2 10.3  >32 14.2 >2.3 
Mean 7.4 1.0 7.2  >25.2 9.4 >3.1 
a refers to the concentration required to double activity of the enzyme QR relative to DMSO treated controls. 
b refers to the concentration required to reduce cell viability to 50% in Hepa-1c1c7 cells.  
c indicates maximal magnitude of activation less than two-fold 
3.3.4. QR-inducing flavonoids from the methanolic A. latifolia root extract  
Disappointingly, the level of QR induction from greenhouse-grown A. latifolia plants 
(maximal induction of 1.1-fold for the root extract) was greatly reduced compared to the extracts 
from wild-grown material (2.52-, and 1.76-fold for root and aerial tissue extracts, respectively). 
Although the reasons for this are not clear, I suspect that a lack of ecological interactions in the 
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controlled growth environment led to decreased production of the active compounds. The 
production of many phytochemicals is reserved until elicited by wounding or other stimuli 
(Harborne 1999). This may decrease the associated metabolic expense of their production. 
Spraying the crop with jasmonic acid, a regulator of plant defense metabolism, could potentially 
overcome this deficiency in future studies (Gundlach et al. 1998). 
I reasoned that, since there was still some activity, the compounds responsible for activity 
in the wild-grown material may still be present in low amounts and that bioassay-guided 
fractionation may yield interesting results. Indeed, following solvent-solvent partitioning of the 
root extract (Figure 3-10), I noted a substantial increase in the activity of the 
chloroform/dichloromethane partition (maximal induction of 1.7-fold).  
During the solvent-solvent partitioning of the root extract I experimented with using the 
less toxic compound dichloromethane in place of chloroform. However, I found that chloroform 
had a greater capacity for extracting compounds in the polarity range of interest. The 
dichloromethane and chloroform partitions were combined.  
Fractionation of the dichloromethane/chloroform partition using silica gel flash 
chromatography revealed that the least polar fractions (A, B and C) contained the active 
constituents. These fractions were subjected to a C18 SPE cartridge to remove very non-polar 
compounds and provide a crude separation of the remaining compounds prior to purification by 
semi-preparative C18 HPLC. Although the yields were low (0.59 - 1.94 mg), a total of 14 
compounds were isolated. Due to the low yields of these compounds, NMR analysis following 
the QR bioassay would not be possible. Therefore I worked on solving the structures of the most 
abundant compounds and collected basic NMR spectra for the remaining compounds prior to 
completing the QR bioassay.  
The first compound, identified on the basis of 
1
H and 
13
C, HMBC, heteronuclear multiple 
quantum coherence (HMQC) and NOE NMR experiments, was a novel C-methyl flavanone, 24. 
Similar to the C-methyl isoflavone, abronisoflavone, that was previously isolated from this plant, 
24 was also C-methylated. In addition to the C-methyl group at position 6, 24 also possessed a 
C-methyl at position 8. Although C-methyl flavonoids are uncommon, this is not the first report 
of a C-methyl flavanone (Wollenweber et al. 2000). 
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Figure 3-10. Separation scheme for methanol extract of A. latifolia roots. Concentrations required to double 
QR-activity (CD) or concentrations required to increase QR-activity by 50% (C50) are indicated in brackets. 
For the SPE cartridge clean-up the percentage composition of the mobile phase (methanol/water) is provided 
for each fraction. 
NMR spectra of the second compound, 25, closely resembled 24 with the exceptions of 
missing a 3H singlet at ~2.0 ppm and a new 1H singlet at 6.12 ppm. When combined with 
accurate mass measurement, these observations indicated that this compound was lacking one of 
the C-methyl groups found in 24. I did not attempt to confirm the position of this methyl group 
as this compound proved to be inactive (see below). 
Of the 14 isolated compounds eight had similar NMR and UV spectra to compounds 24 
and 25 consistent with these compounds also being flavanones. The structures of these 
compounds were not solved, however, on the basis of a lack of activity in the QR bioassay. 
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Unlike the flavanones 24 and 25, which had a single rounded UV maximum at ~292 nm, 
five of the other compounds (f, g, j, k and 26) isolated from the active fraction had a different 
absorbance spectrum with a peak at ~278 nm and shoulders at 300 nm and 340 nm. The most 
abundant of these compounds (1.43 mg) was identified as boeravinone E (26), a rotenone, on the 
basis of 
1
H, 
13
C and HMBC NMR experiments (Figure 3-11).  
 
Figure 3-11. Compounds isolated from A. latifolia. Abronisoflavone was previously identified from A. 
latifolia (Wollenweber et al. 1993). 
All 14 isolated compounds were assayed for QR-inducing activity (Figure 3-12). Only 
compound k caused an increase in QR activity greater than two-fold (CD value = 3.2 µg/mL or 
10 µM (assuming mass of 324 Da)). Compound f was the next most active with a maximal level 
of induction of 1.9-fold achieved at 10 µg/ml. Both compounds f and k had UV absorbance 
spectra nearly identical to boeravinone E (26) indicating that these compounds possessed the 
same chromophore as boerhavinone E (26). NMR spectra for these compounds also shared the 
majority of signals with boerhavinone E (26) consistent with these compounds also being 
rotenones. However, similarly decorated isoflavones could have comparable UV and NMR 
spectra and I was unable to exclude such structural possibilities for compounds f and k. 
70 
 
 
Figure 3-12. QR induction following exposure to A. latifolia compounds. Hepa-1c1c7 cells were exposed to A. 
nudicaulis polyacetylenes for 48 h and QR activity was compared to solvent treated controls. (R)-sulforaphane 
was included as a positive control. Results are the mean of a single experiment with two technical replicates. 
Overall the spectral and QR data suggest that certain rotenones (and possibly isoflavones) 
are moderate QR inducers (10 µM is not groundbreaking), whereas C-methyl isoflavones such as 
24 and 25 are very weak or inactive. These observations are consistent with the expected thiol-
reactivity of these classes of flavonoids. Rotenones (boerhavinone E) or isoflavones 
(abronisoflavone) have an α,β-unsaturated carbonyl group that can act as a Michael addition 
acceptor whereas flavanones such as 24 and 25 do not.  
Although many of the described Nrf2-activating flavonoids identified to date also possess 
a Michael acceptor functionality, it should be noted that flavonoids with ortho- or para-
substituted hydroxyl groups can be oxidized to electrophilic quinones and may therefore modify 
Keap1 indirectly (Lee-Hilz et al. 2006). Additionally, several flavonoids are thought to activate 
QR through the aryl hydrocarbon receptor (Yannai et al. 1998). However, in this circumstance 
the lack of potency precludes further investigation into the mechanism of action of these 
compounds.  
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3.3.5. Induction of QR by cannabinoids from C. sativa  
A methanolic extract of female ‘Finola’ hemp flowers was a weak inducer of QR in 
Hepa-1c1c7 cells (C50 ~ 15 µg/mL). Heat treatment of this extract converted a proportion of 
cannabinoids to their decarboxylated forms (data not shown) and resulted in greater QR 
induction (C50 ~7 µg/mL , CD ~ 15 µg/mL, maximal induction 2.8-fold) consistent with 
decarboxylated cannabinoids being the active components (Figure 3-13). 
 
Figure 3-13. QR induction following exposure to hemp extracts. Hepa-1c1c7 cells were exposed to hemp 
extract for 48 h and QR activity was compared to solvent treated controls. The heated extract was exposed to 
120ºC for 30 min to decarboxylate the acid forms of cannabinoids present in the extract. Result of a single 
experiment with two technical replicates. 
To confirm whether cannabinoids were responsible for the QR-inducing activity of the 
hemp extract, I isolated the major cannabinoids CBDA and THCA and used heating followed by 
HPLC purification to isolate the corresponding decarboxylated cannabinoids CBD and THC 
(Figure 3-14). I found that it was much more efficient to heat crude extracts rather than purified 
CBDA or THCA when producing CBD and THC. Heating a dried ‘Finola’ extract at 120ºC for 
30 min converted the majority of CBDA to CBD (data not shown). 
0.0 
0.5 
1.0 
1.5 
2.0 
2.5 
3.0 
Hemp extract Heat-treated hemp extract 
F
o
ld
-c
h
a
n
g
e
 i
n
 Q
R
 a
c
ti
v
it
y
 
0.32 
1.0 
3.2 
10 
32 
[µg/mL] 
72 
 
   
Figure 3-14. Compounds isolated from C. sativa and the derivatives HU-331 and HU-336.  
The results of the QR bioassay for purified cannabinoids are given in Figure 3-15. A 
summary is provided in Table 3-7. All the cannabinoids tested displayed some degree of QR 
activation. CBDA and CBD treatment resulted in the greatest amplitude of QR activation at 
~2.5-fold, whereas the maximal induction by THCA and THC was ~1.5-fold. In both cases the 
decarboxylated forms were more potent requiring approximately a tenth of the concentration of 
the carboxylated forms for  maximal QR induction. CBD displayed a CD value of approximately 
1.6 μM (0.63 µg/mL).  
Although cannabinoid receptors are present in mouse liver (Osei-Hyiaman et al. 2008), 
current evidence does not suggest that cannabinoid receptors modulate the expression of QR by 
cannabinoids. Furthermore, CBD displays only very weak affinity for CB receptors compared to 
THC and was a much more effective QR inducer than THC. Therefore it is unlikely that 
cannabinoid receptors are mediating the activation of QR. 
Since CBD and THC are not electrophilic, I would not expect these compounds to 
activate Nrf2 directly. Inclusion of the small thiol N-acetylcysteine in the culture medium failed 
to reduce the activity of CBD or THC. However, the phenolic moieties of CBD and THC can be 
oxidized to electrophilic quinones that would be expected to be highly thiol-reactive. Examples 
of non-electrophilic substances being oxidized to Nrf2-activating electrophiles are not 
uncommon and include carnosic acid, acetominophen and polyunsaturated fatty acids (Gao et al. 
2007; Copple et al. 2008; Satoh et al. 2008).  
73 
 
 
Figure 3-15. QR induction following exposure to cannabinoids. Hepa-1c1c7 cells were exposed to 
cannabinoids for 48 h and QR activity was compared to solvent treated controls. (R)-sulforaphane was 
included as a positive control. Results are the mean of at least three independent experiments ± the standard 
deviation. 
Table 3-7. Summary of bioassay results for C. sativa cannabinoids and the positive control (R)-sulforaphane. 
Compound 
QR inducing activity  
CD (µM) 
Cell viability  
IC50 (µM) 
CI  
IC50/CD 
(R)-sulforaphane 0.27 ± 0.04 11.5 ± 3.8 42.6 
27 CBDA 20.8 ± 1.0 29.9 ± 10.6 1.4 
28 CBD 1.6 ± 0.8 4.8 ± 0.3 3.0 
29 THCA N/A
a
 63.2 ± 5.9 - 
30 THC N/A
a
 5.4 ± 0.3 - 
a N/A indicates maximal magnitude of activation less than two-fold 
Electrophilic metabolites of CBD, such as HU-331 (Figure 3-14) are produced via 
metabolism by CYP P450 3A enzymes in vivo (Bornheim et al. 1998) or in vitro under basic, 
oxidizing conditions (Kogan et al. 2004). Such derivatives of CBD form the colored basis of the 
‘Beam test’ for marijuana (Mechoulam et al. 1968). HU-331 can inactivate CYP3A enzymes by 
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covalent modification, which is suspected to occur at cysteine residues (Bornheim et al. 1998; 
Yamaori et al. 2011). 
In contrast to the electrophilic derivative of CBD (HU-331), the analogous derivative of 
THC (HU-336, Figure 3-14) requires stronger oxidizing conditions for production in vitro and 
does not appear to occur in vivo. The free hydroxyl in CBD appears to be required for the 
enzymatic production of HU-331 by CYP3A enzymes (Bornheim et al. 1993). The decreased 
tendency for THC to form electrophilic intermediates is consistent with the hypothesis that 
cannabinoids activate QR via reaction with Keap1 thiols (indirectly via electrophilic 
intermediates) because THC consistently displayed decreased activity in the QR bioassay 
compared to CBD. 
3.4. Conclusions 
Of the two methods used to guide fractionation of potential Nrf2 activators, the QR 
bioassay was the most reliable. The only compound isolated using thiol reactivity as a guide, 
coniferyl ferulate (1), proved to be inactive in the QR bioassay. 
The prominence of the coniferyl ferulate-glutathione product in the thiol-screening assay 
highlights an important shortcoming of the thiol-reactivity-based approach. Thiol-reactive non-
Nrf2-inducing compounds such as coniferyl ferulate may mask less abundant Nrf2 activators 
through shear abundance and by out-competing the less abundant compounds for the model thiol. 
Although nothing can be done regarding the abundance of non-active compounds, an excess of 
model thiol could ensure that all thiol-reactive compounds are represented in the thiol-screening 
assay. Even though I attempted to include an excess of glutathione in the reactions (2:1 molar 
ratio of glutathione to extract compounds based on an average molecular mass of 200 Da of 
compounds in the extract), I would include a larger excess of thiol in any future implementation 
of this approach. 
A further disadvantage to using the thiol-screening assay to identify novel Nrf2-
activating agents is that, since it is based on a single mechanism of action, compounds that act 
through novel mechanisms would be overlooked. Compounds that behave as prodrugs, that is 
compounds that require metabolic activation, would also be overlooked using this method in its 
current form.  
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One disadvantage of the QR bioassay is the variability inherent in the assay itself. For 
example, the dose-reponses for (R)-sulforaphane shown in Figures 3-6 and 3-8 differ in the 
maximal induction achieved. Cultures started from different stocks sometimes displayed 
differences in absolute magnitude of their responses. Importantly, the CD value was similar 
between the two groups of experiments. This result emphasizes the importance of including 
positive controls in the type of experiment so that results between different sets of experiments 
can be compared directly.  
The variety of QR inducers isolated highlights the flexibility of the biological system(s) 
controlling QR activity. Aside from the cannabinoids, all of the active compounds isolated have 
electron-deficient centers that could potentially react with Keap1 thiols in vivo. For compounds 
such as rotenones, isoflavones and phthalides that possess conjugated unsaturated carbonyl 
groups (Michael acceptor functionalities) I expect that these functionalities, if any, would be 
involved in Keap1-adduction. In the case of the polyacetylenes the site of thiol-reactivity is less 
clear. The reactivity of polyacetylenes with model thiols and recombinant Keap1 are discussed in 
Chapter 4. 
Although the QR bioassay has proven reliable for identifying Nrf2 activators, it does not 
predict with certainty that QR inducers are operating through Nrf2. Aside from monitoring Nrf2 
nuclear translocation directly, confirming that the abundance of Nrf2 transcriptional targets is 
elevated and the abundance of AhR transcriptional targets is decreased can provide additional 
evidence to support to the hypothesis that these compounds activate QR via Nrf2. Such 
transcriptional studies are presented in Chapter 5. 
The ecological functions that the above compounds serve in the plant are elusive. As all 
the compounds isolated were obtained from non-fruiting and non-flowering tissues, it seems 
unlikely that these compounds would serve the purpose of attracting seed dispersers or 
pollinators. I think the most reasonable putative functions are as anti-feedants, anti-microbials or 
allelochemicals (compounds that inhibit or interfere with adjacent plants). For instance, the 
polyacetylenes isolated from O. horridus were highly abundant in the inner stem bark. The outer 
bark of O. horridus displays a menacing array of spines. The selective pressure that led to the 
development of the spines of O. horridus may have also led to the production of these 
compounds in the inner stem bark. Also of note is the capability for polyacetylenes such as 
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falcarinol to cause contact dermatitis (Leonti et al. 2010) and contribute to the unpleasant taste of 
old carrots (Czepa et al. 2003). Perhaps the polyacetylenes work in concert with the spines to 
synergistically cause irritation to herbivores.  
It is not necessary, however, for a given phytochemical to serve a single ecological role. 
Indeed, antifungal activities for falcarinol-type polyacetylenes have been reported as have 
allelochemical activities for more distantly related polyacetylenes (Stevens 1986; Olsson et al. 
1996). 
Multi-faceted advantages for phytochemical groups may aid in explaining the tremendous 
phytochemical diversity found in the world’s flora. A given metabolite may at first provide an 
advantage under one set of conditions and later on provide a building block towards a metabolite 
that confers a complimentary advantage. Compounds or groups of compounds that have multiple 
ecological functions (and therefore multiple cellular targets) may be selected for on the basis of 
efficiency. However, specificity rather than promiscuity is usually preferred for drug candidates 
and investigational drugs. Examination of the cellular targets of a panel of QR inducers in 
mammalian cells is one of the goals of examining global changes in gene expression described in 
Chapter 5.  
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CHAPTER 4 
THE MECHANISM OF ACTION OF ARALIACEAE POLYACETYLENES 
4.1. Introduction 
    The data reported in Chapter 3 revealed the structures and potencies of numerous QR 
inducers. Thiol residues of Keap1 are thought to be the primary site of action for QR inducers 
that function through Nrf2 activation. Although the presence of electrophilic functionalities in the 
majority of these compounds are consistent with a mechanism of action involving modification of 
Keap1 and activation of Nrf2, additional mechanisms such as activation of AhR may be 
responsible for QR induction by these compounds. This chapter describes studies aimed at testing 
the hypothesis that the C17-polyacetylenes isolated from O. horridus and A. nudicaulis induce QR 
by modifying the structure of Keap1. These studies include assays to test the thiol-reactivity of 
representative polyacetylenes using low molecular weight thiols and recombinant Keap1 as well as 
a study of the effects of polyacetylenes on the secondary structure of Keap1. 
4.1.1. Low molecular weight model thiols 
Detection of compounds that react with glutathione in vitro using electrospray ionization-
tandem MS (ESI-MS/MS) was discussed in Chapter 3. In addition to glutathione, methyl 
thioglycolate and cysteine (Figure 4-1) have also been used to study thiol-reactivity in vitro 
(Beck et al. 1995; Johnson et al. 2001; Dieckhaus et al. 2005). 
 
Figure 4-1. Structures of low molecular weight model thiols used to test thiol reactivity of QR inducers. 
UV absorbance data and fragmentation patterns detected by MS can provide some 
structural information for the product of a QR activator and model thiol. However, NMR-based 
analysis can often provide an unequivocal solution for the product structure. Cysteine is a 
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preferred model thiol for NMR studies as it contributes a low number of signals to the product 
and therefore facilitates structure elucidation.  
Although Keap1 possesses numerous cysteine residues, these residues vary in their 
reactivity with Nrf2 activators. The intrinsic pKa of cysteine in an average protein is about 9.1 
meaning that, at physiological pH (7.0-7.4), the percentage ionization of these residues would be 
~2% and that these residues would not be highly nucleophilic (Harris et al. 2002). The most 
reactive cysteines of Keap1 are flanked by basic amino acids that increase the effective pH 
environment leading to an increase in the nucleophilicity of the cysteine thiols by stabilization of 
the ionized state, the thiolate ion (Snyder et al. 1981). I have chosen to use a higher than 
physiological pH (8.0 or 10.0) when examining the reactivity of QR inducers with cysteine in 
order to emulate the reactivity of the most reactive Keap1 residues and provide greater reaction 
yields.  
4.1.2. Keap1 
Reactivity with model thiols may serve as a general indicator whether a Keap1-based 
mechanism of action is feasible. However, demonstrating reactivity with recombinant Keap1 will 
provide strong evidence for this mechanism of action. I have used MS to measure changes in the 
mass of Keap1 following incubation with QR inducers as a means of measuring the reactivity of 
these compounds with Keap1.  
4.1.2.1. Production of recombinant Keap1 protein 
Recombinant Keap1 is the most practical means to obtain Keap1 for biophysical studies. 
Several expression and purification systems have been reported for Keap1(Dinkova-Kostova et 
al. 2002; Dinkova-Kostova et al. 2005; Eggler et al. 2005; Hong et al. 2005). Expression hosts 
include E. coli, insect cells and human embryonic kidney-293 cells. Purification strategies have 
included ammonium sulphate precipitation, immobilized metal-affinity chromatography, and gel 
filtration. In general, Keap1 has been a difficult protein to purify. Using a low temperature 
during expression, minimal media and carefully controlling the pH of the harvest medium have 
been reported to increase the yield of Keap1 (Dinkova-Kostova et al. 2002; Dinkova-Kostova et 
al. 2005; Eggler et al. 2005; Hong et al. 2005). 
79 
 
4.1.2.2. MALDI-TOF-based detection of Keap1 adduction 
Detecting changes in the mass of Keap1 resulting from covalent modification by small 
molecules is fundamentally different than detecting alkylation of small molecules. The molecular 
weight of a small molecule such as falcarindiol (260 Da) is small relative to that of Keap1 (70 
kDa) and therefore requires a high resolution detector, such as one based on time-of-flight 
(TOF), for accurate measurement. Furthermore, ionization of large proteins is also subject to 
different constraints than small molecules. Although proteins can be easily ionized under 
electrospray conditions, a variety of charge states typically occur. These charge states can be 
useful when the protein being ionized is homogenous. However, when dealing with a protein 
population with varying degrees of modification (as may be the case when incubating with a 
small molecule) the deconvolution of this data becomes increasingly complex and impractical. 
MALDI is an ionization method used extensively in proteomics that involves laser excitation of a 
matrix that in turn ionizes the protein to be analyzed. In contrast to electrospray ionization, 
MALDI ionization typically yields singly-charged species and thereby simplifies interpretation. 
Therefore I have chosen to use MALDI-TOF for analysis of Keap1 modification by small 
molecules.  
4.1.2.3. Circular dichroism-based detection of Keap1 modification  
Nrf2 activators are thought to cause a conformational change in Keap1. Therefore, I have 
also examined changes in secondary structure of Keap1 in response to putative Nrf2 activators 
(falcarindiol stereoisomers) using circular dichroism spectroscopy  (CD spectroscopy). CD 
spectroscopy involves measuring differences in absorption of left and right circularly polarized 
light over a range of wavelengths. Secondary structures such as α-helices and β-sheets display 
characteristic absorption patterns for circularly polarized light and therefore changes in the 
secondary structure of a protein can be calculated from changes in the protein’s circular 
dichroism spectrum (Greenfield 2007).  
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4.2. Materials and methods 
4.2.1. General experimental procedures 
Cell culture reagents were obtained from Invitrogen. Unless otherwise specified, chemicals 
were obtained from Sigma-Aldrich. Sodium dodecylsulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) was conducted according to Sambrook et al (1989). 
4.2.2. Detecting reactivity of QR inducers with low molecular weight model thiols  
Analytical scale reactions of QR inducers with low molecular weight model thiols 
followed the same procedure as described in Chapter 3 except where methyl thioglycolate or 
cysteine was used in place of glutathione and when conditions (pH, temp, incubation time) were 
altered as described.  
For the preparative isolation of the major reaction product of oplopandiol (16) and 
cysteine, a 4 mL reaction consisting of 33 mM oplopandiol, 250 mM cysteine, 25 mM Tris-Cl, 
pH 10.0, and 40% (v/v) acetonitrile was incubated in the dark for 17 h at 30°C. The most 
abundant product, 31, was isolated by isocratic (69% methanol/water) preparative HPLC on a 
preparative 1100 system (Agilent) equipped with a fraction collector, a flow rate of 12 mL/min 
and a Gemini-NX C18 column (Phenomenex, 250 × 21.20 mm, 5 µm particle size). Methanol was 
removed under vacuum with heating to 28°C. Water was removed by lyophilization. The 
structure of 31 was determined by ESI-MS and NMR (
1
H, 
13
C, HMBC and NOE) experiments in 
MeOD using a Bruker AV500 spectrometer. 
4.2.3. Expression and purification of recombinant Keap1  
Mouse Keap1 was codon optimized for expression in E. coli (NRC Saskatoon DNA 
technologies unit), Gateway
TM
 cloned into the pHIS8GW vector (Invitrogen) and expressed in 
BL21 (DE3) pLysS E. coli cells grown in 4.8 L of lysogeny broth (LB) (Bertani 1951) at 15ºC 
using isopropyl β-D-1-thiogalactopyranoside (IPTG) induction (0.5 mM) for 24 h. The pH of the 
medium was adjusted to 8.0 by adding 48 mL of 1.0 M Tris base prior to collecting the cells by 
centrifugation. E. coli stocks were stored in 25% glycerol at -80 ºC. 
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Table 4-1. NMR spectroscopic data for the major cysteine-oplopandiol product (31) 
position δC δH, (J in Hz) HMBCa 
1 10.0 1.02, t (7.5) 2, 3 
2 31.8 1.73, m 1, 3, 4,  
3 64.7 4.45, t (6.1) 1, 2, 4, 5, 6, 7 
4 101.5 
  5 81.6 
  6 115.9 6.29, s 2, 3, 1', 8, 9, 11 
7 149.4 
  8 72.3 5.07, d (8.0) 6, 7, 9, 10 
9 130.2 
  10 134.8 
  11 31.8 2.13, m 9, 10, 12 
12 30.4
b 
1.3,m 
 13 30.5
 b
 1.3, m 
 14 30.8
 b
 1.3, m 
 15 33.1 1.3, m 
 16 23.8 1.3, m 
 17 14.5 0.89, t (7.1) 15, 16 
1'a 34.9 3.93, dd (14.4, 2.7) 7, 3' 
1'b 
 
2.97, dd (14.4, 10.5) 7, 2', 3' 
2' 55.0 3.65, dd (10.5, 2.7) 1' 
3' 172.5     
aHMBC correlations are from protons stated to the indicated carbon 
bAssignments may be interchanged 
 
Purification technique #1: Cells were resuspended in lysis buffer (50 mM Tris-Cl, pH 8.0, 
250 mM NaCl, 2.5 mM imidazole, 10% glycerol, 10 mM β-mercaptoethanol, and protease 
inhibitors (1:160 dilution, Calbiochem, Protease Inhibitor set III)) and lysed by French press. A 
solution of denatured E. coli proteins was added to the lysate to compete for binding to GroEL as 
described by Rohman et al. (2000). His-tagged Keap1 was purified by immobilized metal affinity 
chromatography on a column of Talon resin (Clontech Laboratories) according to manufacturer’s 
batch protocol using wash buffer consisting of 50 mM Tris-Cl, pH 8.0, 250 mM NaCl, 2.5 mM 
imidazole, 10% glycerol, 10 mM β-mecaptoethanol, and elution buffer consisting of 50 mM Tris-
Cl, pH 8.0, 250 mM NaCl, 150 mM imidazole, 10% glycerol, and 10 mM β-mecaptoethanol. 
Adenosine triphosphate (ATP) was added to 10 mM and the lysate was incubated at 37ºC for 20 
min with shaking prior to loading on the Talon column. Further purification of the protein was 
performed by gel filtration on an AKTA FPLC using a Superdex 200 10/300 GL column (GE 
Healthcare), running buffer consisting of 50 mM Tris-Cl, pH 8.0, 100 mM NaCl, and 10 mM β-
mercaptoethanol. 
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Purification technique #2: Cells were resuspended in a solution of 100 mM Tris-Cl pH 8.4, 
200 mM dithiothreitol (DTT), 100 mM EDTA, a small amount of lysoyzme (~5 mg) and protease 
inhibitors (1:160 dilution, Calbiochem, Protease Inhibitor set III) and lysed by sonication (on ice, 
two cycles of 24 repetitions of 5 seconds on, 6 seconds off, microtip, setting 4.5, Heat Systems 
Sonicator Ultrasonic Processor XL). Lysate was loaded onto an open column of 35 g Sephadex G-
50 and eluted with buffer A (25 mM Tris-Cl buffer, pH 8.0, containing 5 mM EDTA). Fractions 
with protein content (as judged by UV absorbance at 280 nm) were combined, ammonium sulphate 
was added to a concentration of 300 mM and the lysate was frozen overnight at -80ºC. After 
thawing the solution on ice, the precipitate was collected by centrifugation (20,000 g for 20 min) 
and resolubilized in buffer B (25 mM Tris-Cl buffer, pH 8.0, containing 10 mM DTT and 5 mM 
EDTA). Insoluble material was removed by centrifugation (3220 g for 30 min) and the solution 
was desalted using a PD-10 column (GE Healthcare) equilibrated with buffer A, ammonium 
sulphate was added to a concentration of 300 mM and the solution was frozen overnight at -80ºC. 
The precipitate was collected by centrifugation (10000 g for 20 min), resolubilized in buffer B and 
the insoluble material was removed by centrifugation (14000 g for 5 min). The crude Keap1 lysate 
was then subjected to Talon purifcation as described in ‘Purification technique #1’ without the 
inclusion of the ATP incubation or denatured E. coli protein. 
Protein concentration was determined using the Bradford assay. Purified protein was stored 
at -80ºC in buffer A with 10% glycerol. Prior to subsequent analysis, frozen Keap1 was thawed on 
ice and buffer was exchanged using a Zeba 7K MWKO desalting column (Thermo Scientific). 
4.2.4. Mass spectrometric studies with recombinant Keap1 
Purified Keap1 (4.1 µM or 3 µM) was incubated with the small molecule of interest in 25 
mM Tris-Cl buffer, pH 8.0 for 90 min at room temperature or 37ºC. The reactions with varying 
ratios of Keap1 to small molecule also included, 200 µM tris(2-carboxyethyl)phosphine. Half a 
µL of matrix consisting of sinapinic acid dissolved in 50% acetonitrile/water with 0.1% 
trifluoroacetic acid was spotted and dried on a MALDI plate. Sample (0.5 µL) was then added to 
the spot, an additional 0.5 µL of matrix was added, mixed with the sample and dried at room 
temperature. One-thousand laser shots were acquired per spectrum on an Applied Biosystems 
4800 MALDI-TOF/TOF operating in linear mode. 
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4.2.5. Circular dichroism studies with recombinant Keap1 
Purified Keap1 (3 µM) was incubated with 9 µM of the small molecule of interest in 20 
mM Tris-Cl buffer, pH 8.0, for 90 min at 37ºC. Data were acquired over the range of 195 nm to 
260 nm at 0.5 nm intervals using a 0.5 mm pathlength quartz cuvette on an Applied Photophysics 
π*-180 instrument. Each experiment was performed in duplicate. Six spectra were acquired per 
replicate. Secondary structure was calculated using CDNN software.  
4.3. Results and discussion 
4.3.1. Investigations of QR inducer reactivity with model thiols 
To investigate whether select QR inducers act by modifying Keap1 thiols, I have tested 
their reactivity with model thiols in vitro. Certain phthalides, polyacetylenes and alkamides 
(isolated from Echinacea by a colleague, Yuping Lu) display thiol-reactivity in vitro. Here I 
specifically describe the outcome of studies with the polyacetylenes falcarindiol and oplopandiol. 
Due to the publication of a thorough description of the nature of the phthalide (ligustilide) 
reaction (Dietz et al. 2008; Schinkovitz et al. 2008), I don’t report my studies of phthalide 
reactivity. 
4.3.1.1. C17-type polyacetylenes are reactive with model thiols 
As judged by MS, racemic falcarindiol reacted with glutathione or cysteine to give two 
products (not considering stereoisomers) of approximately equal abundance with HPLC elution 
times intermediate to that of the model thiol or falcarindiol. The mass of these products (568 m/z 
under positive ionization for the glutathione adduct for example) was consistent with an addition 
reaction (mass of glutathione is 307, falcarindiol is 260). A major change in UV absorbance of 
the product suggested that there was a modification to the conjugated triple bonds. As shown in 
Figure 4-2 the amount of product increased as the pH of the reaction was increased from 7.5 to 
11.5. This curve parallels the expected thiol deprotonation curve for glutathione shown in blue 
(pKa = 9.12 (The Merck Index)). 
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Figure 4-2. Relationship between reaction pH and yield of major products from reaction between falcarindiol 
and cysteine. Measured by integration of mass spectrogram peak area at m/z 568. The theoretical titration 
curve for the glutathione thiol is also presented for comparison (The Merck Index). 
4.3.1.2. Trends of reactivity 
Thiol reactivity is known to parallel Nrf2 activator potency (Kensler et al. 2010). However, 
strong electrophiles are not desirable for pharmacological interventions as they quickly react 
with less nucleophilic functionalities such as hydroxyls and amines resulting in low specificity 
for Keap1. Therefore, moderately weak electrophiles that selectively modify Keap1 are expected 
to have the greatest ratio of efficacy to adverse effects.  
One of the structure-activity trends observed for C17-type polyacetylenes was that the 
terminal double bond present in falcarindiol and absent in oplopandiol appeared to be required 
for maximal QR-inducing activity. In contrast to falcarindiol, the two major products formed 
from the reaction of oplopandiol with model thiols were not equally abundant. The more 
abundant product was present at roughly the same level as one of the major products of the 
falcarindiol reaction. Therefore I suspected that the double bond was playing a role in the 
reactivity of the nearest triple bond and that the major product would be one in which the 
reaction took place near the existing double bond in oplopandiol. 
4.3.1.3. Structure of the major product of the oplopandiol-cysteine reaction 
In order to determine the exact structure of the major product of the oplopandiol and a 
model thiol reaction I prepared a large scale reaction of oplopandiol and cysteine and isolated the 
major product by preparative HPLC. The structure of the major product is shown in Figure 4-3. 
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Figure 4-3. Structure of the major product (31) of a reaction between oplopandiol (16) and cysteine (shown in 
red in the representation on the left). On the right, HMBC correlations are indicated by dashed and blue arrows 
and an NOE critical to the assignment of the double bond configuration is represented in red. 
The product structure revealed that addition was occurring at position 7 of oplopandiol 
(16). Consistent with a (Z) configuration about the new double bond an NOE was observed 
between the H-6 and H-8 protons. The preference for the attack of the cysteine thiol at the triple 
bond proximal to the double bond may explain why only one product predominates the reaction 
of 1,2-dihyrofalcarindiol with cysteine whereas two products in roughly equal yield 
predominated the reaction of falcarindiol with cysteine and why C17-type polyacetylenes that 
possess the terminal double bond are more potent QR inducers. 
Although alkynes do not typically undergo facile addition with thiols, an adjacent hydroxyl 
group can greatly accelerate this process (See Waters et al. 2000). Therefore, the lack of the C-8 
hydroxyl in falcarinol may explain its reduced QR-inducing activity relative to falcarindiol. It is 
also conceivable that the presence of two reactive centres, as found in falcarindiol-type 
polyacetylenes, is required for most effective modification of Keap1. However, upon examination 
of reactions of falcarindiol (1) with cysteine or glutathione by LC-UV-MS/MS no bi-addition 
products were observed suggesting that the first reaction may impede the second by steric 
hindrance or as a result of a change in electophilicity of the alkyne. This lack of a result should not 
be taken as a strong indication that bi-addition would not take place in vivo, as a second thiol-
reaction with Keap1 could be intramolecular. Intramolecular reactions can be more favorable than 
intermolecular reactions due to the reactive constituents being held in proximity. A better test for 
falcarindiol bi-addition products would include a model thiol with two reactive thiols such as the 
short peptide Lys-Cys-Lys-Cys-Lys. 
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4.3.2 Keap1 reactivity studies 
4.3.2.1. Keap1 expression and purification 
As reported in the literature, yields of recombinantly expressed mouse Keap1 in E. coli 
were low. Optimizing codon usage for expression in E. coli and lowering the temperature of the 
culture to 14ºC during expression increased the levels of soluble Keap1 such that accumulation 
of soluble protein in induced culture could be observed by eye on a Coomassie blue stained SDS-
PAGE gel. 
I initially used Talon purification (a form of immobilized metal affinity chromatography) 
to purify Keap1. However, I consistently co-purified another protein with an apparent molecular 
weight slightly lower than Keap1. The co-purifying protein was identified with the help of the 
NRC Saskatoon MS group as the large subunit of bacterial chaperone GroEL. The identity of the 
the other protein as Keap1 was also confirmed by MS of digested protein. Co-purifying GroEL is 
a commonly encountered problem during purification of overexpressed foreign proteins in E. 
coli (Thain et al. 1996; Rohman et al. 2000). GroEL is a multimeric protein that catalyzes protein 
folding. Proteins with an exposed hydrophobic region associate with a hydrophobic region of 
GroEL. Then, a conformational change in GroEL forces the misfolded protein into a more 
hydrophilic environment causing the hydrophobic area of the misfolded protein to be buried within 
the protein. The protein is then released and GroEL is reset via ATP hydrolysis. 
I employed two methods to eliminate co-purification of GroEL with Keap1. The first 
involved incubating the cell lysate with denatured E. coli proteins to compete for GroEL binding. 
The second involved adding ATP to the lysate prior to loading on the Talon column. Together, 
these approaches considerably reduced the amount of co-purifying GroEL but did not eliminate it 
completely. Furthermore, there were still several other contaminating proteins present in my 
preparation. Therefore I used gel filtration to further purify the Keap1 protein. However, due to the 
similar size of the contaminant, I was unable to resolve the two proteins completely and the yield 
of Keap1 with satisfactory purity was very low (24 µg from 3.3 L of culture or 7.3 µg/L of 
culture). Although this amount of Keap1 allowed me to do some preliminary MS studies, I 
calculated that I needed at least 100 µg for circular dichroism spectroscopy studies and therefore I 
decided to try another approach for purifying Keap1.  
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Aside from immobilized metal affinity chromatography, precipitation has also been used to 
purify Keap1(Dinkova-Kostova et al. 2002). In the absence of DTT, Keap1 precipitates at a 
relatively low ammonium sulphate concentration of 300 mM. However, a reducing agent such as 
DTT is required to maintain solubility of Keap1 during cell lysis. Therefore I removed DTT from 
the lysate by gel filtration prior to adding ammonium sulphate. Precipitation offered a reasonably 
good purification step and avoided co-purification of GroEL (Figure 4-4). In order to get 
satisfactory purity I completed two rounds of precipitation followed by Talon purification. This 
strategy improved yields of Keap1 (226 µg from 4.8 L of culture or 47 µg/L of culture). 
 
Figure 4-4. Purification of recombinant Keap1 expressed in E. coli. Two rounds of ammonium sulphate 
precipitation were followed by Talon purification. SDS-PAGE gel (10%)stained with Coomassie brilliant blue. 
4.3.2.2. Mass spectrometric studies 
Initial analysis of Keap1 by MALDI-TOF MS revealed that the ionization 
efficiency/signal strength of Keap1 was very low compared to the positive control, bovine serum 
albumin (BSA). I experimented with several different spotting techniques and found that a 
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‘sandwich’ method in which I deposited Keap1 onto a spot of matrix and then covered it with an 
additional spot of matrix greatly improved signal strength. 
Incubations with the two falcarindiol stereoisomers revealed that both stereoisomers 
modify Keap1 and that greater ratios of falcarindiol to Keap1 resulted in a greater number of 
modifications (Figure 4-5). The ability to covalently modify Keap1 in vitro is consistent with the 
hypothesis that the falcarindiol stereoisomers and related polyacetylenes activate QR expression 
by modifying Keap1 cysteines. 
 
Figure 4-5. Changes in the mass of recombinant Keap1 following incubation with differing concentration of 
xanthohumol, (3R,8S)-falcarindiol, or (3S,8S)-falcarindiol. Measured by MALDI-TOF MS after a 90 min 
incubation at room temperature. The right axis indicates the corresponding number of modifications based on 
the molecular weights of xanthohumol (354.4) and falcarindiol (260.2). Results are the mean of six technical 
replicates ± standard deviation. Asterisks and hash indicate a significant differences (p <0.05, student’s t-test)  
At a 2.5:1 ratio of falcarindiol to Keap1, the (3S,8S)-falcarindiol stereoisomer resulted in a 
significantly greater average increase in mass (251 Da) than the (3R,8S)-falcarindiol (151 Da). 
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As the mass of falcarindiol is 260 Da, these increases in the mass of Keap1 correspond to 
roughly a single modification or 0.6 modifications of Keap1 for the (3S,8S)-falcarindiol, and 
(3R,8S)-falcarindiol stereoisomers, respectively. The increased propensity for (3S,8S)-
falcarindiol to react with Keap1 at low ratios of small molecule to Keap1 are consistent with the 
higher QR-inducing potency of (3S,8S)-falcarindiol and provides support for a mechanism of 
action involving modification of Keap1 cysteines. At higher ratios (5:1 or 10:1) of small 
molecule to Keap1, greater increases in mass were observed and in contrast to the lowest ratio 
(2.5:1), the (3R,8S)-falcarindiol stereoisomer caused a significantly greater change in mass than 
the (3S,8S)-falcarindiol stereoisomer (924 Da or 585 Da, equivalent to 3.6 or 2.0 modifications, 
respectively). Although it is unclear what concentration Keap1 is present at in vivo, I expect that 
the initial one or two reactions are the most important and that the reactivity at low ratios of 
falcarindiol to Keap1 are the most relevant. 
In order to shed light on whether the falcarindiol stereoisomers differed in the rates at 
which they alkylated Keap1, I performed a small time course with the two compounds. I used a 
low ratio of falcarindiol to Keap1 (3:1) based on the prediction that the first alkylations of Keap1 
are more important in vivo. 
As shown in Figure 4-6, both (3R,8S)-falcarindiol and (3S,8S)-falcarindiol caused time-
dependent increases in the mass of Keap1. The differences between the two stereoisomers were 
not significant (p > 0.05, student’s t-test). Therefore it seems unlikely that a difference in the 
reaction rate of the two stereoisomers with Keap1 is responsible for the differences in their QR-
activating potencies. 
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Figure 4-6. Changes in the mass of recombinant Keap1 over time following incubation with (3R,8S)-
falcarindiol or (3S,8S)-falcarindiol. Reactions consisted of a 3:1 molar ratio of small molecule to Keap1 and 
were measured by MALDI-TOF MS after a 90 min incubation at 37ºC. The right axis indicates the 
corresponding number of modifications based on the molecular weight of falcarindiol (260.2). Results are the 
mean of six technical replicates ± standard deviation. 
4.3.2.3. Falcarindiol stereoisomers differentially affect the secondary structure of Keap1 as 
judged by circular dichroism spectroscopy. 
An alternative hypothesis for the difference in QR-activating potency of the falcarindiol 
stereoisomers is that the two compounds differentially affect the conformation of Keap1. 
Therefore I used circular dichroism spectroscopy to measure changes in secondary structure in 
response to treatment with the two falcarindiol stereoisomers. I again used a low ratio of 
falcarindiol to Keap1 (3:1). The resulting spectra and data deconvolution are provided in Figure 
4-7 and Table 4-2 respectively.  
The two stereoisomers caused opposing shifts to the circular dichroism spectrum of Keap1. 
For (3R,8S)-falcarindiol-treated Keap1 these changes corresponded to an increase in alpha-helix, 
a decrease in antiparallel and parallel beta-sheets and increases in β-turns and random coil with the 
inverse effect on each secondary structure occurring for (3S,8S)-falcarindiol. These findings are 
consistent with a mechanism of action for both stereoisomers involving changes in the secondary 
structure of Keap1 and suggests that the difference in QR induction of the falcarindiol 
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stereoisomers may stem from differences in the way that they alter the secondary structure of 
Keap1. 
 
 
Figure 4-7. Changes in the circular dichroism spectrum of Keap1following incubation with (3R,8S)-
falcarindiol or (3S,8S)-falcarindiol. Keap1 (3µM) was incubated with a falcarindiol stereoisomer (9 µM) or 
solvent (MeOH) at 37ºC for 90 min. Data are the mean of duplicate samples. 
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Table 4-2. Changes in secondary structure of recombinant Keap1 following exposure to (3R,8S)-falcarindiol 
or (3S,8S)-falcarindiol at a molar ratio of 3:1 for 90 min at 37ºC. Circular dichroism data was deconvoluted 
with CDNN.  
 Solvent 
control 
(3R,8S)-
falcarindiol-
treated 
(3S,8S)-
falcarindiol-
treated 
(3R,8S)-Fd 
change 
(3S,8S)-Fd 
change 
α-Helix 11.3 11.7 11.0 0.4 -0.3 
Antiparallel β-sheet 30.6 28.5 31.9 -2.1 1.3 
Parallel β-sheet 5.4 5.2 5.4 -0.2 0.0 
β-Turn 20.4 20.9 20.2 0.5 -0.2 
Random coil 33.8 34.5 33.5 0.8 -0.3 
Total sum 101.4 100.8 102.0 -0.7 0.6 
 
4.4. Conclusions 
In summary, the polyacetylenes oplopandiol and falcarindiol form covalent adducts with 
low molecular weight model thiols and recombinant Keap1 in vitro. The reaction between 
falcarindiol-type polyacetylenes and cysteine occurs at the outer carbons of the triple bonds 
(positions 4 and 7) of these molecules. As judged by circular dichroism spectroscopy the resulting 
changes in secondary structure of Keap1 differs for the two stereoisomers of falcarindiol. These 
results provides support for the hypothesis that (3S,8S)-falcarindiol and (3R,8S)-falcarindiol 
activate QR by increasing the stability of Nrf2 by covalently modifying cysteine residues of its 
negative regulator Keap1 and offer an explanation for their differences in activity. 
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CHAPTER 5 
THE EFFECTS ON TRANSCRIPTION OF QR INDUCERS 
5.1. Introduction 
QR inducers have received much attention due to their potential health benefits. Examples 
include sulforaphane, curcumin, xanthohumol and resveratrol. These compounds activate QR 
through the Keap1-Nrf2-ARE signalling pathway and therefore also increase the expression of 
other Nrf2-regulated cytoprotective genes. Additionally, these compounds modulate other 
signalling pathways including those mediated by NF-κB, FOXOs, and AhR.  Understanding the 
breadth of changes that occur in the cell in response to potential health promoting compounds is 
essential for understanding the positive and negative consequences that may result from their use. 
Here I report changes in gene expression that result from exposure to QR inducers. The goals of 
these studies were to confirm whether QR inducers activate the transcription of additional Nrf2 
targets and to investigate whether other transcriptional pathways are affected by these compounds. 
I have focused these studies on (Z)-ligustilide, cannabidiol and select polyacetylenes due to their 
potency and prevalence in food and drug plants. 
5.1.1. Measuring changes in gene expression as an indicator of Nrf2 activation and off-
target effects 
The enzyme QR has served as a useful marker for activation of Nrf2 in numerous studies 
(Favreau et al. 1991). Although the reductive approach of examining the induction of this single 
Nrf2 target is useful from a screening point of view, it does not provide insight into the wide-
ranging effects of exposure to a given xenobiotic. Identifying changes in expression of Nrf2 targets 
as well as other transcription factors such as AhR could provide evidence to support the hypothesis 
that these compounds induce QR via Nrf2 and indicate whether other signal transduction pathways 
are affected. 
Among the types of information used to identify the effects of a xenobiotic (i.e. changes in 
transcription factor binding, transcription, translation, protein abundance, posttranslational 
modification of proteins), I have focused on transcript levels. Nrf2 is a transcription factor and 
changes in transcription are a primary means by which cells adapt and respond to changes in the 
environment. 
94 
 
The importance of transcription in cell regulation (development, homeostasis) is reflected 
by the large proportion of genes that encode transcription factors. It is estimated that the human 
genome encodes around 1400 transcription factors representing 5% of all genes (Vaquerizas et al. 
2009). Epigenetic changes may also manifest through changes in transcription. 
Although posttranscriptional stability also affects transcript levels, changes in transcription 
can, in general, be inferred from changes in the abundances of transcripts. For example, using, 
lipopolysaccharide (LPS) treated mouse bone marrow-derived dendritic cells, Rabani et al. (2011) 
found that the majority of temporal changes in RNA levels were determined by changes in 
transcription rates. 
Quantitative real-time reverse-transcriptase polymerase chain reaction (qRT-PCR) can be 
used to determine relative changes in a small number of transcripts. Conversely, a more complete 
picture of global changes in transcription can be achieved using RNA sequencing (RNA-seq).  
5.1.1. qRT-PCR 
qRT-PCR is the current standard for quantifying a single transcript. Transcripts are 
reverse transcribed to complimentary DNAs (cDNAs) which are then subjected to PCR-based 
amplification under conditions that allow real-time quantification of the product. Primers define 
the region to be amplified. The number of cycles required to reach a threshold is directly related 
to the amount of starting material and, by comparison with a constitutively expressed transcript, 
relative changes in abundance between treatment groups can be determined. qRT-PCR is limited, 
however, by the requirement of designing and validating primers for each individual transcript to 
be measured and is not practical for examining large numbers of transcripts. 
5.1.2. Transcriptomics and RNA-seq 
Transcriptomics is the study of all RNAs within a cell. Transcriptomic analyses yield a 
global perspective of the changes in transcript abundance that occur in response to a treatment. 
Techniques that allow global analysis of mRNA levels include microarrays, serial analysis of gene 
expression (SAGE) and RNA-seq. Microarrays have a rich history of use and offer a relatively 
inexpensive way to look at widespread changes in gene expression. However, microarrays require 
a priori transcript information and suffer from a limited dynamic range due to their reliance on 
hybridization. SAGE provides a digital snapshot of transcript levels by sequencing small tags 
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derived from mRNAs and comparing the number of tags sequenced for each transcript. Due to the 
practical limitations of Sanger-based sequencing, SAGE was originally designed to facilitate 
transcript abundance measurements using a minimal amount of sequencing by only sequencing a 
short portion (i.e. 9 bp) of each transcript (Velculescu et al. 1995). However, the development of 
next-generation high-throughput sequencing technologies (i.e. Illumina Genome Analyzer) has 
allowed for more thorough analyses such as RNA-seq. RNA-seq involves sequencing fragments of 
cDNA derived from isolated RNA on a massive scale (Wang et al. 2009). Read lengths currently 
range from 25 - 800 bp depending on the technology used. Mapping of these short reads to the 
genome provides a digital reading of gene expression and allows de novo discovery of transcribed 
regions, novel transcriptional start sites and splice isoforms. As RNA-seq has no practical upper 
quantification limit, its dynamic range is only limited by the number of reads and has displayed 
linearity over five orders of magnitude (Mortazavi et al. 2008). The major limitations of RNA-seq 
are cost and the need for sophisticated data analysis.  
I used RNA-seq to analyze global changes in gene expression in Hepa-1c1c7 cells in 
response to the QR inducers (Z)-ligustilide, (3S,8S)-falcarindiol and (3R,8S)-falcarindiol, 6-
isovaleylumbelliferone (6-IVU), (R)-sulforaphane, and xanthohumol (Figure 5-1). (Z)-ligustilide, 
(3S,8S)-falcarindiol and (3R,8S)-falcarindiol were considered the most interesting QR-inducers 
isolated from my work. 6-IVU, isolated by a colleague, was unique amongst coumarins isolated 
from celeriac (Apium graveolens var. rapaceum) in that it possessed marked QR-inducing activity 
(CD value = 5 µM) that correlated with another unique feature, the presence of an isovaleryl 
decoration. (R)-Sulforaphane and xanthohumol are two of the most studied Nrf2 activators and 
were included for comparison. 
qRT-PCR was used to validate the results of RNA-seq studies. I have used the 
transcriptomic data generated by these studies to investigate the following questions: 1) is 
increased QR activity due to increased transcription? 2) Do these QR inducers activate Nrf2 and 
increase transcription of other Nrf2 targets? 3) Is AhR or NF-κB activated by these QR inducers? 
4) Do the falcarindiol stereoisomers differ in effects on transcription? 5) Are any additional 
transcriptional pathways affected by these compounds at the concentration required to induce QR? 
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Figure 5-1. Compounds used to treat cells in RNA-seq analysis and their respective CD or C50 
values. 
5.2. Materials and methods 
5.2.1. General experimental procedures 
Cell culture reagents were obtained from Invitrogen. Unless otherwise specified, chemicals 
were obtained from Sigma-Aldrich.  
5.2.2. RNA collection and cDNA synthesis for qRT-PCR and RNA-seq 
Hepa-1c1c7 cells (ATCC) were grown in a humidified atmosphere composed of 5% CO2 / 
95% air at 37°C in a 225 cm
2
 flask to 80 % confluency and plated in 6-well plates at 250,000 cells 
and 2.5 mL medium per well. After 24 h the medium was replaced and test compounds added such 
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that the final concentration of DMSO in the medium was 0.1%. After a further 12 h the medium 
was removed and RNA was harvested using a QIAGEN RNeasy kit according to manufacturer’s 
instructions including an on-column DNAse I digest. Cells from three biological replicates were 
pooled during RNA isolation. RNA was quantified using a Nanodrop (Thermo Scientific). RNA 
integrity was determined using an Agilent 2100 Bioanalyzer and PicoRNA plate. 
For qRT-PCR analysis, cDNA was synthesised from 0.5 µg of total RNA using a Qiagen 
Quantitect cDNA synthesis kit according to manufacturer’s instructions using the supplied mix of 
oligo-dT and random primers with an extension time of 30 min. cDNA for RNA-seq was 
synthesized from 10 µg of total RNA using the Illumina mRNA-seq sample prep kit according to 
manufacturer’s instructions. 
5.2.3. RNA-seq  
5.2.3.1. Sequencing summary 
Single-ended 36 bp reads were acquired on an Illumina GIIx Genome Analyzer using one 
lane per cDNA sample. One lane per flow-cell was dedicated to the PhiX control DNA. Bases 
were called using Bustard (1.3) and the PhiX control was used for base-call calibration. Reads 
were mapped to the mouse genome (NCBI Mouse build 37.61) using Bowtie (v0.12.7) and splice 
junctions identified de novo using Tophat (v1.2.0) with default parameters (Appendix B). 
Differential expression and splicing was determined using Cufflinks/Cuffcompare/Cuffdiff 
(v0.9.3) with quartile normalization and bias correction.  
5.2.3.2. Online analysis tools 
For the subsequent web-based analyses, Ensembl gene IDs or Entrez gene IDs for the 
genes with differential expression in the ranges of > 1.5-fold and/or < 0.67-fold and mean reads 
mapped per kilobase of gene per million reads mapped (RPKM) values greater than one were 
submitted. Where applicable results with p values greater than 0.001 were excluded. 
5.2.3.2.1. Identification of transcription factor regulation by target gene signature analysis  
Target gene signature analysis was conducted using the TFacts.org web service with 
default parameters (Essaghir et al. 2010) (http://www.tfacts.org/TFactS-new/TFactS-
v2/index1.html). Both up- and down-regulated genes were included. 
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5.2.3.2.2. Detection of over-represented gene ontology terms, pathway-based sets and 
neighbor-based sets 
Over-representation analyses were conducted using the ConsensusPathDatabase-mouse 
web service (http://cpdb.molgen.mpg.de/MCPDB). Network neighborhood-based sets were 
limited to one-next neighbor.  
5.2.4. qRT-PCR  
qRT-PCR was conducted on an StepOnePlus instrument (Applied Biosystems) using 
SYBR green master mix (Applied Biosystems) with a final volume of 20 μL. The concentration of 
each primer was 1.0 μM . Primer efficiency was validated using four two-fold dilutions of an 
arbitrarily chosen cDNA. β-Glucuronidase was used as the normalizing gene. The primer 
sequences are provided in Table 5-1. 
Table 5-1. Primers used for qRT-PCR. 
Gene Forward primer 5’-3’ Reverse primer 5’-3’ 
QR CGACAACGGTCCTTTCCAGA GCAGGATGCCACTCTGAATC 
HO-1 CAAGCCGAGAATGCTGAGTTCATG ACTGGGTTCTGCTTGTTGCGCT 
CYP1A1 GACCCTTACAAGTATTTGGTCGTG GGTATCCAGAGCCAGTAACCTC 
β-GLUCURONIDASE TGCTCTGAAACCCGCCGCAT GGGCCCCCAGGTCTGCATCA 
 
 
5.3. Results and discussion 
5.3.1. Cell treatment and RNA isolation for qRT-PCR and RNA-seq 
The mouse hepatoma cell line Hepa-1c1c7 has been used extensively for studies of 
induction of xenobiotic metabolism. The availability and history of use of this cell line were major 
factors considered when choosing to use this cell line for transcript level analyses. Primary 
(human) cell lines may provide more relevant results with respect to exposure of normal human 
tissues, however, the lack of availability and variability between cell lines would have impaired the 
ability to reproduce the data or draw direct comparisons with other studies (Goyak et al. 2008). It is 
important to note the potential discrepancy in transcriptional behaviour of this cell line compared 
to native human hepatocytes that may be a result of, differences in the level of differentiation and 
the genetic instability of cancer cells, the donor animal species (mouse vs. human), and the lack of 
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physiological interactions in a monoculture compared to in vivo. A whole animal (mouse) model 
was considered, but my familiarity with the Hepa-1c1c7 cell line and its proven responsiveness to 
the compounds of interest, combined with the ease at which I could perform the experiments with 
this cell line, prevailed.  
For the most part, the concentrations of each test compound were chosen to be slightly 
higher than the concentration required to double activity of QR (see Section 3.3). The number of 
cells plated and level of confluency during exposure were chosen to mirror that which was 
optimized in the QR bioassay (see Section 2.3.1).  
The time frame for treatment (12 h) for mRNA analyses was substantially shorter than the 
treatment time used in the QR bioassay (48 h). Since I chose concentrations for exposure that were 
minimal and closest to physiological relevance I wanted to maximize the amount of time for 
changes in transcript levels to manifest. A transcriptional study examining the response of 
dendritic cells (mouse and human) to a variety of immune activators showed that certain groups of 
transcripts peaked as early as 30 min, while others peaked as late as 8 or 12 h (Amit et al. 2009). 
Using a later time point may allow non-linear or secondary responses to be observed. For example, 
where the increased transcription of a transcription factor results in increased expression of the 
targets of the second transcription factor. This may provide a better picture of the ultimate changes 
in transcription resulting from a treatment. 
A commercial kit (Qiagen RNeasy) was chosen for RNA isolation. Although the optional 
DNAse digest was conducted there is still a possibility that some minor degree of DNA 
contamination could exist in the sample. Any low level DNA contamination would have a greatest 
effect on the quantification of low abundance transcripts and may also contribute to reads mapping 
to “non-transcribed” regions of the genome during RNA-seq analysis.  
Isolated RNA was of utmost quality as judged by Agilent 2100 Bioanalyzer with resulting 
RNA integrity numbers (RIN) of 9.9-10. An RIN of 10 represents a state where no degradation 
has occurred. 
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5.3.2. RNA-seq  
5.3.2.1. Sequencing  
The Illumina platform was selected due to its sequencing capacity and availability (NRC 
Saskatoon). Single-end, 36 bp reads were considered sufficient for examining differential 
expression in mouse as the sequenced genome was available for this animal and therefore de novo 
transcript assembly was not required.  
Table 5-2. Number of RNA-seq reads passing quality restrictions. 
Treatment Number of reads  
1st RNA-seq experiment   
DMSO 16,995,319  
(3S,8S)-falcarindiol (1 μM) 19,128,690  
(3R,8S)-falcarindiol (1 μM) 16,129,902  
(R)-sulforphane (1 μM) 17,323,370  
(Z)-ligustilide (10 μM) 268,231  
6-isovaleryl-umbelliferone (10 μM) 3,417,980  
xanthohumol (5 μM) 109,911  
   
2nd RNA-seq experiment   
DMSO 21,830,250  
(3R,8S)-falcarindiol (10 μM) 22,891,773  
(3R)-falcarinol (2 μM) 13,411,510  
(Z)-ligustilide (10 μM) 11,693,528  
6-isovaleryl-umbelliferone (10 μM) 35,302,747  
xanthohumol (5 μM) 47,695  
   
mean 13,734,685  
 
Approximately 14 million high-quality reads were obtained per sample (Table 5-2). 
However, three of the original samples (ligustilide (10 μM), 6-isovaleryl-umbelliferone (10 μM), 
xanthohumol (5.0 μM)) yielded low numbers of quality reads. The three unsuccessful samples 
were later re-run along with three additional samples that were collected according to the same 
procedure as the first set (an additional DMSO control, 10 μM (3R,8S)-falcarindiol, 2.0 μM 
falcarinol). These were needed to fill out the remaining lanes on the flow cell. Unfortunately the 
second xanthohumol run was also unsuccessful. The few reads that were collected for the 
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xanthohumol experiments were subjected to bioinformatics analysis but did not yield meaningful 
data. 
5.3.2.2. RNA-seq data processing  
Sequence analysis was carried out using the Bowtie/Tophat/Cufflinks workflow jointly 
developed between UC Berkeley, the University of Maryland and Caltech (Langmead et al. 2009; 
Trapnell et al. 2010). This workflow uses a Burrows-Wheeler index when mapping which results 
in high performance and a low memory footprint. Additionally, this software can correct for 
biases inherent to RNA-seq experiments and has a high level of community support, including 
support at NRC Saskatoon. 
5.3.2.3. Bias corrections 
Despite the power of RNA-seq, the technique is not without limits. During preparation 
for RNA-seq (cDNA production, fragmentation, amplification) both positional and sequence 
specific biases are created. For instance, amongst a collection of random primers certain primer 
sequences appear to be favored by reverse transcriptases leading to a non-random distribution of 
cDNA fragments and inaccurate calculations of differential expression (Oshlack et al. 2009). 
Detecting primer biases and normalizing the data based on these biases is a recent improvement 
to the Tophat software (v1.2.0) and was implemented during analysis. 
Another bias affecting analysis of differentially expressed genes arises from the way that 
transcripts are quantified in RNA-seq. Transcript abundance is expressed as RPKM. As a result 
of changes in the abundance of other transcripts, the relative proportion of a given transcript to 
the total pool can change without a change in the absolute level of this transcript. Highly 
expressed transcripts have the greatest effect on the relative proportions of other transcripts. For 
example, consider a highly expressed gene that makes up 50% of the transcript population. If the 
abundance of this transcript increases as a result of a treatment the RPKM values for unaffected 
transcripts would proportionately decrease although their absolute levels were unaffected. 
Quartile normalization allows the use of only the lowest expressed 75% of loci in calculating the 
RPKM denominator and thereby decreases the bias introduced by changes in high abundance 
transcript levels (Bullard et al. 2010). It is important to note that RPKM values obtained using 
this normalization will be higher than those obtained without it as the denominator will be 
smaller. 
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5.3.2.4. Analysis parameters 
As the default parameters for RNA-seq using Bowtie/Cufflinks/Tophat have been 
optimized for mammalian analysis, these setting were left unaltered. A maximum of two 
mismatches were allowed per alignment. Allowing mismatches during sequence alignment is 
important due to the possibility of errors inherent in the study design and due to biological 
variability. Experimental errors include those introduced during the reverse transcription step 
(approximately 1 in 20,000) or due to sequencing inaccuracy (Roberts et al. 1988). Differences 
due to biological variability include those resulting from genomic changes in the cancer cell line 
and from RNA-DNA differences that arise from RNA-editing or unknown processes (Li et al. 
2011). 
Although differential expression data exist for each transcript, and several transcripts were 
often identified per gene, I have reserved analysis and interpretation to the gene-level expression 
data for the sake of simplicity and manageability. 
5.3.2.5. General observations  
Of the 35556 genes and putative genes annotated in the NCBI Mouse genome annotation 
~ 14000 were consistently detected by RNA-seq (Table 5-3). The significantly lower number of 
genes with transcript level data (Grubbs’s test, p < 0.05) for the (Z)-ligustilide treatment set 
correlate with the lower amount of quality reads that were produced from that sample (see Table 
5-2, Grubb’s test, p < 0.05). 
Table 5-3. Number of genes with RNA-seq transcript level data per treatment. 
 
 
Treatment 
Number of genes with 
expression data 
(3S,8S)-falcarindiol (1μM) 13,852 
(3R,8S)-falcarindiol (1 μM) 13,933 
(3R,8S)-falcarindiol (10 μM) 14,022 
(3R)-falcarinol (2 μM) 13,878 
(R)-sulforphane (1μM) 13,898 
6-isovaleryl-umbelliferone (10 μM) 13,962 
(Z)-ligustilide (10 μM) 12,958 
mean 13,786 
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A breakdown of the distribution of global RPKM values is given in Figure 5-2. The median 
and mean RPKM values were 63.2 and 220.8, which translates into median and mean transcript 
coverage of approximately 32- and 109-fold, respectively (based on 36 bp-read length, not 
corrected for quartile normalization). Ferritin, an iron-binding protein was the most abundant 
transcript with an average RPKM of 27,284. Amongst the 50 most abundant transcripts, as judged 
by RPKM, 10 coded for ribosomal proteins, 10 coded for enzymes involved in primary metabolism 
and cellular respiration, five coded for translation factors and five coded for structural or scaffold 
proteins. Of the top 50 most highly expressed transcripts six were of unknown function or 
predicted pseudogenes. Genes with transcript abundance less than one RPKM were excluded from 
subsequent analysis as their abundance estimations were considered unreliable. Filtering of data to 
remove RPKMs <1 reduced the mean number of genes with transcription information from 13,786 
to 13,069.  
 
Figure 5-2. Distribution of average genic RPKM values. 
5.3.2.6. Relative changes in gene expression level per treatment 
The distribution of differential expression for each treatment group is provided in Figure 
5-3. In general, treatments using higher concentrations (10 µM vs. 1 μM) resulted in greater overall 
perturbations of transcript levels as demonstrated by increases in the proportion of genes with 
differential expression (> 1.5 or < 0.5 in Figure 5-3). (3R,8S)-Falcarindiol was the only compound 
to be tested at more that one concentration (1 µM and 10 µM). Not surprisingly, the treatment at 10 
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µM resulted in a larger perturbation of transcript levels. Remarkably, the more potent QR-inducing 
stereoisomer, (3S,8S)-falcarindiol resulted in a lower degree of global changes than (3R,8S)-
falcarindiol (p < 0.001, chi-square test of goodness of  fit). With 1 μM (3S,8S)-falcarindiol 11% of 
transcripts fell outside of the 0.5-1.5-fold change range, while 19% of transcripts were outside of 
this range for 1 μM (3R,8S)-falcarindiol suggesting that (3R,8S)-falcarindiol has greater 
widespread effects on transcript levels. One μM (3S,8S)-falcarindiol also resulted in fewer 
transcript levels increasing to greater than 1.5-fold compared to (R)-sulforaphane (4% vs. 11%) 
which was tested at the same concentration (1 µM). 
 
Figure 5-3. Distribution of fold-changes for all genes detected in response to treatment. Hepa-1c1c7 cells were 
exposed to the indicated compounds for 12 h and transcript levels were measured by RNA-seq. Due  to 
rounding total percentage for each treatment may not equal 100. 
5.3.2.7. Induction of QR enzymatic activity is correlated with increased transcript 
abundance 
The levels of induction of QR activity determined by bioassay and QR transcript levels 
determined by RNA-seq and qRT-PCR are provided in Figure 5-4. In every case except for (Z)-
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ligustilide, the fold difference in transcript level of QR after 12 h was closely correlated with 
enzyme activity after 48 h, consistent with transcriptional regulation of QR enzyme activity. 
Transcript levels in the (Z)-ligustilide treatment increased as judged by both RNA-seq and qRT-
PCR but did not correlate with enzymatic activity to the same degree as the other treatments. It is 
unclear whether this difference is do to variability in measurement.. Due to the difference in 
sampling time points between transcript (12 h) and enzyme activity (48 h), it is possible that QR 
induction by (Z)-ligustilide is delayed compared to the other treatments. As (Z)-ligustilide 
induces phase I enzyme expression (see below), it is possible that a phase I enzyme-dependent 
metabolite of (Z)-ligustilide may mediate the full induction of QR through Nrf2 and confer this 
delay. 
 
Figure 5-4. Comparison of QR enzyme activity (48 h) and transcript levels (12 h) in Hepa-1c1c7 cells after 
exposure to the indicated compounds. QR enzyme activity is the mean of two technical replicates. qRT-PCR 
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results are the mean of two technical replicates. RNA-seq results are from a single replicate of three pooled 
samples. 
5.3.2.8. Effects of treatments on transcription of Nrf2 targets 
A summary of transcript level changes for the most commonly used Nrf2 marker genes can 
be found in Table 5-4. In general, the compounds tested at concentrations that resulted in 
substantial QR induction (measured in the QR bioassay) caused induction of transcriptional 
markers for Nrf2 activity (1 µM (3S,8S)-falcarindiol, 10 µM (3R,8S)-falcarindiol, 1 µM (R)-
sulforaphane, 10 µM 6-IVU, and 10 µM (Z)-ligustilide) whereas the treatments that did not 
produce a substantial activation of QR did not share this level of marker induction (1 µM (3R,8S)-
falcarindiol and 2 µM (3R)-falcarinol). These findings are consistent with a mechanism of action of 
1 µM (3S,8S)-falcarindiol, 10 µM (3R,8S)-falcarindiol, 1 µM (R)-sulforaphane, 10 µM 6-IVU, and 
10 µM (Z)-ligustilide involving increased Nrf2-directed transcription. A comparison between 1 
µM (3S,8S)-falcarindiol and 1 µM (R)-sulforaphane showed that 1 µM (R)-sulforaphane caused a 
greater increase in the levels of these transcripts at the same concentration, consistent with (R)-
sulforaphane having greater activity in the QR-bioassay. The results for (Z)-ligustilide were 
unclear as two of the genes showed high levels of induction whereas the other three were more or 
less unchanged. 
Table 5-4. Fold-changes in transcript levels of Nrf2 target genes. Hepa-1c1c7 cells were exposed to the 
indicated compounds for 12 h and transcript levels were measured by RNA-seq. 
Description 
(3S,8S)-
falcarindiol 
(1 μM) 
(3R,8S)-
falcarindiol 
(1μM) 
(3R,8S)-
falcarindiol 
(10 μM) 
(3R)-
falcarinol 
(2 μM) 
(R)-
sulforphane 
(1 μM) 
6-isovaleryl-
umbelliferone 
(10 μM) 
(Z)-
ligustilide 
(10 μM) 
QR 2.4 (2.5) 1.2 (1.4) 2.3 1.3 3.8 (4.7) 3.1 (3.8) 1.3 (2.0) 
HO-1 2.0 (2.8) 1.4 (1.2) 9.1 2.0 3.2 (3.8) 2.3 (1.8) 3.8 (2.2) 
GLUTAMATE-
CYSTEINE 
LIGASE-C 
1.5 1.1 1.2 1.2 1.7 1.3 1.2 
GLUTAMATE-
CYSTEINE 
LIGASE-M 
1.6 0.8 1.9 0.9 2.6 1.5 5.4 
GLUTATHIONE 
S-TRANSFERASE, 
A3 
2.2 1.0 1.9 1.2 3.4 1.5 0.9 
mean 1.9 1.1 3.3 1.3 3.0 1.9 2.5 
Parentheses denote values obtained from qRT-PCR analysis 
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  Table 5-5 provides an expanded summary of Nrf2 targets for which Nrf2 regulation is not 
as well characterized as those used in Table 5-4. In addition to regulation by Nrf2, I would expect 
that the regulation of the gene listed in Tables 5-4 and 5-5 to be mediated by other co-operative or 
competitive factors. Even in a simplistic case where several genes are regulated by a single specific 
transcription factor, the number of binding elements and the degree of consensus for the specific 
transcription factor, as well as general transcription factors (e.g. TATA-binding protein (TBP), 
TFIIB, TFIID), can result in unique expression levels for each gene. Additionally, accessibility of 
the promoter region (Berger 2007), mRNA processing efficiency (Furger et al. 2002), and 
posttranscriptional stability (Lai 2002) will contribute to the variability of transcript abundance 
reported in Tables 5-3 and 5-4. The HO-1 gene is an example of an Nrf2 target under complex 
regulation. At least four transcription factors (Nrf2, NF-κB, activator protein-1, and heat shock 
factor-1) regulate HO-1 transcription (Alam et al. 2007). Additionally, the protein Bach1 represses 
Nrf2-mediated transcription through competitive binding to regulatory elements. One of the 
substrates for HO-1, heme, binds to and inhibits Bach1 from associating with the HO-1 promoter.  
For comparison I have also included the proportion of all genes measured that were 
substantially upregulated (greater than 1.5-fold) in each treatment group at the bottom of Table 5-5. 
(R)-sulforaphane (1 µM) treatment upregulated 17 of 28 (61%) of the Nrf2 targets compared to 
7.8% of all transcripts measured. (3S,8S)-falcarindiol (1 µM) upregulated 10 of 28 (36%) of Nrf2-
targets compared to 3.5% of all transcripts measured. These changes for (R)-sulforaphane and 
(3S,8S)-falcarindiol were statistically significant (Pearson’s chi-square test, (p < 0.01) and provide 
support for the hypothesis that these compounds cause QR induction by activating Nrf2. In marked 
contrast to the 1 µM (3S,8S)-falcarindiol treatment, 1 µM (3R,8S)-falcarindiol treatment only 
upregulated a single Nrf2 target (3.6%) compared to 11.3% of all genes. As this concentration of 
(3R,8S)-falcarindiol did not greatly induce QR enzyme activity it is not surprising that Nrf2 targets 
were not activated. Conversely, a higher concentration of (3R,8S)-falcarindiol (10 µM) 
substantially increased the transcript levels of 15 of the 28 Nrf2-targets (54%) compared to 26% of 
all transcripts which was statistically significant (p < 0.01). This transcriptional signature is 
consistent with Nrf2 activation but less supportive than that of (3S,8S)-falcarindiol (1 µM) or (R)-
sulforaphane (1 µM). 
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(Z)-ligustilide (10 µM) and 6-IVU (10 µM) also showed upregulation of a high proportion 
(39% and 36%, respectively) of the Nrf2 target genes listed in Table 5-5. However, this proportion 
did not greatly exceed the global proportion of upregulated genes (28% and 27%, respectively). 
Similarly, (3R)-falcarinol (2 µM) treatment also increased transcript levels for a higher proportion 
of Nrf2 targets (14%) than all targets (8%). This information is consistent with Nrf2 activation by 
these compounds but was not statistically significant (p values > 0.01). 
Amongst the targets summarized in Table 5-5, QR, HO-1, GLUTATHIONE SYNTHETASE, 
GLUTATHIONE S-TRANSFERASE-ALPHA-3 and KEAP1 were the only targets that showed 
increases of greater than three-fold in any of the treatment conditions. Epoxide hydrolase 1, 
leukotriene A4 dehydrogenase, cullin 3, ring-box 1 and Maf G showed very little induction or were 
down-regulated in all of the treatment conditions.  
5.3.2.9. Effects on transcription of AhR targets 
AhR is the other primary transcription factor involved in regulating the expression of QR. 
Comparing the expression of additional AhR targets can provide an indication of whether this 
transcription factor was responsible for, or contributed to QR induction. Changes in transcript 
levels of AhR targets are summarized in Table 5-6. RPKM plots highlighting the Nrf2 and AhR 
targets summarized in Tables 5-5 and 5-6 can be found in Figure 5-5. 
Consistent with AhR activation, 6-IVU (10 µM) caused a three-fold or greater increase in 
the transcript levels of all five AhR. (Z)-ligustilide (10 µM), (3R,8S)-falcarindiol (10 µM), and to a 
lesser extent, (R)-sulforaphane (1 µM), (3R,8S)-falcarindiol (1 µM), and (3R)-falcarinol (2 µM) 
also displayed upregulation of these targets, consistent with moderate to modest activation of the 
AhR receptor. AhR activation for sulforaphane was previously reported (Anwar-Mohamed et al. 
2009).  
(3S,8S)-falcarindiol (1 µM) was the only compound that completely lacked an AhR 
signature. Excluding the possibility of AhR-mediated QR activation provides support for an Nrf2-
based mechanism for (3S,8S)-falcarindiol. 
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Table 5-5. Expanded list of fold-changes in transcript levels of Nrf2 target genes. Hepa-1c1c7 cells were exposed to the indicated compounds for 12 h and 
transcript levels were measured by RNA-seq. 
Description 
ENSEMBL 
identifier 
(3S,8S)-
falcarindiol 
(1μM) 
(3R,8S)-
falcarindiol 
(1μM) 
(3R,8S)-
falcarindiol 
(10μM) 
(3R)-
falcarinol 
(2 μM) 
(R)-
sulforphane 
(1μM) 
6-IVU 
(10μM) 
(Z)-
ligustilide 
(10μM) 
Reference for Nrf2-regulation 
Oxidant metabolism and sequestration 
QR ENSMUSG00000003849 2.44 1.22 2.31 1.34 3.85 3.06 1.27 (Ross et al. 2000) 
CATALASE ENSMUSG00000027187 1.31 1.13 2.77 1.33 1.56 1.60 1.54 
(Otieno et al. 2000; Cho et al. 
2005) 
SUPEROXIDE 
DISMUTASE 1 
ENSMUSG00000022982 1.18 1.05 1.32 0.83 1.53 1.83 1.44 (Otieno et al. 2000) 
FERRITIN HEAVY CHAIN ENSMUSG00000024661 1.16 1.11 1.81 1.40 1.45 2.16 2.57 
(Pietsch et al. 2003; Cho et al. 
2005) 
EPOXIDE HYDROLASE 1 ENSMUSG00000038776 1.02 1.00 1.18 1.07 1.32 1.07 0.99 (Thimmulappa et al. 2002) 
SULFIREDOXIN 1 ENSMUSG00000032802 1.41 1.31 2.61 1.65 1.74 2.12 3.36 (Bae et al. 2011) 
Small molecule antioxidant production and reduction 
HO-1 ENSMUSG00000005413 1.96 1.36 9.15 2.03 3.19 2.26 3.81 (Shan et al. 2006) 
THIOREDOXIN 1 ENSMUSG00000028367 1.09 0.70 0.69 0.51 1.02 0.53 0.43 (Kim et al. 2001) 
THIOREDOXIN 
REDUCTASE 1 
ENSMUSG00000020250 1.34 1.08 1.46 0.94 1.89 1.17 1.06 (Reisman et al. 2009) 
GLUTAMATE-CYSTEINE 
LIGASE, CATALYTIC 
SUBUNIT 
ENSMUSG00000032350 1.46 1.13 1.25 1.16 1.72 1.33 1.20 (Reisman et al. 2009) 
GLUTAMATE-CYSTEINE 
LIGASE, MODIFIER 
SUBUNIT 
ENSMUSG00000028124 1.55 0.83 1.85 0.91 2.60 1.52 5.41 (Reisman et al. 2009) 
GLUTATHIONE 
SYNTHETASE 
ENSMUSG00000027610 1.07 1.59 11.53 1.40 1.98 1.26 1.34 (Lee et al. 2005) 
GLUTATHIONE 
REDUCTASE 
ENSMUSG00000031584 1.59 1.01 2.15 1.41 2.29 0.73 0.82 (Ansher et al. 1986) 
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Table 5-5 cont. 
Description 
ENSEMBL 
identifier 
(3S,8S)-
falcarindiol 
(1 μM) 
(3R,8S)-
falcarindiol 
(1 μM) 
(3R,8S)-
falcarindiol 
(10 μM) 
(3R)-
falcarinol 
(2 μM) 
(R)-
sulforphane 
(1 μM) 
6-IVU   
(10 μM) 
(Z)-
ligustilide 
(10 μM) 
Reference for Nrf2-regulation  
Conjugating and detoxification enzymes 
GLUTATHIONE S-
TRANSFERASE, A3 
ENSMUSG00000025934 2.21 0.97 1.88 1.25 3.42 1.46 0.85 
(Jowsey et al. 2003; Malhotra et 
al. 2010) 
UDP 
GLUCURONOSYLTRANSFE
RASE 2B34 
ENSMUSG00000029260 1.59 0.83 0.59 0.85 1.59 0.46 0.38 (Reisman et al. 2009) 
AFLATOXIN ALDEHYDE 
REDUCTASE 
ENSMUSG00000028743 0.81 1.22 2.06 1.26 1.13 1.40 1.99 (Thimmulappa et al. 2002) 
LEUKOTRIENE A4 
DEHYDROGENASE 
ENSMUSG00000015889 1.11 1.00 0.99 1.10 1.06 0.91 0.94 (Primiano et al. 1998) 
MULTIDRUG RESISTANCE 
PROTEIN 1 
ENSMUSG00000040584 0.96 0.76 0.49 0.55 0.91 0.93 0.63 (Song et al. 2009) 
MULTIDRUG RESISTANCE 
PROTEIN 2 
ENSMUSG00000025194 1.13 0.94 0.95 1.53 1.05 0.77 0.87 (Vollrath et al. 2006) 
Production of reducing equivalents - pentose phosphate pathway 
HEXOSE-6-PHOSPHATE 
DEHYDROGENASE 
ENSMUSG00000028980 0.97 1.47 2.27 1.00 1.36 2.45 1.70 (Reisman et al. 2009) 
GLUCOSE-6-PHOSPHATE 
DEHYDROGENASE 2 
ENSMUSG00000089992 1.75 1.35 1.66 1.08 2.23 1.10 0.94 (Wu et al. 2011) 
GLUCOSE-6-PHOSPHATE 
DEHYDROGENASE X-
LINKED 
ENSMUSG00000031400 1.52 1.23 2.03 1.80 2.61 1.23 1.53 (Wu et al. 2011) 
PHOSPHOGLUCONATE 
DEHYDROGENASE 
ENSMUSG00000028961 1.76 1.47 3.65 1.46 2.71 1.82 2.58 (Thimmulappa et al. 2002) 
Signal transduction 
KEAP1 ENSMUSG00000003308 0.96 1.26 3.37 1.46 1.54 2.02 1.95 (Lee et al. 2007) 
SEQUESTOSOME 1 ENSMUSG00000015837 1.51 1.19 1.93 1.33 1.69 1.43 1.04 (Copple et al. 2010) 
CULLIN 3 ENSMUSG00000004364 1.06 0.66 0.30 0.61 0.81 0.48 0.19 (Kaspar et al. 2010) 
RING-BOX 1 ENSMUSG00000022400 1.01 0.80 0.71 0.85 0.76 0.88 0.47 (Kaspar et al. 2010) 
MAF G ENSMUSG00000025138 0.82 1.02 1.05 1.02 0.85 1.36 1.65 (Katsuoka et al. 2005) 
Number of Nrf2-targets upregulated (>1.5-fold) 10 1 15 4 17 10 11  
Proportion of 28 Nrf2 targets upregulated (%)  35.7 3.6 53.6 14.3 60.7 35.7 39.3  
Proportion of genes with >1.5-fold expression globally (%)  3.5 11.3 26.0 8.4 7.8 27.7 26.9  
P value (calculated using Pearson’s chi-square test, * 
indicates significance (p < 0.01))  
2.03E-
08* 
9.66E-01 1.72E-03* 2.05E-01 1.36E-12* 2.38E-01 1.08E-01  
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Table 5-6. Fold-changes in transcript levels for AhR target genes. Hepa-1c1c7 cells were exposed to the 
indicated compounds for 12 h and transcript levels were measured by RNA-seq 
Gene 
(3S,8S)-
falcarindiol 
(1 μM) 
(3R,8S)-
falcarindiol 
(1 μM) 
(3R,8S)-
falcarindiol 
(10 μM) 
(3R)-
falcarinol  
(2 μM) 
(R)-
sulforphane 
(1 μM) 
6-isovaleryl-
umbelliferone 
(10 μM) 
(Z)-
ligustilide 
(10 μM) 
CYP1A1 0.9 (0.8) 1.1 (0.7) 1.2 (1.4) 1.4 (1.6) 1.3 (1.6) 6.7 (7.5) 1.6 (1.4) 
CYP1A2 1.0 1.7 5.3 1.7 2.1 23.7 3.4 
CYP1B1 0.4 0.7 1.2 1.2 1.3 3.6 2.4 
CYP2S1 1.2 1.4 1.4 1.1 1.5 3.2 2.1 
C-MYC 1.1 1.3 2.7 1.5 1.3 3.1 3.8 
mean 0.9 1.2 2.4 1.4 1.5 8.1 2.7 
Parentheses denote values obtained from qRT-PCR analysis 
6-IVU and (Z)-ligustilide are similar to known AhR ligands in that they are planar, 
aromatic and relatively non-polar with moderate molecular weights (190 and 246 Da respectively). 
Likewise, the polyacetylenes tested here have some similarity to an endogenous AhR ligand 
lipoxin A4, an oxidized fatty acid derivative (Schaldach et al. 1999). However, the lack of 
induction of AhR at the 1 μM concentration for the polyacetylenes is consistent with these 
compounds being weak ligands for the AhR and is encouraging with respect to the beneficial 
potential of these compounds. 
5.3.2.10. Computational analysis of transcriptional patterns resulting from exposure to QR 
inducers 
Given the prior knowledge of QR induction, manual analysis of activation of Nrf2 and 
AhR was warranted. However, detailed analysis of all known transcription factors on a manual 
basis is prohibitively time consuming. I exploited available tools to expedite the identification of 
trends in the data. I used the database at Tfacts.org to search for transcriptional signatures 
(patterns of transcriptional regulation) of a wide range of transcription factors. Also, functional 
consequences of exposure to the test compounds were investigated by looking for enrichment of 
gene ontology (GO) terms, biochemical pathways and groups of interacting proteins (neighbor-
based sets). Finally, I used principal component analysis (PCA) to compare the global effects on 
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transcription amongst the treatment groups. 5.3.2.11. Analysis of transcription factor binding 
signatures. 
Tfacts (Essaghir et al. 2010) was used to look for transcriptional signatures indicative of 
transcription factor involvement. This service takes a list of up or down regulated genes and cross-
references it with a database of known transcription factor targets (transcriptional signatures) to 
identify candidate transcription factors. A summary of the top hits for each treatment are provided 
in Table 5-7 in order of declining statistical likelihood. 
Nrf2 was identified in all the treatments except that of (3R,8S)-falcarindiol (1 µM), and was 
one of the top three hits for both (3S,8S)-falcarindiol (1 µM) and (R)-sulforaphane (1 µM). This 
outcome is in accord with my prior manual analysis that supported Nrf2 activation by these 
compounds. 
Although the TFACTs database does not appear to include the AhR, the aryl hydrocarbon 
receptor nuclear translocator (ARNT) was among the transcription factors identified in the 6-IVU 
treatment. AhR activity is dependent on formation of a complex with ARNT which functions as a 
transcriptional co-activator. Although ARNT may form complexes with other transcription factors 
such as hypoxia inducible factor (HIF)-α, ARNT transcriptional activation is often synonymous 
with AhR transcriptional activation and therefore the identification of this transcription factor as 
being activated by 6-IVU is consistent with my manual analysis that supported AhR activation by 
6-IVU. 
5.3.2.11. Over-representation of gene ontology, pathway and neighbour-based sets 
ConsensusPathDB (CPDB) is a meta-database of protein interactions and annotations 
(Kamburov et al. 2011). Using lists of up and down regulated genes for each treatment group I 
queried CPDB to look for over-representation of GO terms, pathway-based sets and neighbour-
based sets. 
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 Figure 5-5. RPKM plots for treated vs. DMSO-treated cells. Dots on the left and right side of the line correspond to up and down 
regulated transcripts respectively. The Nrf2 and AhR targets listed in tables 5-4 and 5-5 are highlighted in blue and red respectively. 
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GO annotations are an attempt to provide a consistent set of terms describing the 
biological process, molecular function and cellular component with which a gene product is 
associated. These annotations are divided into levels with level 1 being the most general. Here, I 
only report enrichment of GO terms at level 3. I found levels 1 and 2 to be vague to provide 
useful information. This analysis is summarized in Table 5-8. 
Pathway-based sets and neighbor-based sets represent groups of genes involved in the 
same biochemical pathway or that are known to interact, respectively. Tables 5-8 and B-1 
(appendix) summarize the highest ranking sets for the two analyses. 
Consistent with Nrf2 activation both (3S,8S)-falcarindiol (1 µM) and (R)-sulforaphane (1 µM) 
treatments showed enrichment in the GO terms ‘response to oxidative stress’ and ‘pigment 
metabolic process’ (heme metabolism is in part regulated by Nrf2 through regulation of HO-1). 
Additionally, (R)-sulforaphane treatment showed enrichment in glutamate-cysteine ligase complex 
and response to nitrosative stress. Terms associated with cell cycle regulation were well 
represented in the polyacetylene treatments while annotations involving regulation of metabolic 
processes were well represented in both (3R,8S)-falcarindiol treatments, the 6-IVU (10 µM) and 
(Z)-ligustilide (10 µM) treatments. 
Pathway-based sets that were over-represented in the (3S,8S)-falcarindiol (1 µM) and (R)-
sulforaphane (1 µM) treatments such as glutathione metabolism and the pentose phosphate 
pathway are consistent with Nrf2 activation. The (3R,8S)-falcarindiol (10 µM) treatment was 
associated with many pathways involved in translation. Both (3S,8S)-falcarindiol (1 µM) and (3R)-
falcarinol (2 µM) treatments were commonly associated with transcript processing pathways. 
Finally, the 6-IVU (10 µM) and (Z)-ligustilide (10 µM) treatments showed a high number of 
associations with toll-like receptor (TLR), NF-κB, and nerve growth factor signalling. 
 
115 
 
Table 5-7. Filtered list of transcription factors signatures. Determined using TFACTS.org 
(3S,8S)-
falcarindiol 
(3R,8S)-
falcarindiol 
(3R,8S)- 
falcarindiol 
(3R)-
falcarinol 
(R)-
sulforphane 
6-isovaleryl-
umbelliferone 
(Z)-
ligustilide 
(1 μM) (1 μM) (10 μM) (2 μM) (1 μM) (10 μM) (10 μM) 
SP1 P53 ESR1 P53 WT1 FLI1 SMAD 
NRF2 FOXO1 SREBP FLI1 EGR1 WT1 FLI1 
SRF SREBP FOXO3 NFKB1 NRF2 SMAD SMAD3 
RARB ATF1 SMAD TFAP2A JUN ESR1 STAT3 
FLI1 CREB STAT BRCA1 RELA SREBP FOXO3 
ESR1 ESR1 PPARD AR SMAD ELK1 ESR1 
JUN ELK1 JUND RELA AP1 CREB ELK1 
GLI RARB GLI1 USF1 TBP RARA JUN 
SREBP FOXO3 STAT3 GLI1 GLI1 SMAD3 SREBP 
NFKB1 BRCA1 CREB NFKB PPARG JUN AR 
USF2 SRF HIF1A ATF4 JUND HIF1A NFKB 
TCF/BETA-
CATENIN 
ATF4 JUN CREB1 GLI2 JUND JUND 
TFAP2A STAT5B RELA FOXO3 USF1 E2F WT1 
ETV4 GLI1 NFKB CEBPA FLI1 PPARD RELA 
EGR1 AR AR STAT PPARD SMAD7 TBP 
ETS1 EGR1 NRF2 JUN FOS GLI1 E2F 
STAT3 RARA JUNB HIF1A P53 ETV4 ID1 
HIF1A STAT5A SMAD3 PPARG NFKB1 STAT5 FOXO4 
USF1 HIF ELK1 RARB CREB STAT1 PPARD 
SMAD HIF1A RARA ATF1 NFIA HIF HIF1A 
RARA PPARG STAT5 WT1 NFKB SRF SRF 
AP1 STAT ATF4 PPARD STAT5B BRCA1 BRCA1 
STAT USF1 TBP FOXO HIF1A REL RARA 
CREB CEBPA HIF GLI2 
NOTCH/ 
RBP-J 
ID1 PPARG 
TBP TFAP2A PPARG ELK1 JUNB FOS E2F1 
GLI1 STAT5 GATA1 SMAD AR STAT5B STAT1 
ATF1 FLI1 BRCA1 FOS SMAD3 ATF4 MYBL2 
RELA 
NOTCH/ 
RBP-J 
E2F1 LEF1 CEBPA NFIC NFIC 
CREB1 GLI2 FOS RARA STAT1 JUNB SMAD4 
NFKB USF2 LXR USF2 HIF SMAD4 JUNB 
P53 RELA FLI1 ESR1 STAT5A PPARG MYB 
SPI1 ETS2 E2F EGR1 FOXO ATF6 GLI1 
GLI2 JUND ATF1 NRF2 NFIC ARNT PAX6 
SP3 STAT1 PPARA JUNB SREBP STAT5A HIF 
FOXO1 NFIC MYBL2 SMAD3 RARB RARB CREB 
FOXO ETS1 NFAT1 E2F RARA PPARA STAT5 
 
JUN LEF1 
NOTCH/ 
RBP-J 
ESR1 PAX6 STAT5B 
 
SPI1 NFIA STAT5 ETS1 RARG ATF2 
 
RXR/RAR PAX6 RXR/RAR FOXO1 CREM ATF1 
 
STAT3 RARB JUND USF2 GATA1 STAT5A 
 
FOS ATF2 STAT3 TFAP2A LEF1 FOS 
 
ETS STAT1 SREBP STAT3 BCL6 TCFAP2A 
 
SP3 TCFAP2A SP3 FOXO3 NFIA ATF4 
 
POU2F1 ETV4 FOXO1 STAT5 MYBL2 ETS 
 
AP1 SMAD4 ETV4 SPI1 NFAT1 ETV4 
 
NFKB1 NFIC CREB CREB1 POU5F1 PPARA 
  
WT1 TBP STAT NRF2 NRF2 
  
ETS NFIA ATF1 ATF2 CREM 
  
POU2F1 ETS1 POU2F1 E2F4 POU2F1 
  
CEBPB ATF2 HNF4A FOXA1 E2F4 
   
AP1 SP3 E2F1 REST 
   
NFIC 
 
FOXA2 RARB 
 
116 
 
Table 5-8. Over-represented gene ontology sets. 
(3S,8S)-falcarindiol 
(1 μM) 
(3R,8S)-falcarindiol 
(1 μM) 
(3R,8S)-falcarindiol 
(10 μM) 
(3R)-falcarinol 
(2 μM) 
(R)-sulforphane 
(1 μM) 
6-isovaleryl-umbelliferone 
(10 μM) 
(Z)-ligustilide 
(10 μM) 
Negative regulation of 
cell cycle process 
Negative regulation of 
nitrogen compound 
metabolic process 
Cytoplasm Negative regulation of 
cell cycle process 
Response to 
oxidative stress 
Transcription factor binding Transcription factor 
binding 
Mitotic 
metaphase/anaphase 
transition 
DNA binding Intracellular membrane-
bounded organelle 
Mitotic 
metaphase/anaphase 
transition 
Peptide metabolic 
process 
Negative regulation of 
nitrogen compound metabolic 
process 
Negative regulation of 
nitrogen compound 
metabolic process 
Vitamin transport Regulation of nitrogen 
compound metabolic 
process 
Cytoplasmic part Negative regulation of 
cell cycle 
Glutamate-
cysteine ligase 
complex 
Regulation of nitrogen 
compound metabolic process 
Negative regulation of 
biosynthetic process 
Response to oxidative 
stress 
Regulation of cellular 
metabolic process 
Cellular macromolecule 
metabolic process 
DNA binding Cell junction 
assembly 
Negative regulation of 
biosynthetic process 
Macromolecule 
biosynthetic process 
Pigment catabolic 
process 
Negative regulation of 
biosynthetic process 
Nuclear part Microtubule Microtubule-based 
movement 
Regulation of macromolecule 
metabolic process 
Regulation of 
macromolecule metabolic 
process 
Negative regulation of 
cell cycle 
Regulation of 
macromolecule 
metabolic process 
Intracellular non-
membrane-bounded 
organelle 
Intracellular non-
membrane-bounded 
organelle 
Negative 
regulation of cell 
cycle process 
Regulation of cellular 
metabolic process 
Negative regulation of 
cellular metabolic process 
Regulation of cell cycle 
process 
Negative regulation of 
cellular metabolic 
process 
Purine nucleotide 
binding 
Cell junction assembly Transcription 
factor binding 
Regulation of biosynthetic 
process 
Regulation of nitrogen 
compound metabolic 
process 
Regulation of female 
receptivity 
Regulation of primary 
metabolic process 
Ribonucleotide binding Gene expression Pigment catabolic 
process 
Regulation of primary 
metabolic process 
DNA binding 
Kinetochore Regulation of metabolic 
process 
RNA binding Developmental growth 
involved in 
morphogenesis 
Response to 
nitrosative stress 
DNA binding Regulation of biosynthetic 
process 
 Regulation of 
biosynthetic process 
Ligase activity, forming 
carbon-nitrogen bonds 
Regulation of nitrogen 
compound metabolic 
process 
Vitamin transport Macromolecule biosynthetic 
process 
Enzyme binding 
 Negative regulation of 
macromolecule 
metabolic process 
Protein metabolic 
process 
Macromolecule 
biosynthetic process 
 Negative regulation of 
cellular metabolic process 
Cell junction assembly 
   
 
   
1
1
6
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Table 5.8 cont.       
(3S,8S)-falcarindiol  
(1 μM) 
(3R,8S)-falcarindiol 
(1 μM) 
(3R,8S)-falcarindiol 
(10 μM) 
(3R)-falcarinol 
(2 μM) 
(R)-sulforphane 
(1 μM) 
6-isovaleryl-umbelliferone 
(10 μM) 
(Z)-ligustilide 
(10 μM) 
 Oxidoreductase activity, 
acting on the CH-NH 
group of donors 
Ribosome Cerebellar Purkinje cell 
layer development 
 Gene expression Regulation of cellular 
metabolic process 
 Gene expression Macromolecule catabolic 
process 
  Negative regulation of cell 
cycle process 
Gene expression 
 Macromolecule 
biosynthetic process 
Intracellular organelle 
lumen 
  Transcription coactivator 
activity 
Post-embryonic camera-
type eye development 
 Cell junction assembly Intracellular transport   Cellular macromolecule 
metabolic process 
Flotillin complex 
 Adenosine deaminase 
activity 
Mitotic cell cycle   Regulation of cell shape Negative regulation of 
macromolecule metabolic 
process 
 Specific transcriptional 
repressor activity 
Hydrolase activity, acting 
on acid anhydrides 
  Negative regulation of 
macromolecule metabolic 
process 
Regulation of primary 
metabolic process 
 
Regulation of signaling 
pathway 
Protein localization   Regulation of metabolic 
process 
Cell leading edge 
 Microtubule Protein transport   Cell junction assembly Specific RNA polymerase 
II transcription factor 
activity 
 Maintenance of location 
in cell 
Cell cycle phase   Flotillin complex Transforming growth 
factor-beta production 
 Regulation of cell cycle Macromolecule 
modification 
  Cell leading edge Transcription factor 
complex 
 Transcription factor 
binding 
Energy derivation by 
oxidation of organic 
compounds 
  Regulation of signaling 
pathway 
Positive regulation of 
nitrogen compound 
metabolic process 
 Embryonic heart tube 
development 
Generation of precursor 
metabolites and energy 
  Nucleobase, nucleoside, 
nucleotide and nucleic acid 
metabolic process 
Negative regulation of cell 
cycle process 
  Cellular macromolecule 
localization 
  Specific RNA polymerase II 
transcription factor activity 
Regulation of metabolic 
process 
  Cellular catabolic 
process 
 
 Regulation of signaling 
process 
Microtubule 
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Table 5-9. Over-represented pathway-based sets. 
(3S,8S)-falcarindiol  
(1 μM) 
(3R,8S)-falcarindiol 
(1 μM) 
(3R,8S)-falcarindiol 
(10 μM) 
(3R)-falcarinol 
(2 μM) 
(R)-sulforphane 
(1 μM) 
6-isovaleryl-umbelliferone 
(10 μM) 
(Z)-ligustilide 
(10 μM) 
Metabolism of 
carbohydrates 
Gap junction trafficking 
and regulation 
Metabolism of 
proteins 
Transport of Mature 
mRNA Derived from an 
Intronless Transcript 
Pentose phosphate 
pathway (hexose 
monophosphate 
shunt) 
TRAF6 mediated induction 
of NFkB and MAP kinases 
upon TLR7/8 or 9 activation 
Signalling by NGF 
Regulation of 
Glucokinase by 
Glucokinase Regulatory 
Protein 
Gap junction degradation Gene Expression Transport of Mature 
mRNAs Derived from 
Intronless Transcripts 
Glutathione 
metabolism - Mus 
musculus (mouse) 
MyD88 dependent cascade 
initiated on endosome 
Toll Like Receptor 
TLR1:TLR2 Cascade 
Glucose transport Acute myeloid leukemia 
- Mus musculus (mouse) 
SRP-dependent 
cotranslational protein 
targeting to 
membrane 
Transport of the SLBP 
independent Mature 
mRNA 
Glutathione synthesis Toll Like Receptor 7/8 
Cascade 
MyD88:Mal cascade 
initiated on plasma 
membrane 
Hexose transport Gap junction trafficking Translation Transport of the SLBP 
Dependant Mature mRNA 
Pentose phosphate 
pathway - Mus 
musculus (mouse) 
Toll Like Receptor 9  
Cascade 
Toll Like Receptor 4 
Cascade 
Transport of the SLBP 
independent Mature 
mRNA 
Resolution of AP sites 
via the multiple-
nucleotide patch 
replacement pathway 
GTP hydrolysis and 
joining of the 60S 
ribosomal subunit 
Regulation of Glucokinase 
by Glucokinase 
Regulatory Protein 
Glutathione 
conjugation 
Activated TLR4 signalling TRAF6 mediated 
induction of NFkB and 
MAP kinases upon 
TLR7/8 or 9 activation 
Transport of the SLBP 
Dependant Mature 
mRNA 
Removal of DNA patch 
containing abasic residue 
Eukaryotic 
Translation 
Termination 
Glucose transport Insulin effects 
increased synthesis of 
Xylulose-5-Phosphate 
Toll Receptor Cascades MyD88 dependent 
cascade initiated on 
endosome 
Transport of Mature 
mRNA Derived from an 
Intronless Transcript 
Gap junction - Mus 
musculus (mouse) 
Formation of a pool 
of free 40S subunits 
Hexose transport Vitamin C (ascorbate) 
metabolism 
Toll Like Receptor 3 Cascade Toll Like Receptor 7/8 
Cascade 
Transport of Mature 
mRNAs Derived from 
Intronless Transcripts 
Signalling by NGF Cap-dependent 
Translation Initiation 
snRNP Assembly Gap junction - Mus 
musculus (mouse) 
Signalling by NGF Toll Like Receptor 9 
Cascade 
snRNP Assembly C6 deamination of 
adenosine 
Eukaryotic 
Translation Initiation 
Metabolism of non-coding 
RNA 
Prefoldin mediated 
transfer of substrater 
to CCT/TriC 
Toll Like Receptor 
TLR1:TLR2 Cascade 
Activated TLR4 
signalling 
Metabolism of non-
coding RNA 
Formation of editosomes 
by ADAR proteins 
L13a-mediated 
translational silencing 
of Ceruloplasmin 
expression 
Transport of Mature 
Transcript to Cytoplasm 
Post-chaperonin 
tubulin folding 
pathway 
MyD88:Mal cascade initiated 
on plasma membrane 
Toll Like Receptor 
TLR6:TLR2 Cascade 
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Table 5.9 cont. 
      
(3S,8S)-falcarindiol 
(1 μM) 
(3R,8S)-falcarindiol 
(1 μM) 
(3R,8S)-falcarindiol 
(10 μM) 
(3R)-falcarinol 
(2 μM) 
(R)-sulforphane 
(1 μM) 
6-isovaleryl-umbelliferone 
(10 μM) 
(Z)-ligustilide 
(10 μM) 
Transport of Mature 
mRNA derived from an 
Intron-Containing 
Transcript 
mRNA Editing: A to I 
Conversion 
3, -UTR-mediated 
translational 
regulation 
Transport of Mature 
mRNA derived from an 
Intron-Containing 
Transcript 
Acute myeloid 
leukemia - Mus 
musculus (mouse) 
MyD88-independent cascade 
initiated on plasma 
membrane 
Toll Like Receptor 2 
Cascade 
Transport of Mature 
Transcript to Cytoplasm 
NGF signalling via 
TRKA from the plasma 
membrane 
Peptide chain 
elongation 
Metabolism of RNA RNA Polymerase III 
Transcription 
Termination 
Toll Like Receptor 4 (TLR4) 
Cascade 
Toll Receptor Cascades  
Metabolism of RNA Adherens junction - Mus 
musculus (mouse) 
Eukaryotic 
Translation 
Elongation 
Processing of Capped 
Intron-Containing Pre-
mRNA 
Cooperation of 
Prefoldin and 
TriC/CCT  in actin 
and tubulin folding 
NFkB and MAP kinases 
activation mediated by TLR4 
signaling repertoire 
NGF signalling via 
TRKA from the plasma 
membrane 
Transmembrane 
transport of small 
molecules 
Integrin alphaIIb beta3 
signaling 
Cell Cycle TRAF6 mediated NF-kB 
activation 
Chaperonin-mediated 
protein folding 
TRAF6 Mediated Induction 
of proinflammatory cytokines 
NFkB and MAP kinases 
activation mediated by 
TLR4 signaling 
repertoire 
SLC-mediated 
transmembrane 
transport 
Resolution of Abasic 
Sites (AP sites) 
Cell Cycle, Mitotic mRNA Processing Metabolism of 
carbohydrates 
Toll Like Receptor 
TLR6:TLR2 Cascade 
TRAF6 Mediated 
Induction of 
proinflammatory 
cytokines 
Pentose phosphate 
pathway (hexose 
monophosphate shunt) 
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Detection of over-representation of neighbor-based sets (Figure B-1) centered around 
glutathione synthesis (GSHB-glutathione synthetase and GSH0-gamma-glutamyl-cysteine 
synthase regulatory subunit) in the sulforaphane (1 µM) treatment is consistent with Nrf2 
activation. The detection of an over-represented neighbor-based set centered around IKK-B in the 
6-IVU (10 µM) and (Z)-ligustilide (10 µM) was in agreement with the enrichment of NF-κB and 
TLR signalling pathways detected in the pathway-based analysis. Also, detection of a set centered 
around ARNT in response to 6-IVU (10 µM) is consistent with activation of the AhR by this 
compound. 
5.3.2.12. Principal components analysis 
Principal components analysis (PCA) is a method used to detect patterns in highly 
dimensional data. PCA relies on calculating metrics to represent the degree that each variable 
accounts for differences amongst sample sets. In other words, PCA can reduce complex sample 
sets (gene expression data for 14000 genes under a range of conditions) to single points by 
simplifying the variability amongst samples to principal components that are represented by chart 
axes. I chose to use PCA to look for trends amongst the RNA-seq data and as a means to verify 
differences between the falcarindiol stereoisomers. The results of this analysis are shown in Figure 
5-6. Table 5-10 is a summary of the statistics associated with this analysis. 
As a verification of the computational outcome, I completed an analysis of a subset of the 
data (946 genes beginning with the letter A). The outcome of this subset (not shown) followed a 
nearly identical pattern to that of the whole set.  
Principal components 1 and 2 accounted for 46% and 20% of the variance between 
sample groups. On the basis of these principal components the gene expression patterns of 
(3R,8S)-falcarindiol (1 µM) and (3S,8S)-falcarindiol (1 µM) were both more alike (R)-sulforaphane 
(1 µM) than they were each other. This finding provides support for the hypothesis that the two 
falcarindiol stereoisomers display different pharmacological effects. The grouping of 6-IVU (10 
µM) and (Z)-ligustilide (10 µM) when plotted on principal components 1 and 2 was in agreement 
with the high level of similarity that was observed between these two treatments in the TFACTS 
and CPDB analysis mentioned above. Principal components 3 and 4 accounted for 15% and 9% of 
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the variance between sample groups and captured similarities between the (3R,8S)-falcarindiol (1 
µM), (3R,8S)-falcarindiol (10 µM), (3S,8S)-falcarindiol (1 µM) and (R)-sulforaphane (1 µM). 
 
 
 
Figure 5-6. Principal components analysis of differential gene expression patterns. Treatments groups are 
plotted on A) principal components 1 and 2, and B) principal components 3 and 4. Calculated using R.  
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Table 5-10. Summary statistics for PCA analysis of differential gene expression patterns. 
 
PC1 PC2 PC3 PC4 PC5 PC6 
Standard deviation 75.4257 50.0795 42.8448 33.69789 26.20258 23.15927 
Proportion of 
variance 
0.4591 0.2024 0.1482 0.09164 0.05541 0.04329 
Cumulative 
proportion of 
variance 
0.4591 0.6615 0.8097 0.90131 0.95671 1 
 
5.3.2.13. Follow-up on computational studies 
Upon completing the above computational analyses some trends in the data were 
apparent. (3S,8S)-falcarindiol and (3R,8S)-falcarindiol differ substantially in their global effects 
on transcription. Aside from the differences in Nrf2 activation, (3R,8S)-falcarindiol treatment 
appeared to cause changes associated with cellular metabolism. This was based on the over-
representation of GO terms associated with metabolic processes and the presence of many 
transcription factors involved in metabolism in the TFACTs analysis for the (3R,8S)-falcarindiol 
treatments. This signature was common to (3R,8S)-falcarindiol (10 µM), 6-IVU (10 µM) and (Z)-
ligustilide (10 µM) treatments and appeared to be captured to a degree in principal component 1 
of the PCA. Also of interest, was the activation of NF-κB associated signalling pathways. 
Transcription factors associated with these pathways were detected for all of the treatments by 
TFACTS analysis but for the other analyses these pathways were particularly enriched in the (Z)-
ligustilide, 6-IVU and falcarinol treatments. Therefore I decided to look further into the 
regulation of metabolism with particular focus on lipid homeostasis as well as NF-κB signalling.  
5.3.2.14. Regulators of lipid homeostasis   
Sterol-responsive element binding proteins (SREBPs) are basic-helix-loop-helix 
transcription factors that regulate lipid metabolism reviewed in Eberle et al. (2004). Three SREBP 
isoforms SREBP-1a, SREBP-1c, and SREBP-2 have been identified in mammals. SREBP-1a and -
1c are derived from alternate transcriptional start sites of the SREBP-1 gene and differ in their 
transactivation domains.  
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In the transcriptional signature analysis (TFACTS), SREBP was one of the top three hits in 
response to both 1 µM and 10 µM (3R,8S)-falcarindiol, and was also identified in the 1 µM 
(3S,8S)-falcarindiol, (3R)-falcarinol (2 µM), (Z)-ligustilide (10 µM) and 6-IVU (10 µM) 
treatments. TFACTS does not distinguish between SREBP isoforms. Consistent with SREBP 
activation, GO terms associated with metabolic processes were over-represented in both (3R,8S)-
falcarindiol treatments and the (Z)-ligustilide (10 µM) and 6-IVU (10 µM) treatments.  
A summary of transcript level changes of SREBP-1 and -2 targets and regulators is 
provided in Table 5-11. Most of these targets were identified by microarray analysis of 
overexpression and deletion lines and validated using an additional technique (i.e. qRT-PCR) 
(Horton et al. 2003). On average the transcript levels of these targets were increased with  (3R,8S)-
falcarindiol (1 µM), (3R,8S)-falcarindiol (10 µM), (Z)-ligustilide (10 µM) and 6-IVU (10 µM) 
treatments. The genes that were subjected to the largest and most consistent changes were 
acetoacetyl-CoA synthetase, the LDL-receptor, fatty acid synthase and ABC1 which is known to 
be negatively regulated by SREBP-2 (Zeng et al. 2004; Tamehiro et al. 2007).  
SREBPs share a level of identity with Nrf2 as both are basic helix-loop-helix 
transcriptions factors. Could it be that Keap1 regulates SREBPs via ubiquitylation and that the 
small molecules tested also interfere with this process? Interestingly the mouse SREBP-1 gene 
possesses an ETGD sequence in the N-terminus which is very similar to the ETGE / ESGE 
sequences recognized by Keap1 for two of its known substrates, Nrf2 and phosphoglycerate 
mutase family member 5 (PGAM5), respectively (Lo et al. 2006; Tong et al. 2006). However,  
the literature suggests that Nrf2 is involved in down-regulating SREBP mediated transcription 
(Tanaka et al. 2008; Zhang et al. 2010) which reduces the likelihood of this mechanism of action. 
Upon further investigation, it was revealed that the SREBP-1 and SREBP-2 transcripts are 
themselves upregulated suggesting that activation of SREBP transcription was secondary to 
activation of another transcription factor (or other means of increasing transcript levels) rather 
than a mechanism involving changes in the stability or transcriptional activity of the SREBP 
proteins.  
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Table 5-11. Transcript levels of validated SREBP-1 and SREBP-2 targets and regulators. Hepa-1c1c7 cells were exposed to the indicated compounds 
for 12 h and transcript levels were measured by RNA-seq. 
Description ENSEMBL identifier 
(3S,8S)-
falcarindiol 
(3R,8S)-
falcarindiol 
(3R,8S)-
falcarindiol 
(3R)-
falcarinol 
(R)-
sulforphane 
6-isovaleryl-
umbelliferone 
(Z)-
ligustilide 
 
 
(1 μM) (1 μM) (10 μM) (2 μM) (1 μM) (10 μM) (10 μM) 
Targets 
        
ACETOACETYL-COA SYNTHETASE ENSMUSG00000029482 0.95 1.22 1.94 1.16 1.21 1.77 2.03 
ATP CITRATE LYASE  ENSMUSG00000020917 0.78 1.09 1.01 0.90 1.09 1.45 0.58 
7-DEHYDROCHOLESTEROL 
REDUCTASE  
ENSMUSG00000058454 0.61 1.14 1.07 0.78 0.63 0.67 0.75 
FARNESYL DIPHOSPHATE 
SYNTHETASE 
ENSMUSG00000059743 0.91 0.85 1.32 1.13 0.89 1.31 0.90 
HMG-CO A REDUCTASE  ENSMUSG00000021670 0.98 1.61 1.10 1.33 1.34 1.16 1.11 
LOW DENSITY LIPOPROTEIN 
RECEPTOR  
ENSMUSG00000032193 1.18 1.43 1.72 1.03 1.34 1.73 1.68 
CYTOCHROME P450, FAMILY 51 
(CYP51) 
ENSMUSG00000001467 0.91 0.68 0.51 0.77 0.87 0.55 0.31 
FATTY ACID SYNTHASE  ENSMUSG00000025153 1.05 1.78 2.22 1.53 1.14 2.68 4.19 
ATP-BINDING CASSETTE, SUB-
FAMILY A, MEMBER 1 (ABCA1) 
(DOWN-REGULATION, INVERSE USED 
IN CALCULATING MEAN) 
ENSMUSG00000015243 1.00 0.84 0.60 0.88 0.73 0.71 0.59 
Mean 
 
0.93 1.22 1.39 1.09 1.10 1.41 1.47 
Regulators 
        
STEROL REGULATORY ELEMENT 
BINDING FACTOR 1  (SREBP1) 
ENSMUSG00000020538 0.81 1.45 2.30 1.25 1.20 2.29 2.98 
STEROL REGULATORY ELEMENT 
BINDING FACTOR 2 (SREBP2)  
ENSMUSG00000022463 1.02 1.51 2.39 1.28 1.22 2.15 2.62 
ESTROGEN RECEPTOR 1 (ESR1) ENSMUSG00000019768 1.24 1.73 1.63 1.66 1.72 2.91 3.23 
FORKHEAD BOX O3 (FOXO3) ENSMUSG00000048756 0.93 1.38 1.91 1.34 1.07 2.25 3.28 
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Numerous transcriptional regulators of SREBPs have been documented. These include 
the liver X receptor / retinoid X receptor, ROR-alpha, the cannabininoid-1 receptor (CB1), the 
estrogen receptor-1 (ESR-1) and hepatocyte nuclear factor-4a (Sampath et al. 2004; Wang et al. 
2006). Furthermore, the SREBP-1c isoform directs it’s own transcription in a positive feedback 
loop (Horton et al. 2003). 
TFACTS analysis had highlighted ESR-1 and a transcriptional regulator of ESR-1, 
FOXO3, as being active in the same treatments that produced an SREBP signature. Examination 
of the RNA-seq data revealed that the transcript levels of these transcription factors were 
elevated and correlated with that of SREBPs and their targets. Therefore, it is feasible that a 
transcriptional cascade of FOXO3, ESR-1, SREBPs and their targets may occur in the presence 
of (3R,8S)-falcarindiol, (Z)-ligustilide or 6-IVU. However, a mechanism responsible for activation 
of FOXO3 under these conditions is not clear. Indeed, it is difficult to draw any conclusions 
regarding the mechanism(s) underlying these gene expression changes without further study.  
5.3.2.15. NF-κB 
As a central transcription factor mediating the expression of inflammatory genes, the 
effects of NF-κB activation are antagonistic to those of Nrf2 activation. Certain Nrf2 activators 
decrease activation of NF-κB by directly modifying cysteines of either the DNA-binding domain 
of the NF-κB subunit RelA, the catalytic cysteines of IKK or through other means such as 
causing competition for mutual co-factors such as CBP. A summary of the expression patterns of 
NF-κB targets genes are provided in Table 5-12. 
 The overall pattern of expression of NF-κB target genes was downregulation for the two 
most convincing Nrf2 activators in the screen, (3S,8S)-falcarindiol (1 µM) and (R)-sulforaphane 
(1 µM) and upregulation for 6-IVU (10 µM) and (Z)-ligustilide (10 µM). Interestingly, the pattern 
of NF-κB activation was similar to that of AhR activation with 6-IVU (10 µM) and (Z)-ligustilide 
(10 µM) appearing to be the most potent inducers of both systems. As the AhR is involved in NF-
κB mediated inflammatory gene expression during exposure to lipopolysaccharide (Wu et al. 
2011) it would be interesting to determine whether AhR activation is also involved in NF-κB 
mediated transcription under these conditions.  
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Table 5-12. Fold-changes in transcript levels of NF-κB targets. Hepa-1c1c7 cells were exposed to the indicated compounds for 12 h and transcript levels 
were measured by RNA-seq. 
 
ENSEMBL identifier 
(3S,8S)-
falcarindiol 
(1 μM) 
(3R,8S)-
falcarindiol 
(1 μM) 
(3R,8S)-
falcarindiol 
(10 μM) 
(3R)-
falcarinol 
(1 μM) 
(R)-
sulforphane 
(1 μM) 
6-isovaleryl-
umbelliferone 
(10 μM) 
(Z)-
ligustilide 
(10 μM) 
CASPASE 4 ENSMUSG00000033538 1.21 1.19 0.55 0.91 1.08 1.02 0.34 
CHEMOKINE LIGAND 2  ENSMUSG00000058427 0.43 1.09 0.37 0.26 0.66 2.80 2.43 
TELOMERASE REVERSE 
TRANSCRIPTASE  
ENSMUSG00000021611 0.44 1.54 1.16 0.55 0.91 0.97 0.62 
ADP-RIBOSYLATION 
FACTOR RELATED 
PROTEIN 1  
ENSMUSG00000038671 0.89 0.90 0.75 0.75 0.98 0.84 0.92 
CHEMOKINE (C-X-C 
MOTIF) LIGAND 1  
ENSMUSG00000029380 0.64 0.93 1.34 2.04 0.77 0.66 0.46 
PROTEIN 
PHOSPHATASE 2A, 
REGULATORY SUBUNIT 
B (PR 53)  
ENSMUSG00000039515 0.53 0.93 1.33 0.78 0.69 0.69 0.91 
IMMEDIATE EARLY 
RESPONSE 3  
ENSMUSG00000003541 0.64 0.89 1.75 1.47 0.56 1.75 1.04 
TRANSFORMATION 
RELATED PROTEIN 53 
(P53) 
ENSMUSG00000059552 0.81 1.04 1.71 1.08 0.87 1.84 1.76 
E74-LIKE FACTOR 3 ENSMUSG00000003051 0.75 1.19 1.32 1.11 0.65 1.23 0.88 
MATRIX 
METALLOPEPTIDASE 3  
ENSMUSG00000043613 0.77 0.84 0.43 0.72 1.02 0.79 0.32 
MYELOCYTOMATOSIS 
ONCOGENE C-MYC 
ENSMUSG00000022346 1.05 1.28 2.68 1.51 1.33 3.08 3.85 
SUPEROXIDE 
DISMUTASE 2, SOD2 
ENSMUSG00000006818 0.85 0.82 1.17 0.73 0.91 1.24 1.20 
Mean 
 
0.75 1.05 1.21 0.99 0.87 1.41 1.23 
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5.3.3. qRT-PCR validation of RNA-seq results 
I used qRT-PCR to validate the RNA-seq results. Using validated primers and six targets 
a total of 32 qRT-PCR quantifications were performed. The correlation of  these results with the 
RNA-seq results is provided in Figure 5-7. There was a general agreement between the two sets 
of data (slope = 1.06, R
2  
= 0.82).  
 
Figure 5-7. Correlation between fold-changes in transcript levels determined by RNA-seq and qRT-PCR. 
5.3.4. Transcriptional investigation of QR induction by cannabidiol 
Although CBD was not included in the RNA-seq analysis, I was interested to investigate 
whether the induction of QR by this compound was being mediated by Nrf2 and/or AhR. Using 
qRT-PCR, I examined the changes in the transcript levels of the Nrf2 targets (QR and HO-1) and 
AhR target (CYP1A1). 
Changes in the transcript levels of QR, HO-1 and CYP1A1 following 12 h of exposure to 
CBD are shown in Figure 5-8. The level of QR transcript induction measured at 12 h (2.0) was 
y = 1.06x - 0.20 
R² = 0.82 
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similar to that of the enzyme induction measured at 48 h consistent with a transcriptional control 
mechanism. Induction of HO-1 is consistent with activation of Nrf2 while induction of CYP1A1 
is suggestive of activation of AhR. Thus it appears that CBD may activate QR through both the 
Nrf2 and AhR pathways and lead to induction of both phase I and II of xenobiotic metabolism. 
 
Figure 5-8. Changes in tranascript levels of QR, HO-1 and CYP1A1 following exposure to CBD. Hepa-1c1c7 
cells were exposed to the indicated compounds for 12 h and transcript levels were measured by qRT-PCR. 
Values are the mean of three experiments ± the standard deviation. 
5.4. Conclusions 
Transcriptional analysis by RNA-seq and qRT-PCR provide further support for Nrf2 
activation by (3S,8S)-falcarindiol. The transcriptional analyses also strongly support Nrf2 
activation by (R)-sulforaphane and to a lesser extent by (3R,8S)-falcarindiol, 6-IVU, (Z)-ligustilide 
and CBD. AhR appears to be moderately activated by (3R,8S)-falcarindiol, (Z)-ligustilide and (R)-
sulforaphane, and strongly activated by 6-IVU and CBD.  
In addition to varying in their propensities for activating Nrf2, the two falcarindiol 
stereoisomers also differ in their specificity for this transcription factor, with (3R,8S)-falcarindiol 
having greater promiscuity. Several of the compounds ((3R,8S)-falcarindiol 6-IVU and (Z)-
ligustilide) appeared to cause changes in metabolism and lipid homeostasis although the 
mechanism(s) involved remain unclear. 
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CHAPTER 6 
GENERAL DISCUSSION 
6.1. General conclusions 
 Screening of plant extracts for QR induction provided a large number of lead extracts and 
an overall indication of the prevalence of QR inducers in Western Canadian plants. The direct 
antioxidant activity of these extracts did not correlate with QR-inducing activity. Therefore 
direct antioxidant activity should not be used as an indicator of QR-inducing activity (indirect 
antioxidant activity). Based on findings of the bioassay guided fractionation, I suggest that 
phthalides and C17-polyacetylenes may confer QR-inducing activity within the uninvestigated 
extracts of the Apiaceae and Araliaceae such as pestle parsnip and Siberian ginseng. 
Taken as a whole, the results of the screening, isolation, biochemical and genomic 
experiments provide strong evidence for activation of Nrf2 by C17-polyacetylenes, in particular 
(3S,8S)-falcarindiol, and support a mechanism of action involving modification of Keap1 
cysteines. The results with the falcarindiol stereoisomers also underscore the impact that a 
difference in configuration can have on biological activity. Not only was this difference responsible 
for the substantially different effects these compounds had on the structure of Keap1 and QR-
induction, but also the differences in their global effects on transcription. 
These studies support the involvement of both Nrf2 and AhR in the induction of QR by 
(3R,8S)-falcarindiol, (Z)-ligustilide, CBD, (R)-sulforaphane, and 6-IVU. AhR appears to be 
moderately activated by (3R,8S)-falcarindiol, (Z)-ligustilide and (R)-sulforaphane, and strongly 
activated by 6-IVU and CBD. The widespread effects on transcription caused by (3R,8S)-
falcarindiol, 6-IVU, (Z)-ligustilide indicate that other signal transduction pathways, such as those 
involved in lipid homeostasis, are also likely affected. Even the most specific Nrf2 activator 
isolated here, (3S,8S)-falcarindiol, appears to affect additional signal transduction pathways ( e.g. 
cell cycle regulation). Given the abundance of cellular thiols, including those in enzyme active 
sites, I suspect that it will be difficult to find thiol-reactive Nrf2 activators that are devoid of off-
target effects.  
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6.2. Technical and methodological considerations 
   As demonstrated by compounds such as (Z)-ligustilide and 6-IVU, the activation of the 
AhR can also contribute to QR induction and reduce the reliability of QR as a marker for Nrf2 
activation. For this reason I would consider using an ARE-luciferase screen or similar reporter 
with minimal interference from alternative signal transduction pathways in future studies. Cell 
lines related to Hepa-1c1c7 with impaired AhR signalling could also be used to screen out QR 
inducers that act via AhR, although false negatives in cases where metabolic activation is 
required for Nrf2 activation could be problematic. 
   Following the isolation of falcarindiol and other QR-inducing polyacetylenes from O. 
horridus I looked to the related plant A. nudicaulis to identify additional QR-inducing 
polyacetylenes. This approach was quite successful as I was able to isolate several distinct 
polyacetylenes including the highly potent epoxyfalcarindiol. 
Additional direct evidence for Nrf2 activation could be provided by examining changes 
in the cellular abundance and localization of Nrf2 by Western blot or subcellular localization. 
Unfortunately the Western blots I performed for this purpose were equivocal due to the lack of 
specificity of the Nrf2 antibody. An antibody with greater specificity is desirable to allow 
Western blots in future studies. 
6.3. Physiological implications 
Coping with exposure to xenobiotics is an important aspect of human biology. 
Intriguingly, the stresses associated with xenobiotic exposure are similar to stresses associated 
with redox stress and inflammation, namely, electrophilic and oxidative stresses. Therefore it is 
not that surprising that the response to these stresses is mediated by a common pathway through 
Nrf2.  
As a signalling system that antagonizes inflammation and redox signalling, activation of 
Nrf2 is not without compromise. Inflammation and redox signalling are crucial for innate and 
acquired immunity as well as a multitude of regulatory pathways. Therefore, it makes sense that 
Nrf2 is inducible. It can offer protection against acute toxicity and provide negative feedback for 
redox signalling in times of need while a low baseline allows the greatest sensitivity for redox 
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signalling in the absence of stressors. This system is in general highly effective – diseases  
associated with inflammation and redox stress do not typically manifest until later in life. Having 
a higher basal level of Nrf2-directed transcription may provide increased protection against 
chronic diseases, but may come at other costs (i.e. decreased immunity) and therefore reduced 
fitness. It would be interesting to investigate whether there is an inverse correlation between 
susceptibility to infection and chronic disease incidence. As chronic diseases are greater 
contributors to death and disability than infectious diseases in industrialized nations, Nrf2 
activators – whether dietary or pharmaceutical – remain an attractive intervention. 
Although it is apparent that many compounds can activate Nrf2 at some concentration, 
few compounds have been shown to strongly activate Nrf2 at concentrations that are typically 
obtained through fruit and vegetable consumption. The compounds isolated in this research are 
no exception. Although these compounds are present in food plants it is doubtful that the 
concentrations achieved through their daily consumption ever surpass the CD value obtained in 
the QR bioassay. For instance, drinking 900 mL (containing 12 mg of falcarinol) of carrot juice 
only led to plasma falcarinol concentrations of ~10 nM (Haraldsdóttir et al. 2002), much lower 
than the CD value of the most potent polyacetylene isolated in this work (epoxyfalcarindiol (26), 
240 nM). However, we must consider that there are typically several related compounds present 
and that more than one compound is active. There is also the possibility that more than one class 
of Nrf2 activator is present in a given plant. For instance (Z)-ligustilide (phthalide), (3R,8S)-
falcarindiol (polyacetylene), and 6-IVU (coumarin) are present in the plant celeriac (Apium 
graveolens var. rapaceum, Apiaceae). Synergism between classes of Nrf2 activators is also 
possible. Then again, I did not encounter any great reduction in QR-induction during my 
fractionations which is consistent with a lack of synergy between components of those extracts. 
Another consideration with respect to dosage is the impact of local exposure. For example, 
concentrations greater than those achieved in plasma are expected locally for epithelia of the 
digestive tract following ingestion or the lung following inhalation due to the lack of metabolism 
or dilution of the active compounds at the area of first exposure (Olsson et al. 2011). Therefore the 
high nM or low µM concentrations that are required for activity in the QR bioassay may be 
achieved in these areas despite lower plasma concentrations. For instance, after smoking a 
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cannabis cigarette containing 19 mg equivalents of CBD, CBD plasma levels decreased from 320 
nM  to 6 nM over 4 h (Agurell et al. 1986). While these concentrations are still much lower than 
the 2.0 µM CD value, the initial levels of exposure in the lung epithelia would be expected to be 
much higher and may come close to the CD value for this compound. In cases where local 
exposure is much greater than systemic exposure a greater localized effect is expected. 
Consistently, the digestive tract and lung are the tissues in which increased fruit and vegetable 
consumption appear to have the greatest protective effect against cancer (WHO 2003). 
6.4. Safety 
The presence of many of the compounds identified here in everyday foods provides a 
sense of safety surrounding their consumption. This is bolstered by the evidence supporting the 
health benefits of fruit and vegetable consumption. Despite this evidence, I suggest that adverse 
effects from overconsumption of a given phytochemical are not only possible but simply a matter 
of dosage.  
The ability to cause stress by reacting with cellular thiols is inherent in Keap1-modifying 
Nrf2 activators. This property also underlies the hormetic nature of their dose responses. At low 
concentrations, they produce protection whereas at high levels, which overwhelm adaptive 
cellular defences, toxicity occurs. While this may be unlikely at the low doses of these 
compounds that occur in food plants it remains a major consideration with respect to consuming 
concentrated doses.  
Although it appears that many of the aforementioned compounds activate Nrf2, it is 
apparent that additional signalling pathways are also affected. In particular, the effects on lipid 
homeostasis genes are potentially alarming and warrant further investigation. Furthermore, it is 
possible that these compounds affect signalling pathways (e.g. endocrine signalling) as reflected 
in the gene expression data collected from Hepa-1c1c7 cells. The isoflavone and estrogen 
receptor agonist genistein provides an example of endocrine disruption by an Nrf2 activator 
(Kuiper et al. 1998; Yannai et al. 1998).  
I must also advise caution if considering using any of the plants used in this study for 
medicinal purposes. Just because something is natural does not mean it is safe. Nor does the 
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presence of potentially beneficial compounds exclude the potential for detrimental compounds to 
be present. For example, falcarindiol can be found along with the highly toxic polyacetylene, 
oenanthotoxin in Oenanthe fistulosa (Appendino et al. 2009). Although the fact that some of 
these plants have traditional uses suggests that they do not exhibit high toxicity, they have not 
been subjected to rigorous toxicological studies. Unfortunately, these types of body system 
effects cannot be predicted by the study of an individual cell type such as Hepa-1c1c7.  
6.5. Implications for traditional medicine 
Despite having less toxicological documentation, using non-food plants for Nrf2 
activation may be advantageous as non-food plants may contain higher concentrations of Nrf2 
activators than food plants. Because many Nrf2 activators are distasteful, they may have been 
bred out of food crops. Also, the number of plants used as food is relatively small and food 
plants mainly belong to a handful of plant families. Therefore, expanding use to non-food plants 
allows a much larger natural pharmacopeia. Additionally, many plants that are rich 
phytochemical sources are simply not useful as foods. Take for example the C17- polyacetylenes. 
Judging by HPLC, these compounds comprise the majority of compounds present in extracts 
from the inner stem bark of O. horridus, which is not used as a food, while being only a minor 
component of carrot root extracts.  
The finding that many extracts of plants used in traditional medicine activate QR and 
confirmation of the presence of Nrf2 activators in some of these samples is an important finding 
with respect to understanding their traditional use. Nrf2 activation could provide some rationale 
for uses such as treating diseases linked to inflammation and oxidative stress. For other 
indications such as tuberculosis, a connection to Nrf2 activation is not apparent. Although 
demonstrating a biological activity for these traditional medicines does not confirm their efficacy 
it does provide some basis for understanding whether their use is justified.  
6.6. Future directions 
 Screening for QR-inducing extracts provided more leads than could be followed up. 
Compositae plants figured prominently amongst the top inducers. Yuping Lu (Page lab) and I 
have shown that unique polyacetylenes are responsible for QR-induction in these plants (data not 
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shown) however, we have not investigated which signal transduction pathways are involved. 
Also, I am interested in isolating the active compounds from members of the Grossulariaceae as 
this family consistently displayed QR-inducing activity in the screen and includes a number of 
food plants (currants, gooseberries). 
 Only limited pharmacokinetic (absorption, distribution, metabolism and exception) data 
exist for the most promising Nrf2-activator classes identified here, the phthalides and C17-
polyacteylenes. Improving our understanding of the pharmacokinetics of these compounds 
would be useful in accessing dose requirements for further studies in vivo and understanding the 
physiological relevance of their exposure.  
The basic phytochemical information gained as part of this work contributes to our 
knowledge of the structures, distribution and abundance of phytochemicals. This information 
could be useful for cataloguing the phytochemicals present in foods and herbal medicines and  
their abundances. Combining this information with detailed cohort studies on nutrition may 
provide insight into the impact that these compounds have on human health. 
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Table A1. Additional details for plant material used for QR bioassay screening 
Common name Species and Author Family 
Max 
QR
a Extractor Additional notes 
Date 
Collected 
san qi 
Panax pseudoginseng Wall. 
Araliaceae 1.35 D. Konkin Botanicum Herbs - 5260 Nov-05 
ren shen -ginseng 
Panax ginseng L. 
Araliaceae 1.53 D. Konkin Botanicum Herbs - 5090 Nov-05 
siberian ginseng 
Eleutherococcus senticosus (Rupr. & 
Maxim.) Maxim. 
Araliaceae 1.84 Eric Bol Richter's H2864  
wild sarsparilla Aralia nudicaulis L. Araliaceae 1.43 Eric Bol   
wild sarsparilla Aralia nudicaulis L. Araliaceae 0.93 Eric Bol   
devil's club Oplopanax horridus (Sm.) Miq. Araliaceae 2.45 Eric Bol BC  
devil's club Oplopanax horridus (Sm.) Miq. Araliaceae 2.02 D. Konkin BC  
gymnema Gymnema sylvestre (Retz.) Sm. Asclepiadaceae 1.53 D. Konkin Source Naturals Nov-05 
Oregon grape Mahonia aquifolium (Pursh) Nutt. Berberidaceae 0.98 D. Konkin Purchased in Vancouver Nov-05 
Oregon grape Mahonia aquifolium (Pursh) Nutt. Berberidaceae 1.08 Eric Bol  Jul-05 
horny goat weed 
Epimedium sagittatum (Sieb. & Zucc.) 
Maxim. 
Berberidaceae 1.38 D. Konkin Planetary Formulas Nov-05 
cretan viper's-bugloss Echium creticum L. Boraginaceae 2.11 D. Konkin  Jan-06 
comfrey Symphytum offincinale L. Boraginaceae 1.09 D. Konkin Purchased in Vancouver Nov-05 
codonopsis  Codonopsis sp. Campanulaceae 1.00 D. Konkin Planetary Formulas Nov-05 
jie geng Platycodon sp. Campanulaceae 1.37 D. Konkin Botanicum Herbs - 7310 Nov-05 
hop Humulus lupulus L. Cannabaceae 0.97 D. Konkin Purchased in Saskatoon Nov-05 
high-bush cranberry Viburnum sp. Caprifoliaceae 1.38 D. Konkin Jasper Aug-05 
elderberry Sambucus calliicarpa Caprifoliaceae 1.51 Eric Bol   
high-bush cranberry Viburnum sp Caprifoliaceae 0.83 D. Konkin   
common snowberry Symphoricarpos albus (L.) S.F. Blake Caprifoliaceae 1.17 D. Konkin BC Sep-05 
western snowberry Symphoricarpos occidentalis Hook. Caprifoliaceae 1.44 D. Konkin Saskatoon, SK Sep-05 
red elderberry Sambucus racemosa  L. Caprifoliaceae 1.25 D. Konkin   
tai zi shen Pseudostellaria sp. Caryophyllaceae 1.78 D. Konkin Botanicum Herbs - 5093 Nov-05 
wang bu liu xing Vaccaria hispanica (Miller) Rauschert Caryophyllaceae 1.14 D. Konkin Botanicum Herbs - 5620 Nov-05 
vaccaria Vaccaria saponaria Caryophyllaceae 0.86 D. Konkin Wild Nov-05 
qu mai Dianthus sp. Caryophyllaceae 1.50 D. Konkin Botanicum Herbs - 8950 Nov-05 
valley seed Bassia scoparia (L.) Voss Chenopodiaceae 0.51 D. Konkin Wild Nov-05 
arjuna Terminalia arjuna (DC) Wight & Arn. Combretaceae 0.68 D. Konkin Planetary Formulas Nov-05 
lettuce Lactuca sativa L. Compositae 1.28 Eric Bol   
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calendula Calendula sp. Compositae 0.78 D. Konkin Wild Nov-05 
iceberg lettuce Lactuca sativa L. Compositae 0.91 D. Konkin Grocery Store in S'toon Dec-05 
milk thistle Silybum marianum (L.) Gaertn. Compositae 1.65 Eric Bol   
elecampane Inula helenium L. Compositae 1.85 D. Konkin Purchased in Vancouver Nov-05 
dandelion Taraxacum officinale Weber ex Wigg. Compositae 1.54 Eric Bol Vancouver, BC  
feverfew Tanacetum parthenium (L.) Schultz-Bip. Compositae 2.00 Eric Bol   
wild chicory Cichorium intybus L. Compositae 2.97 Eric Bol   
american arnica Arnica chamissonis Less. Compositae 1.74 Eric Bol   
French artichoke Cynara scolymus L. Compositae 1.66 Eric Bol   
black salsify Scorzonera hispanica  Compositae 1.01 D. Konkin   
echinacea Echinacea sp. Compositae 1.81 D. Konkin Purchased in Vancouver Nov-05 
goldenrod Solidago virgaurea Compositae 0.74 D. Konkin Purchased in Vancouver Nov-05 
burdock Arctium minus (Hill) Bernh. Compositae 1.75 D. Konkin Kamsack, SK (DK)  
boneset Eupatorium perfoliatum L. Compositae 2.01 Eric Bol   
big sagebrush Artemisia tridentata Nutt. Compositae 2.07 D. Konkin   
balsam root Balsamorhiza sp. Compositae 1.72 D. Konkin   
echinacea Echinacea angustifolia DC Compositae 1.80 D. Konkin   
entire-leaved 
gumweed 
Grindelia integrifolia DC. Compositae 1.39 D. Konkin   
elecampane Inula helenium L. Compositae toxic D. Konkin   
common tansy Tanacetum vulgare L. Compositae 2.51 D. Konkin   
bindweed Convolvulus sp. Convolvulaceae 1.54 D. Konkin Wild Nov-05 
red-osier dogwood Cornus alba L. Cornaceae 2.09 Eric Bol Vancouver, BC  
bunchberry Cornus canadensis L. Cornaceae 1.24 D. Konkin Coquitlam watershed Sep-05 
wasabi Wasabia wasabi (Siebold) Makino Cruciferae 1.43 Eric Bol   
radish Raphanus sativus L. Cruciferae 1.85 Eric Bol   
broccoli Brassica oleracea L. Cruciferae 1.10 Eric Bol   
dijon mustard Brassica juncea (L.) Czerniak Cruciferae 1.72 Eric Bol   
broccoli Brassica oleracea L. Cruciferae 1.32 Eric Bol   
bitter gourd Momordica charantia L. Cucurbitaceae 1.77 Eric Bol Purchased  dried  
bitter gourd Momordica charantia L. Cucurbitaceae 1.14 D. Konkin Purchased  fresh  
angled luffa Luffa acutangula (L.) Roxb Cucurbitaceae 1.80 Eric Bol Purchased Jul-2005 
creeping juniper Juniperus horizontalis Moench Cupressaceae 1.40 D. Konkin Saskatoon, SK Sep-05 
poracher root Pteridium aquilinium (L.) Kuhn Dennstaedtiaceae 0.88 D. Konkin   
wolf willow Elaegnus commutata Bernh. ex Rydb. Elaegnaceae 1.34 D. Konkin Saskatoon, SK Nov-05 
soapberry Shepherdia canadensis (L.) Nutt Elaegnaceae 1.84 Eric Bol Near Lilloet BC  
wolf willow Elaegnus commutata Bernh. ex Rydb. Elaegnaceae 0.34 D. Konkin Saskatoon, SK Nov-05 
crowberry Empetrum nigrum L. Empetraceae 0.99 D. Konkin   
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cranberry Vaccinium oxycoccus L. Ericaceae 0.92 Eric Bol   
red huckleberry Vaccinium parvifolium Sm.  Ericaceae 1.15 Eric Bol   
cranberry Vaccinium oxycoccus L. Ericaceae 0.99 D. Konkin 
No Name Frozen 
Cranberries 
Mar-06 
lingonberry Vaccinium vitis-idaea L. Ericaceae 0.84 D. Konkin Jasper Aug-05 
domestic blueberry Vaccinium corymbosum L. Ericaceae 0.82 D. Konkin Surrey, BC Sep-05 
bilberry Vaccinium myrtillus L. Ericaceae 1.51 Eric Bol Richter's H1410-050  
blueberry  Vaccinium sp. Ericaceae 0.77 D. Konkin Strathcona, BC  
blueberry Vaccinium sp. Ericaceae 0.65 D. Konkin Strathcona, BC  
blueberry Vaccinium sp. Ericaceae 0.73 D. Konkin Strathcona, BC  
labrador tea Ledum groenlandicum Oeder  Ericaceae 0.81 Eric Bol Jasper Aug-05 
kinnikinick Arctostaphylos uva-ursi (L.) Sprengel Ericaceae 1.65 D. Konkin UBC campus Aug-05 
salal Gaultheria shallon Pursh Ericaceae 0.79 Eric Bol UBC campus Jul-05 
pispsissewa 
Chimaphila umbellata (L.) W. Barton 
(Euras.) 
Ericaceae 1.16 Eric Bol Richter's H4489  
yellow gentian Gentiana lutea L. Gentianaceae 1.12 Eric Bol Richter's H2820  
European centaury Centaurium erythaea Raf. Gentianaceae 2.40 D. Konkin   
king gentian Gentiana sceptrum Griseb. Gentianaceae 2.18 D. Konkin   
irish moss Chondrus crispus Stackhouse Gigartinaceae 0.99 D. Konkin North Cap PEI Jun-05 
red currant Ribes rubrum L. Grossulariaceae 1.51 Eric Bol   
stink currant Ribes bracteosum Dougl. ex Hook Grossulariaceae 1.78 D. Konkin 
Nossom Cr. Port Moody 
BC 
Sep-05 
black gooseberry Ribes lacustre (Pers.) Poir. Grossulariaceae 1.24 D. Konkin Jasper Aug-05 
wax currant Ribes cereum Dougl. Grossulariaceae 1.61 Eric Bol   
red flowering currant Ribes sanguineum Pursh Grossulariaceae 1.44 Eric Bol Page Farm, Courtenay, BC  
mangosteen Garcinia mangostana L. Guttiferae 1.20 Eric Bol   
basil Ocimum basilicum L. Labiatae 1.67 Eric Bol   
blue skull cap Scutellana lateriflora L. Labiatae 2.24 Eric Bol Richter's H5360  
astragalus Astragalus sp. Leguminosae 1.04 D. Konkin Planetary Formulas Nov-05 
genistein soy complex Glycine max (L.) Merr Leguminosae 0.92 D. Konkin Source Naturals Nov-05 
licorice Glycyrrhiza glabra L. Leguminosae 1.72 D. Konkin 
Fresh, purchased by Jon 
Page 
 
licorice Glycyrrhiza glabra L. Leguminosae 1.60 Eric Bol Richter's H3701-100  
springbank clover Trifolium wormskioldii Lehm. Leguminosae 1.91 D. Konkin   
lady's leek Allium cernuum Roth Liliaceae 0.95 D. Konkin  Sep-05 
false lily-of-the-valley 
Maianthemum dilatatum (A. Wood) 
Nels. & J.F. Macbr. 
Liliaceae 1.22 D. Konkin   
twisted stalk Streptopus sp. Liliaceae 1.27 D. Konkin   
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yellow sand-verbena Abronia latifolia Eschsch. Nyctaginaceae 1.76 D. Konkin 
Goose Spit dunes, Comox 
BC 
 
yellow sand-verbena Abronia latifolia Eschsch. Nyctaginaceae 2.52 D. Konkin   
bloodroot Sanguinaria canadensis L. Papaveraceae 1.29 Eric Bol Richter's H1450  
old man's beard Usnea sp. Parmeliaceae 1.84 D. Konkin   
passion flower Passiflora sp. Passifloraceae 1.06 D. Konkin Eclectic Institute Nov-05 
pokeweed Phytolacca americana L. Phytolaccaceae 1.22 Eric Bol   
ribgrass/ribwort 
plantain 
Plantago lanceolata L. Plantaginaceae 1.56 Eric Bol   
ribwort Plantago lanceolata L. Plantaginaceae 1.33 D. Konkin 
Purchased in Vancouver, 
BC 
Nov-05 
yuan zhi Polygala sp. Polygalaceae 0.69 D. Konkin Botanicum Herbs - 8510 Nov-05 
sheep sorrel Rumex acetosella L. Polygonaceae 2.08 Eric Bol   
rhubarb Rheum rhabarbarum L. Polygonaceae 0.97 Eric Bol   
yellow dock 
Rumex crispusL. Polygonaceae 0.88 D. Konkin 
Purchased in Vancouver, 
BC 
Nov-05 
bitter root Lewisia sp. Portulacaceae 2.32 D. Konkin   
cascara Rhamnus purshiana DC Rhamnaceae 1.47 D. Konkin 
Purchased in Vancouver, 
BC 
Nov-05 
cherry Prunus sp. Rosaceae 1.36 D. Konkin   
domestic plum Prunus sp. Rosaceae 1.67 D. Konkin Lillooet, BC Aug-05 
chokecherry Prunus virginiana L. Rosaceae 1.45 D. Konkin   
chokecherry Prunus virginiana L. Rosaceae 1.36 Eric Bol Lilooet, BC Jul-05 
American mountain-
ash 
Sorbus americana Marsh. Rosaceae 2.32 D. Konkin U of S campus, SK Sep-05 
pin cherry Prunus pensylvanica L. f. Rosaceae 0.81 Eric Bol Jasper Aug-05 
red delicious apple Malus sp. Rosaceae 0.90 Eric Bol   
hawthorn Crataegus sp Rosaceae 1.27 D. Konkin Osoyous, BC Aug-05 
saskatoon berry Amelanchier alnifolia Nutt. Rosaceae 0.67 Eric Bol   
European mountain-
ash 
Sorbus aucuparia L. Rosaceae 2.15 D. Konkin Lilloet Valley BC Sep-05 
cotoneaster Cotoneaster sp. Rosaceae 1.57 D. Konkin Saskatoon, SK Nov-05 
black hawthorn Crataegus douglasii Lindley Rosaceae 1.37 D. Konkin 
Tynehead Regional Park 
Surrey, BC 
Aug-05 
himalaya blackberry Rubus discolor Weihe & Nees Rosaceae 1.17 D. Konkin 
Strathcona Park 
Vancouver, BC 
Sep-05 
salmon berry Rubus spectabilis Pursh Rosaceae 0.78 Eric Bol   
bitter cherry Prunus sp. Rosaceae 1.07 D. Konkin   
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a
indicates the highest QR induction value for the extract. 
n/d indicates that the value could not be determined. 
 
 
 
nootka rose Rosa nutkana Presl  Rosaceae 1.02 D. Konkin   
trailing blackberry Rubus ursinus Cham. & Schlecht. Rosaceae 0.88 Eric Bol   
carolina rose Rosa carolina L. Rosaceae 0.99 Eric Bol PEI  
common wild rose Rosa woodsii Lindl. Rosaceae 0.85 D. Konkin Saskatoon, SK Sep-05 
antelope-brush Purshia tridentata (Pursh) DC. Rosaceae toxic D. Konkin   
bacopa Bacopa sp. Scrophulariaceae 1.30 D. Konkin Planetary Formulas Nov-05 
potato Solanum tuberosum L. Solanaceae 0.94 D. Konkin Purchased in Saskatoon Nov-05 
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APPENDDIX C 
SUPPORTING INFORMATION FOR RNA-SEQ ANALYSIS 
 
C.1. Tophat analysis parameters 
min-anchor: 8 
splice-mismatches: 0         
min-report-intron: 50            
max-report-intron: 500000        
min-isoform-fraction: 0.15       
max-multihits: 40            
segment-length: 25            
segment-mismatches: 2             
min-closure-exon: 100           
min-closure-intron: 50            
max-closure-intron: 5000          
min-coverage-intron: 50            
max-coverage-intron: 20000         
min-segment-intron: 50            
max-segment-intron: 500000        
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Table C-1. Over-represented neighbour-based sets. 
(3S,8S)-
falcarindiol 
(3R,8S)-
falcarindiol 
(3R,8S)-
falcarindiol 
(3R)-
falcarinol 
(R)-
sulforphane 
6-isovaleryl-
umbelliferone 
(Z)-
ligustilide 
(1 μM) (1 μM) (10 μM) (2 μM) (1 μM) (10 μM) (10 μM) 
HXK4 PO5F1 RS27 HXK4 SLMAP MK01 SMCA4 
GCKR P4HA1 RS27A SLBP GSH0 ACTB IKKA 
PHAX SMRC1 RPN1 GCKR NR4A3 TBA1A SMRC1 
SLBP KDM1A RL40 PHAX CSF1 1433G PO5F1 
SPN1 TIF1A S61A2 GEMI2 GSHB CTNB1 TF2L1 
DDX20 MATR3 S61A1 SPN1 MALT1 2AAA SMCA2 
SMN ARI3B INS1 LMBL2 
 
L1CAM TF65 
GEMI2 MTA1 SRPRB DDX20 
 
KS6A3 MATR3 
GEMI5 CTBP2 SRPR AAAS 
 
1433E KDM1A 
AAAS P66B INS2 PCGF6 
 
IKKA MTA1 
NUPL1 ZN513 SC11A NUPL1 
 
KAP3 MK01 
NXF1 HELLS IF1AX SMN 
 
KALRN EPN1 
RAE1L JADE1 RS8 MGAP 
 
SRC TBCE 
NUP93 MTA2 RL5 RAE1L 
 
MYH11 D3YXI3 
IF4E XRCC5 RS15 KDM1A 
 
AKT2 MED1 
B2RQL0 SALL4 ERF1 NXF1 
 
JIP1 CTBP2 
Q6PFD9 CHD4 RS3 RING2 
 
RALA SMCA5 
RBP2 A2A8L1 EF2 MAX 
 
DYN1 DDB1 
D3YXJ1 BRWD1 IF2P MATR3 
 
KPCG PARP1 
SMD3 NACC1 RL14 MTA1 
 
NMDZ1 KIF5C 
RSMB ACINU RL13A NUP93 
 
MYH9 ACL6A 
NCBP1 ZBT43 RSSA IF4E 
 
Q4VA56 XRCC5 
B1APM6 TRI33 D3YYM6 GEMI5 
 
MYH10 SRC 
MGN DNLI3 RS11 ACL6A 
 
MYO1B TIF1A 
CPSF1 ZIC2 RS19 XRCC5 
 
CADH2 O35171 
NFX1 HCFC1 D3YW44 B2RQL0 
 
MYO5A 2AAA 
D3Z4G3 RFX2 UBIM Q6PFD9 
 
KPCB P4HA1 
RNPS1 XRCC1 RL19 SMCA5 
 
ARNT ZFHX3 
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